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ABSTRACT
In this project, a number of monoclonal antibodies were developed which 
recognised an oligopeptide tag known as the Pk tag. These antibodies were used for the 
development of an affinity purification protocol in order to purify Pk tagged recombinant 
proteins. These proteins, in turn, were to be used for the development of multiple epitope 
vaccines.
The Pk tag is a 14 amino acid oligopeptide which was originally mapped to the 
binding epitope of the monoclonal antibody SV5-P-k, raised to the Paramyxovirus 
Simian Virus 5 (SV5) phospho- (P) protein. The tag has been cloned into the bacterial 
expression vector pQ9cPk so that when expressed, any recombinant protein produced 
will have a Histidine tag at the N terminus and the Pk tag at the C terminus. These two 
tags are the basis of a two step purification system, utilising a nickel affinity column for 
the Histidine tag capture, and monoclonal antibody (mAb) SV5-P-k immobilised on 
Sepharose beads for Pk tag capture.
The genes encoding the Simian Immunodeficiency Virus (SIV) precursor protein 
Pr55§^§ and the auxiliary protein Nef were cloned into pQ9cPk and the recombinant 
proteins produced purified using the current two step purification protocol. However, the 
affinity of the mAb SV5-P-k for the Pk tag is so strong, that denaturing conditions were 
needed to separate the antibody from the tagged protein. Due to this it was decided to 
develop a number of mAb’s to the Pk tag with the aim of creating antibodies whose 
binding affinities varied from that of SV5-P-k.
A number of hybridoma clones expressing mAb’s which recognise the Pk tag 
were created and after initial characterisation it was demonstrated that of the twenty four 
clones produced, only four recognised Pk tagged recombinant proteins or the SV5 P 
protein. The epitopes and binding affinities of these four mAb’s were determined, and 
when compared to SV5-P-k, it was observed that all five mAb’s had similar affinities for 
the Pk tag. Therefore, antibodies to the Pk tag which had lower binding affinities were 
not obtained.
In order to utilise the five anti-Pk mAb’s in the two step purification system, the 
original primary sequence of the Pk tag was modified, creating three new tags. On further 
analysis of the binding of the five anti-Pk mAb’s to the modified tags, elution conditions 
were determined which allowed the elution of Pk tagged recombinant proteins from a 
mAb bound affinity column.
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INTRODUCTION
The work to be presented in this thesis is part of a long term effort to develop a 
multiple subunit vaccine against the Human Immunodeficiency Virus (HIV), using the 
infection of Macaques by the Simian Immunodeficiency Virus macaque strain (SlVmac) as 
an animal model. To develop the most efficient vaccine to HIV (and SIV), proteins of high 
purity are required, in a format which allows the immune system to produce a strong 
humoral and cellular response. This is to reduce any potential interference by contaminating 
proteins. To achieve this, a two step purification protocol was developed. This protocol 
utilised fusion proteins containing peptide tags at both the amino (N) and carboxy (C) 
termini. The tags currently used for this protocol are the hexahistidine peptide tag at the N 
terminus and the oligopeptide Pk tag at the C terminus. This protocol ensured the affinity 
purification of full length recombinant proteins. Both of these tags can be used for the 
affinity purification of tagged recombinant proteins; the hexahistadine tag by nickel chelate 
affinity chromatography; and the Pk tag by immunoaffinity chromatography.
Section one of the Introduction gives a brief overview of the most commonly used 
protein purification protocols currently in use in biochemistry today. This gives an insight 
into the many different ways of purifying recombinant proteins derived from either 
eukaryotic or prokaryotic expression systems. In addition to this. Section one also reviews 
the most commonly used affinity tag purification systems, and provides a basis with which 
to introduce the Pk affinity peptide tag developed by our research group.
Much of the work presented in this thesis concentrates on the development and 
characterisation of a number of monoclonal antibodies (mAb) which were raised against the 
Pk tag. The recognition of the Pk tag by the mAbs forms the second stage of the two step 
affinity purification system, and is also a way of presenting the antigenic vaccine to an 
animals immune system in the form of solid matrix antibody antigen (SMAA) complexes. 
Section two of the Introduction details the alternative ways that mAbs can be developed and 
the most efficient methods for purifying mAbs.
Section three of the Introduction concentrates on the molecular aspects of HIV and 
SIV, detailing some of the more recent progresses in the understanding of the retroviral life 
cycle and how this has helped in the development of a vaccine strategy. Section three also 
details some of the difficulties experienced when trying to develop a vaccine to HIV or 
SIV.
The final part of the Introduction states the objectives of the work to be presented in 
this thesis.
1. PROTEIN AFFINITY PURIFICATION
The purification of proteins is a prerequisite for many biochemical applications. 
Thus, a large number of protocols have been devised over recent years to obtain maximum 
yields of purified proteins, with minimal effort. As there are a wide range of purification 
protocols available, before choosing which to use, a single question must be addressed : 
what is the purified protein needed for?
The intended use of the protein can have a significant effect on how well the protein 
needs to be purified. For example, if the protein is to be used for structural analysis then it 
must be more than 95% pure, as any impurities can effect the results obtained. However, if 
the protein is needed for protein activity assays, the purity of the protein is not as important 
as obtaining sufficient amounts of protein with minimal loss of protein activity (Phizicky & 
Fields 1995, Nilsson et ai 1996, Scopes 1996).
Other considerations need to be addressed when choosing a method of protein 
purification, for example, the properties of the protein. Knowledge of the proteins location 
within a cell; the presence of any post-translational processing e.g. phosphorylation, the 
addition of carbohydrates or lipids; the solubility of the protein; and whether it is membrane 
bound or located within a subceliular organelle, are some of the properties which need to be 
determined before deciding which purification protocol to use. The more that is known 
about the protein, the easier it becomes to determine the most efficient method of 
purification. For example, if the protein is extracellular, then centrifugation of the cells may
2
be the best way of obtaining pure proteins. However, if the protein is glycosylated then 
affinity purification on a lectin column may be satisfactory for obtaining relatively pure 
protein (Scopes 1996).
A way of simplifying the purification protocol and eliminating the necessity of 
determining the properties of the protein is to express the protein in vir?‘o from a controlled 
expression system. The most common organism used for the expression of recombinant 
proteins is Escherichia coll. (E.coli) The full length genome of E. coli has now been 
sequenced, making it one of the most studied organisms to date. By designing expression 
plasmids with the optimal signals for transcription and translation, yields of up to 40% total 
cell mass of recombinant protein can be obtained.
One disadvantage of using E. coli for the expression of recombinant proteins, is 
that the proteins are not secreted and are usually found in inclusion bodies. To obtain 
secreted recombinant proteins, the Bacillus subtilis expression system can be used. 
Although the genetics of this bacterial species are not as well known as those of E. coli, 
high yields of secreted recombinant protein have been obtained. However, a disadvantage 
to using B, subtilis, is that highly active proteases are also secreted. Both of these bacterial 
systems can be used for the expression of eukaryotic and prokaryotic genes.
One of the fundamental differences of proteins produced in eukaryotic and 
prokaryotic systems is post-translational processing. Many eukaryotic proteins undergo 
post-translational modifications such as glycosylation or phosphorylation, processes which 
do not occur in prokaryotes. To overcome this, if a protein is known to be post- 
translationally processed, it can be expressed in the yeast Saccharomyces cerevisiae. This is 
a single cell yeast which exhibits all the characteristics of a eukaryote, ensuring that when 
eukaryotic genes are expressed, post-translational modifications can be added, A 
disadvantage of using S. cerevisiae occurs if protein secretion is required, as this yeast only 
usually secretes small proteins or peptides.
Regardless of how the protein has been produced, there are four fundamental ways 
of purifying a protein; size dependent separation (gel-filtration and membrane exclusion); 
charge dependent separation (ion exchange chromatography and electrophoresis); solubility
dependent separation i.e. the interaction between the surface of the protein and the solvent 
(reverse phase chromatography, hydrophobic interactions and ammonium sulphate 
precipitation); and affinity chromatography (Nilsson era/ 1996, Scopes 1996).
Part 1 of the Introduction describes some of the protein purification methods which 
are available, concentrating specifically on affinity chromatography.
Affinity chromatography is a system based on the molecular interactions of a 
protein to its specific ligand (Nilsson et al 1996). This technique was first used for the 
determination of phage and host proteins which interacted with the E. coli RNA polymerase 
(Phizicky & Fields 1995). The efficiency of affinity purification depends on the selectivity 
and tightness of binding of the required protein to its ligand. Proteins purified in this way 
tend to have high affinities for their ligands (Scopes 1996). If all conditions are optimised, 
affinity chromatography is a highly specific technique in which large yields of highly 
purified proteins can be obtained in a single purification step. This makes affinity 
chromatography a valuable tool for the detection, purification and immobilisation of 
proteins.
The different ways of affinity purifying a protein fall into four main categories : (i) 
the built in affinity of a fusion protein, (ii) the affinity of a protein for its natural ligand, (iii) 
the use of immobilised antibodies (immuno-affinity purification), and (iv) the unnatural 
interactions observed between individual proteins and organic molecules such as dyes and 
pharmaceutical drugs. Examples of each of these categories, with the exception of immuno- 
affinity purification (see section 2.2), will be discussed in turn.
1.1 Affinity chromatography using fusion proteins
The affinity chromatography of fusion proteins is one of the most efficient ways of 
purifying a protein. The production of fusion proteins is completely dependent upon 
recombinant DNA technology and the expression of recombinant proteins from a controlled 
expression system.
There are a number of well defined fusion proteins which are commonly used. 
They can consist of small peptide affinity tags / epitopes or full length proteins which are 
then recognised by either an antibody, an inorganic ligand or another biological ligand.
The development of affinity peptide tags is currently one of the fastest growing 
areas of biochemistry. Affinity tags tend not to be more than 20 amino acids in length and 
they can consist of the consensus sequence of antibodies, or other biological ligands, or be 
completely synthetically designed.
If an affinity tag is to be useful for protein purification and detection, it must adhere 
to a number of requirements. Firstly, the tag should not interfere with the folding, or the 
activity, of the protein to which it is fused. An affinity tag should be soluble and retain a 
high degree of exposure in aqueous solution. If it is to be useful in affinity purification, the 
tag should not have special requirements for binding and should allow elution under 
relatively mild conditions. Finally, if necessary, it should be easy to remove in a such a 
way that does not alter the target protein in any way. This final consideration is necessary if 
untagged target proteins are required (Nilsson etal 1996).
In addition to peptide affinity tags, complete proteins can be fused to target proteins 
for affinity purification. In most cases the binding ligand and the conditions for separation 
are well defined.
There are many commercially available plasmid vectors which are used for the 
production of fusion proteins. This section details some of the most commonly used 
affinity tags and fusion proteins and states the advantages and disadvantages of each one.
I.
One of the most common affinity tags used for protein affinity purification is the 
polyhistidine tag. Histidine is a basic amino acid (figure la), with a highly polarised side 
chain. Due to the chemical nature of the imidazole ring in its side chain, histidine can be 
charged or uncharged depending upon its external environment (Stryer 1988).
Histidine has a natural affinity for cations and binds Nickel with a high affinity. For 
efficient affinity purification, a number of consecutive histidine residues and a nickel
containing resin, such as nickel - nitrilo - tri- acetic acid (Ni-NTA) from Qiagen, are 
required (Hoculi et al 1988). The number of histidines in the tag vary from 6 histidine 
residues, the most commonly used number, to 10 or 11 residues. The interaction between 
the histidine residues and the Ni-NTA resin is pH dependent, but tends to be stable 
between pH 6.0 - 8.0 (Takacs etal 1991).
NH3+— CH —GOO­
CH
H
a. Histidine
H
b. Imidazole
Figure 1 : Structures of histidine and imidazole
Elution of the proteins from the column can be achieved by one of three methods;
by the reduction of the buffer pH; competitive elution using imidazole (figure lb); and the
addition of ethylenediaminotetra-acetic acid (EDTA; Paborsky etal 1996). A reduction of
the pH to pH 4.0 is sufficient for tagged protein elution. Due to tlie stability of the histidine
- nickel interaction at neutral pH, non-specifically bound proteins can be removed by
washing with high salt concentrations and detergents with no affect to binding. To elute
tagged proteins by competition with imidazole, concentrations of 0.2 - 0.5 M are required.
By washing the column with lower concentrations of imidazole (e.g. 25-50 mM), weak
and non-specifically bound proteins can be removed. The addition of EDTA to the elution
buffer acts to chelate the nickel cations, making them inaccessible for histidine binding.
Histidine tagged protein eluted from nickel chelate columns using any of these elution
methods may be >90% pure (Takacs etal 1991).
One advantage of the histidine tag over the use of other affinity tags is its stability
under denaturing conditions. This ensures that this system can be used to affinity purify
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insoluble proteins to a similar purity as soluble proteins. This also means that denaturing 
compounds such as guanidine hydrochloride can be used to ensure the removal of all non- 
specifically bound proteins from the resin (Paborsky etal 1996).
The histidine affinity tag has been adapted for use in a number of expression 
vectors including £■. cy; / / (Takacs er <:// 1991. Waine e ta l 1994. Rasmussen e ta l 1996). 
yeast (Zhao et al 1997), Dictyostelium discoideiim (Manstein et al 1995), insect cells 
(Kuusinen etal 1995) and mammalian cell lines (Caldecott etal 1994), for the purification 
of a range of gene products, including eukaryotic (Takacs et al 1991, Dang eta l 1996, 
Kuusinen et al 1995, Zhao et al 1997), plant (Rasmussen et al 1996), and bacterial 
(Sriwanthana etal 1996, Abramochkin & Shrader 1995) proteins.
Initially, the major disadvantage to using the histidine tag was its unsuitability for 
detection assays. Now, however, there are two ways of detecting histidine tagged 
recombinant proteins. A method devised by Piesecki & Hochuli (1994), and modified by 
Botting & Randall (1995), conjugated the enzyme alkaline phosphatase to the Ni-NTA 
complex. In this system, when the conjugate is charged with nickel ions, it can be used for 
the direct detection of histidine tagged recombinant proteins, and in immunological assays 
to detect antibodies which have been labelled with a histidine tag (Piesecki & Hochuli 
1994, Botting & Randall 1995). There is also a mAh commercially available from Qiagen 
which recognises the epitope Met. Arg. Gly. His. His. His. His. His. His. This mAh can 
be used for the detection of a histidine tag, only if the three amino acids Met, Arg and Gly 
directly preceed it (Qiagen).
a. Strep tag affinity purification
The Strep tag is a decameric peptide (figure 2) which was selected from a genetic 
fusion peptide library for its ability to bind specifically and reversibly to the tetrameric 
biotin binding protein Streptavidin (the biotin / avidin system is discussed in more detail in 
section 1.1.2). It was also selected on the basis of its resistance to host cell proteases and 
on its hydrophilicity (Wojczyk etal 1996). It is the hydrophilicity of the tag which ensures
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that it will be expressed as a surface epitope, thus allowing it to be used for both the 
purification and detection of tagged recombinant proteins (Schmidt etal 1996).
Ser. Ala. Trp. Arg. His. Pro. Gin. Phe. Gly. Gly
AGC GCT TGG CGT GAG GGG GAG TTG GGT GGT
Figure 2 ; the amino acid and nucleotide sequences o f the Strep tag.
Tagged proteins can be affinity purified on immobilised recombinant core 
streptavidin affinity columns. Core Streptavidin is an N and C terminally truncated form of 
the mature Streptavidin polyprotein. This truncated form of Streptavidin is used as it has 
been shown that the Strep tag does not efficiently bind to native Streptavidin when used in 
affinity chromatography (Wojczyk er a/ 1996). Elution from a core streptavidin affinity 
column is achieved by the addition of 50 mM diaminobiotin to the wash buffer. Native 
biotin or other biotin-related compounds such as iminobiotin and lysoic acid can also be 
used for elution (Schmidt etal 1996).
The Strep tag can, like the His tag, also be used for the detection of tagged 
recombinant proteins. The binding partner of the Strep tag, Streptavidin, can be radio- or 
chemically-labelled and used in immunoblots and other assays (Wojczyk etal 1996).
There are, however, a number of disadvantages to using this system. The most 
important being that the presence of any biotin in the cell extract significantly reduces the 
efficiency of the interaction between Streptavidin and the Strep tag (Schmidt et al 1996). 
This is because the streptavidin binds to biotin with a higher affinity than the Strep tag. To 
obtain efficient protein purification, all biotin must be removed from the protein extract by 
chelating with avidin. The Strep tag does not bind to avidin, ensuring only the biotin is 
removed (Skerra 1994).
Another disadvantage to using this system is that the tag is only permissible if 
expressed from a prokaryotic expression system. Attempts have been made to express the 
Strep tag from a eukaryotic expression system but the tag does not recognise Streptavidin
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and so cannot be used for affinity purification. Also, the Strep tag can only be fused to the 
C terminus of the target protein, because for Streptavidin binding to occur, there needs to 
be a free C terminal glycine residue (Skerra 1994. Schmidt etal 1996),
Hi. FLAG qffîniiy piirificanon
Another small peptide which is useful for both the affinity purification and detection 
of tagged recombinant proteins is the FLAG'^'’ tag (figure 3). This is an octameric, 
hydrophilic peptide which was specifically designed to ensure that it is exposed for 
detection. This tag was also designed so that the five C terminal amino acids in its primary 
sequence were the consensus sequence for cleavage by the protease enterokinase, ensuring 
easy removal of the peptide, if required (Hopp etal 1988, Georgiev etal 1996).
The FLAG™ tag is recognised by three different mouse mAbs; M l, M2 & 1VI5 
(Sioostra eta l 1996). M l is the mAb which was originally developed to recognise the 
FLAG™ tag sequence. The binding of M l is Ca^+-dependent and requires a free a  amino 
group. This signifies that the tag needs to be after a cleavage site or N terminal to the target 
protein. The chelation of the Ca^+ ions by EDTA, destroys binding. The first three amino 
acids in the tag are essential for antibody binding (Sioostra etal 1996).
Asp. Tyr. Lys. Asp. Asp. Asp. Asp. Lys
GAG TAG AAA GAG GAT GAG GAT AAA
Figure 3 : the amino acid and nucleotide sequences of the FLAG™ tag.
The binding of the mAbs M2 and M5 are Ca^^-independent and they can recognise 
the FLAG' '^* tag when fused to either end or within the target protein. Elution from 
immunoaffinity columns using these two mAbs is obtained by the addition of 0.1 M 
glycine pH 3.0 to the column. As with mAb M l, the first three amino acids in the tag are 
essential for antibody binding (Sioostra etal 1996).
The FLAG^'' tag has been used for the purification of both eukaryotic and 
prokaryotic proteins produced from mammalian (Chu etal 1995), yeast (Hopp e ta l 1988), 
insect (Sioostra etal 1996) and bacterial expression systems (Hopp etal 1988, Mazundar et 
al 1996). Since this tag is recognised by mAbs. it can also be used to study the target 
protein in other applications such as immunoprécipitation, immuno-blotting and 
immunofluorescence.
tv. Other examples o f affinity tags
The affinity tags described in detail in this section of the Introduction are by no 
means the only affinity tags which are available. Many others are the binding epitopes of 
mAbs to specific proteins, for example, the c-myc tag, the influenza haemagglutinin tag, 
and the Pk tag.
The Pk tag is a peptide of 14 amino acids which was developed by our laboratory 
(figure 4; Southern etal 1991, Randall etal 1993, 1994), and is the sequence of a synthetic 
peptide which was used to compete with the binding of the mAb SV5-P-k to the 
Paramyxovirus Simian Virus 5 (SV5) Phospho (P) protein. The mAb SV5-P-k binds to the 
Pk tag with a very high affinity, which makes this tag useful for immunoblotting. 
immunofluorescence and immunoprécipitation (Randall er d  1987. Southern eta l 1991). 
However as denaturing conditions are required for the separation of the mAb from the tag, 
it is generally not used for affinity purification.
pro gly lys pro ile pro asn pro pro leu leu gly leu
A ATT CCA GGA AAG CCG ATC CCA AAC CCT TTG CTG GGA TTG GAC
GGT CCT TTC GGC TAG GGT TTG GGA AAC GAC CCT AAC CTG
ser thr OPA 
TCC ACC TGA 
AGGTGG ACTTTAA
Figure 4 : A DNA linker encoding the Pk tag sequence.
The oligoniicelotides encoding the positive and negative strand DNA sequences of the 
linker coding for the Pk tag were designed to give after annealing EmRI compatible ends.
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The c-myc tag is a peptide of 12 amino acids (figure 5). This tag is an epitope 
recognised by a mAb which was initially raised against the full length c-myc protein. 
Elution of tagged proteins is obtained by the reduction of pH or by an increase of the buffer 
salt concentration.
Met. Glu. Gin. Lys. Leu. lie. Ser. Glu. Glu. Pro. Leu. Lys.
F igure 5 ; A m ino acid  sequence o f  the c- m yc a ffin ity  peptide tag
The influenza haemagglutinin affinity tag was also the epitope of a mAh originally 
raised against the haemagglutinin protein of an Influenza Virus. It is a peptide of 9 amino 
acids (figure 6). The tag can be used for immunoaffinity purification with the elution of 
tagged proteins being controlled by an increase of the salt concentration and/or a reduction 
in the pH of the wash buffer.
Tyr. Pro. Tyr. Asp. Val. Pro. Asp. Tyr. Ala.
Figure 6 : The am ino acid  sequence o f  the in flu en za  h aem agg lu tin in  a ffin ity  
t a g -  _________________________________
Another interesting affinity tag is the Bio tag (Wang eta/ 1996). This works in a 
different way to the other tags as it contains the consensus sequence for the targeting of 
protein biotinylation. Once the tagged protein has been translated, it is targeted for the 
addition of a biotin molecule, which then allows the purification of the tagged protein on a 
streptavidin affinity matrix. The avidin / biotin affinity system is discussed in more detail in 
section 1.1.2 (i) of the Introduction.
V. Glutathione S-transferase affinity chromatography
Glutathione S-Transferase is the most common full length protein to be used for 
fusion protein affinity purification. Glutathione S-Transferase is derived from Schistosoma
1 1
japoniciimmd expressed from many expression vectors, including pGEX-2T and pGEX- 
3X (Smith & Johnson 1988). Glutathione S-Transferase is a 26 kiloDalton (kDa) enzyme 
which binds to a glutathione affinity matrix. Glutathione S-Transferase can be fused to the 
N or C termini of the target protein with no adverse effect on its ability to bind to 
glutathione. Fusion protein elution is obtained by the addition of excess reduced glutathione 
5 mM) to the column (Smith & Johnson 1988).
Glutathione S transferase fusion proteins have been used for the purification of a 
number of eukaryotic proteins, and in most cases the GST increases the solubility of the 
target protein [e.g. Plasmodium falcipajium antigens (Smith & Johnson 1988), the core 
antigens of the human and simian immunodeficiency viruses (Mills et al 1992), human 
papillomavirus type 6 E7 protein (Romanos etal 1995)]. The soluble fusion proteins are 
purified under non-denaturing conditions (Smith & Johnson 1988). In addition, GST can 
be expressed in many systems including bacteria (Mills etal 1992. Ghosh etal 1995), yeast 
(Ward etal 1994, Romanos etal 1995) and insect cells (Boublik etal 1995), and has been 
shown to have no effect on the post-translational modifications (e.g. glycosylation or 
phosphorylation) which can be added to eukaryotic target proteins (Ward et al 1992. 
Romanos etal 1995). This ensures that the post-translational modifications of a protein can 
be studied from GST purified proteins.
As the GST fusion system is a popular expression system, a number of 
commercially available expression plasmids have been adapted for use in bacteria, yeast, 
and insect cells. As with most fusion proteins, E. coli is the most commonly used system 
for GST fusion protein expression, with yields of up to 15 pg of recombinant protein per 
ml of bacterial culture. The two expression vectors pGEX-2T and pGEX-3X have been 
specifically designed for the production of large quantities of GST fusion proteins in E. 
coli. These two plasmids are identical except that pGEX-2T contains genetic sequence for a 
thrombin cleavage site and pGEX-3X contains the genetic sequence for a blood coagulation 
factor Xa protease cleavage site (Smith & Johnson 1988). Both of these cleavage sites are 
situated between the GST and the target protein. The two cleavage sites allow the 
separation of the GST from the target protein, should untagged target protein be required.
1 2
To obtain highly purified untagged target protein, after the initial affinity purification step, 
the fusion protein undergoes cleavage by the relevant protease. The digestion mixture is 
then applied to the affinity column again, but this time only the GST or uncleaved fusion 
proteins are retained, and the target protein passes through for collection. A schematic of 
this protocol can be seen in figure 7.
With GST being a complete protein, monoclonal and polyclonal antibodies have 
been raised to it. This allows the tag to be used for a number of other applications including 
im m unoassays (e.g. immunoprécipitation, immunoblotting and immunoaffinity 
purification) and detection. Glutathione S-T ransferase tags are also being used for the study 
of a target proteins function, the purification of interacting factors to the target proteins and 
to generate antibodies against the fusion proteins (Bar=Pelad & Raikhel 1996, Hengen
1996).
vi. Maltose binding protein affinity chromatography
The maltose binding protein (MBP) is encoded by the gene malE in £. coli. Tagged 
proteins are affinity purified on a crosslinked amylose agarose column and fusion protein 
elution is obtained by the addition of maltose (5-1 mM) to the column. Affinity purification 
must be carried out under non-denaturing conditions (Maina etal 1988, Yang etal 1994).
To obtain the purified protein without the fused MBP, the consensus sequence for 
the blood coagulation factor Xa protease (ile. Glu. Gly. Arg) can be cloned into the 
expression plasmid between the genes of MBP and the target protein. After cleavage, the 
affinity purification step is repeated, but this time only the MBP and uncleaved fusion 
protein is retained. The target protein flows through the column (Maina et al 1988). This is 
identical to the method described for GST (figure 7).
vii. Protein A /  Protein G affinity chromatography
One of the first proteins to be used for the purification of target proteins was the 
bacterial immunoglobulin G (IgG) binding protein. Protein A from Staphylococcus aureus. 
This protein binds to the Fc fragment of IgG molecules from many species of animals, and
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Figure 7 : Schematic diagram of the two step protocol for the purification of 
GST fusion proteinsAdapted from Maina e t a l  1988
has a differing affinity for the different sub-types of IgG (see section 2.2.1; Harlow & 
Lane 1988).
There are a number of advantages to using Protein A as a fusion protein: it is 
proteolytically stable and hydrophilic in nature making it ideal for external display; it is 
highly soluble and appears to increase the solubility of most of the proteins to which it is 
fused; and finally it has the targeting signals required for secretion into the bacterial 
periplasmic space.
Protein A has been expressed and purified from many expression systems including 
E. coli, Saccharomyces cerevisiae, plants, insect cells and mammalian cells (Stahl & 
Nygren 1997). Tagged recombinant proteins are purified on an immobilised IgG affinity 
column and elution is achieved using a low pH buffer (e.g. pH3). This can be harmful to 
the target protein, and is the main disadvantage of using Protein A affinity tags. However, 
from this purification system, 90% purity of proteins has been obtained (Stahl & Nygren
1997).
" Streptococcal Protein G is similar to Protein A but it can bind to serum albumin in 
addition to IgG. One characteristic of Protein G is that it binds strongly to most of the IgG 
subtypes which Protein A binds weakly to (see section 2.2.1). This protein is also 
proteolytically stable, highly soluble (it has a structure similar to Protein A) and can be 
produced in high yields from a bacterial expression system. Protein G is less well studied 
than Protein A, and so far has only been expressed in E. coli and mammalian cell lines. 
Tagged recombinant proteins are purified using either an IgG affinity column or an 
immobilised human serum albumin affinity chromatography. Like Protein A, elution is also 
achieved by lowering the pH of the column (Stahl & Nygren 1997).
Both proteins, and their affinity matrices, are resistant to 0.5 M guanidine 
hydrochloride, which means they can be used for the purification of insoluble proteins, as 
well as soluble proteins (Goding 1986, Harlow & Lane 1988, Stahl & Nygren 1997).
Owing to the ability of Proteins A & G to bind to immunoglobulins, they can also 
be used for the purification of monoclonal and polyclonal antibodies (Harlow & Lane
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1988). This characteristic also means that these tags can be used for immunodetection as 
well as purification purposes.
1.2 Affinity chromatography of a protein using its natural ligand
Although the use of fusion proteins is the most popular way of affinity purifying 
proteins, it is not always practical. The production of fusion proteins depends on the use of 
recombinant DNA technology and the expression of recombinant proteins from a controlled 
expression system. In many cases this is not the most efficient method of obtaining the 
target protein. For example if the protein is a membrane protein, the gene of the protein 
may not have been cloned, or the levels of protein obtained from an expression system may 
be very low (e.g. HIV gp40 in an E. coli expression system; Scopes 1996). If these 
problems arise, it may be more efficient to obtain the target protein from its natural source, 
and to purify it in its native form. If this is the case then in depth knowledge of the 
properties of the protein becomes very important.
In many situations, the target protein interacts with other proteins or biological 
molecules. The most common biological interactions are antibody - antigen complexes, 
enzyme - substrate interactions and agonist - receptor complexes, but these are not the only 
interactions which occur naturally. Described in more detail in this section are the most 
common ways that natural protein interactions have been exploited for the affinity 
purification of target proteins.
i. Biotin /  Avidin
The binding of biotin to the egg white protein avidin, is one of the strongest non- 
covalent interactions found in nature. It has been shown that if the biotin molecule is 
coupled covalently to other macromolecules, it’s binding to avidin is unaffected. This 
makes the interaction between these two molecules useful for a number of biological assays 
(Wilchek & Bayer 1990).
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Biotin is a small, water soluble vitamin (figure 8) required in small quantities for a 
number of cellular processes. Biotin is also the prosthetic group, essential for enzyme 
function, for the carboxylase and transcarboxylase enzyme families, by acting as a 
covalently bound carbon dioxide (CO2) carrier (Dakshinamurti & Chauhan 1990. Wilchek 
& Bayer 1990). In bacteria such as E. coli, biotin is not essential for the function of these 
enzymes. A deficiency in biotin in the diet can cause a number of diseases.
enzyme / target molecule
F igure 8 : the structure o f b iotin .
Avidin was shown in hen egg whites to have a bacteriostatic effect, protecting the 
embryo from bacterial infection. It is a highly specialised glycoprotein which is rarely 
expressed. It is found as a tetramer, with each subunit containing a single biotin binding 
site. Each subunit binds to biotin through four tryptophan residues and a lysine residue 
(Green 1990).
The strong binding of biotin to avidin, and the ability of avidin to continue to 
recognise the biotin even when coupled to a larger protein, has made it an invaluable tool in 
molecular biology. By labelling one or both of the molecules with substances such as gold, 
horseradish peroxidase, alkaline phosphatase, radioactive or fluorescent labels, this 
interaction has been exploited for a number of assays including cytochemical localisation 
studies, protein blotting, immunoassays and gene probing as well as affinity 
chromatography (Wilchek & Bayer 1990a).
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Affinity chromatography using the biotin / avidin system was originally restricted to 
the enzymes which used biotin as a prosthetic group or coenzyme (e.g. Acetyl - CoA 
carboxylase, sodium transport enzyme), the enzymes involved in the metabolism of biotin 
(e.g. biotinilase, biotin holocarboxylase synthetase), proteins which interacted with biotin 
(e.g. avidin, egg-yolk biotin binding protein 1 & 2, nuclear biotin binding protein), or 
proteins which interacted with avidin (Bayer & Wilchek 1990).
The main disadvantage to using the biotin / avidin system for the affinity 
purification of proteins is the high affinity that avidin has for biotin. This makes protein 
elution from an affinity column extremely difficult. Conditions such as 1 M guanidine 
hydrochloride pH2.0, Sodium dodecyl sulphate (SDS) or acetate pH4.0, sometimes with 
the addition of heating, are usually required for elution. However, there are cases, such as 
the purification of acetyl CoA carboxylase, where the addition of excess biotin is sufficient 
for efficient protein elution (Wilchek & Bayer 1990,1990a).
These highly denaturing elution conditions can be overcome by using Streptavidin, 
another biotin binding protein. Streptavidin is an avidin homologue derived from the 
h2icten2iStreptomyces avidinii (Green 1990). This avidin homologue has not been found in 
any other bacterial species. Streptavidin has 33% homology with avidin and like avidin it is 
found as a tetramer, with each subunit having a single biotin binding site. Also like avidin, 
streptavidin binds to biotin through four tryptophan residues. One major difference 
between these two protein is that streptavidin is not glycosylated. This, combined with its 
slightly lower affinity for biotin, makes it ideal for use in biotin protein affinity 
chromatography (Bayer era/ 1990, Green 1990).
Biotin affinity chromatography can be used for the direct and indirect purification of 
proteins. Both purification methods involve the use of a streptavidin - Sepharose affinity 
column. For the direct purification of proteins (figure 9a), the target protein is either a 
biotin derivative (e.g. 2-iminobiotin) or biotinylated. The biotin molecule is directly 
coupled to the protein of interest. The biotin moiety then interacts with the affinity column. 
Elution of the biotinylated protein is by competition with free biotin molecules 
(Krachenbuhl & Bonnard 1990).
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F igure 9 : a schem atic d iagram  o f  the b iotin  - streptavid in  affin ity  
p u rifica tion  system s.a. a directly biotinylated target protein is captured by the immobilised streptavidin. b. indirect purification using the biotin-streptavidin system. A natural binding partner of the target protein is biotinylated and captured by the immobilised streptavidin. The target protein is then captured 
by its binding partner.
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Indirect affinity purification (figure 9b) is achieved using a biotinylated intermediary 
which recognises and binds the protein of interest. This could be any substance which is 
known to bind to the protein of interest, e.g. lectins for glycoproteins, antibodies for 
antigens, receptors for specific ligands. In this case, elution of the protein from the affinity 
column is dependent upon the type of interaction shown between the biotinylated molecule 
and the protein of interest (Wilchek & Bayer 1990a).
/ l  Lectins
The most commonly used method for the affinity purification of glycoproteins is 
lectin affinity chromatography. Lectins are a group of proteins which recognise a specific 
sequence of sugar residues. They were originally derived from plant seeds (e.g. 
Concanavalin A, wheat germ agglutinase) and slime moulds {Dictyostelium discoideum 
discoidin-1) but animal lectins have now been discovered. Lectins were originally 
discovered due to their ability to agglutinate the different human erythrocyte types. They are 
now thought to have many different functions, including the initiation of the proliferation of 
lymphocytes, to facilitate cell-to-cell interactions, and the polarisation and capping of 
phagocytes and other motile cells (Sutton 1993).
Lectins are composed of one or more subunits in the form of multimers. The 
number of subunits, and therefore the size of the molecule, differ for each lectin. A 
summary of the number of subunits found in some of the more commonly used lectins can 
be seen in table 1. A lectin can be composed of either homologous or heterologous 
subunits. If the lectin contains homologous subunits, it may have multiple binding sites for 
a single saccharide. However, if the subunits within the lectin are heterologous, the lectin 
may be able to bind two or three different saccharides (Sutton 1993).
The affinity of lectins for saccharides is weaker than antibody - antigen complexes 
or agonist - receptor complexes (Persson & Jergil 1995), but of sufficient strength for the 
affinity purification of glycoproteins, proteoglycans and glycolipids. For the purpose of 
this review, only glycoproteins will be discussed.
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Lectin
(abbreviation)
molecular weight number of 
subunits
simple sugar 
specificity
metal ions 
required
Concanavalin A 
(ConA) 
(Jack bean)
55 000 2
4
a-D-man > 
a-D-glu > 
a-D-GlcNAc
Ca^+,
Lentil Lectin 
(LCA)
49 000 2 a-D-man > 
a-D-glu > 
a-D-GlcNAc
Soybean Lectin 
(SBA)
110-120 000 4 a-D-GalNAc > 
P-D-GalNAc> 
a-D-Gal
Ca2+, Mn-'*'
Wheatgerm
agglutinin
(WGA)
36 000 2 (|3-D-G1cNAc)3>
(P-D-G1cNAc)2
Ca^+, Mn^+. 
Zn2+
Peanut agglutinin 
(PNA)
120 4 (a p ) (3-D-Gal-(l-3)- 
D-GalNAc > D- 
GalNHz
Table 1 : Biochemical characteristics of some o f the more common lectins used for affinity 
purification. This table also shows the sugar specificity for each lectin, from the simple 
structures recognised by LCA to the more complex oligosaccharides recognised by PNA. The 
table also highlights the different divalent cations necessary for the binding of some lectins to 
the specific saccharides. ConA has a dimer structure under conditions below pH5,5, as a 
tetramer between pH5.6 and 7.0 and as aggregates above pH7.0 (Adapted from Sutton 
1993).
The choice of a lectin for the affinity purification of glycoproteins is dependent 
upon the oligosaccharide-protein linkage. The sugar - moiety is usually bound to the 
protein through one of two linkages; a 0-glycosylation linkage and a N-glycosylation 
linkage.
The O-glycosylation linkage is usually an N-acetylgalactosamine bound to the side 
chains of either serine or threonine residues (figure 10a; Stryer 1988). This form of linkage 
is usually found in mucins and of the common lectins, peanut agglutinin (PNA) and
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Figure 10 : a schem atic rep resen tation  o f the tw o d ifferen t g lycosid ic  
l in k a g e s .a. an O linked glycoprotein; b. an N linked glycoprotein, the asparagine is usually only glycosylated if part of the sequence Asp-X-Ser of Asp-X-Thr.
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wheatgerm agglutinin (WGA) preferentially bind this form of glycoprotein. The 
oligosaccharide tends to be no longer than four sugar units long.
The N-glycosylation linkage is usually between N-acety I glucosamine and the side 
chain of the amino acid asparagine (figure 10b; Stryer 1988). The oligosaccharides bound 
to proteins using this linkage tend to be longer, usually twelve sugar units, and more 
complex with a high mannose content. Of the commonly used lectins, Concanavalin A 
(ConA) and lentil lectin (LCA) bind this form of glycoprotein. The specific affinities each 
lectin has for the specific sugar moiety allows them to be exploited for the purification of 
different groups of glycoproteins.
A number of physiological conditions are important for lectin binding to 
saccharides. For example, the binding is pH dependent and needs to kept at physiological 
levels (pH 6.8 - 7.5). Also in many cases a specific divalent cation is needed for lectin 
binding, usually Mn^+ or Ca^+ (table 1). As binding is not an ionic interaction, high salt 
concentrations do not interfere with the lectin-oligosaccharide interaction. It is beneficial, 
therefore, to use a wash buffer of high salt concentration as this reduces non-specific 
interactions which can occur (Sutton 1993).
The main advantage of using lectins for the affinity purification of glycoproteins is 
the relatively mild conditions which can be used for protein elution. One way of eluting the 
glycoprotein from the affinity column is by chelating the divalent cation necessary for lectin 
binding. Another is by changing the buffer pH to either mildly acidic or mildly alkaline 
conditions. The most commonly used method for glycoprotein elution is competition with 
free mono saccharide s. For example, when using a ConA affinity column, the addition of 
0.5 M a-D-methyl mannoside to the equilibration buffer is sufficient for glycoprotein 
elution (Sutton 1993).
1.3 Affinity chromatography using organic compounds
One of the most recent methods devised for the purification of target proteins is the 
use of reactive textile dyes. It was originally observed that the triazine dye Cibacron Blue
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F3G-A, from blue dextran, bound to the liver enzyme alcohol dehydrogenase (Lowe etal 
1992, Cusack & Beynen 1993). This interaction was thought to be due to the structural 
similarities exhibited between the reactive dye and the enzyme interactant NAD+. Since that 
time a number of other proteins have been purified using Cibacron Blue F3G-A, including 
the ricin A-chain, albumin, numerous coenzyme-dependent enzymes, decarboxylases, 
nucleases, polymerases and hydrolases (Lowe etal 1992). From this original discovery, a 
variety of triazine dyes have been purposely constructed to produce high yields of highly 
purified protein (Garg etal 1996). A summary of the most commonly used dyes and the 
proteins which they have been used to purify can be seen in table 2.
Protein Dye Average Yield (%) Eluent
Alcohol Procion Red HE3B 44 eluted in flow through
dehydrogenase Procion Blue MX4GD 94 NAD+
Ricin A chain Procion Red H3B 
Procion Red HE3B 
Procion Red F1E7B 
Procion Yellow HE4R
all 95 pure NaCl
inositol 1,3,4,5,6- Cibacron Blue 3GA 93 NAD+
phosphokinase
Phosphatidic acid Cibacron Blue F3GA 75 NaCl
phosphohydrolase A
Phosphatidic acid Cibacron Blue F3GA 3 NaCl
phosphohydrolase B
luciferase OrangeA 100 eluted in flow through
glucose-6-phosphate Blue A 71 KCl
dehydrogenase Red A 57 KCl
Red A 47 KCl
placental protein 12 Cibacron Blue 92 eluted in flow through
Table 2 ; A selection of proteins purified using dye affinity chromatography
Table 2 also shows the dyes used for the purification of each protein and the average protein 
yields obtained from the purification process. (Adapted from Garg et al 1996)
The choice of a lectin for the affinity purification of glycoproteins is dependent 
upon the oligosaccharide-protein linkage. The sugar - moiety is usually bound to the
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protein through one of two linkages; a O-glycosylation linkage and a N-glycosylation 
linkage.
The reactive dyes usually consist of a chromophore. which give the dye its 
distinctive colouration, and a reactive group capable of effecting a nucleophilic substitution, 
to allow binding to the protein. The majority of the dyes are anionic although there are 
cationic dyes available, such as the 6-aminohexyl analogue which has been used to purify 
pancreatic kallikrein (Garg etal 1996).
The separation of the proteins from the dyes is achieved in three ways; by 
competition with polymers which form stable complexes with the dyes; using very high or 
very low pH buffers; and by the addition of chaotropic ions to the buffer (Lowe etal 1992, 
Garg etal 1996).
There are a number of advantages to using dye affinity chromatography including, 
the moderate to high selectivity for enzymes, low cost, high reactivity of the dyes making 
them easier to couple to matrices, and their resistance to chemical and biological 
degradation. However, there are two main disadvantages for using dye affinity 
chromatography the cross-reactivity of the dyes to other proteins present in the crude 
extract; and they are generally unsuitable for immobilisation on a resin for column 
chromatography. Triazine dyes are more suited to other forms of partition, such as two 
phase aqueous partition (Garg etal 1996).
2. MONOCLONAL ANTIBODIES
One of the most widely used tools in molecular biology today are antigen - specific 
monoclonal antibodies (mAbs). Monoclonal antibodies have been used in many ways to 
expand the understanding of a number of biological processes. Their usefulness in many 
techniques is because of three properties; their specificity of binding; their homogeneity; 
and their ability to be produced in large quantities. The production of unlimited quantities of 
mAbs is a definite advantage over the use of anti-sera, as is the fact that mAbs can be raised
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against an impure antigen. To produce antigen specific anti-sera, a highly purified antigen 
must be used (Goding 1986, Harlow & Lane 1988).
Any antigen which elicits a humoral immune response can be used for the 
production of mAbs. This means that not only can mAbs be raised against proteins, but 
also against carbohydrates, lipids and nucleic acids (Harlow & Lane 1988). The type and 
purity of the antigen defines the specificity of the mAb and the affinity of the mAb for its 
antigen. The selection of high or low affinity mAbs can usually be controlled during the 
screening process. The use of mAbs also reduces the potential of obtaining cross-reactivity 
between unrelated proteins, although cross-reactivity will occur if a large enough 
population of antigens are screened. It is very rare that an unexpected cross-reaction occurs 
(Goding 1986).
This section of the Introduction details the main protocols for the development of 
antigen - specific mAbs, and also gives details of the most common methods in which 
mAbs are purified.
2.1 Methods of Monoclonal Antibodies Development
Monoclonal antibodies can be developed in a number of ways. The traditional method 
involves the isolation of mAb secreting hybridoma clones. The isolation, care and 
screening of the hybridoma clones is very time consuming. An alternative method involves 
the cloning of the immunoglobulin (Ig) variable (V) genes, and the displaying of the gene 
products on the surface of bacteriophage. Again the screening and expansion of the antigen 
specific mAbs is time consuming. Consequently, it is essential that the requirement of 
mAbs is weighed against the effort made in developing them. The traditional and alternative 
methods of developing antigen - specific mAbs are discussed in more detail in this section.
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2.1 .1  T rad ition a l M ethod
This protocol was developed by Kohler and Mil stein in 1975. They also determined 
that this method could be adapted for the production of mAbs which were specific for any 
antigen. Kohler and Milstein fused the antibody producing cells of mice to MOPC-21 
myeloma cells, and produced a successful hybrid cell line which produced antigen specific 
mAbs. The most common myeloma cell type used today is the SP2/0 cell type. The SP2/0 
myeloma cell type was chosen for its inability to salvage purine nucleotides through the 
salvage pathway, due to it’s lack of the purine salvage enzyme hypoxanthine guanosine 
phosphoribosyl transferase (HGPRT). The salvage of nucleotides is one method that a cell 
has of producing nucleic acids, the other is by de novo synthesis. By exploiting this 
salvage pathway deficiency, a highly effective way of selecting for hybrid cells is 
developed. After cell fusion, if the de novo synthesis pathway is blocked by drugs, such as 
aminopterin or azaserine, then the cell is forced to use the salvage pathway. However, in 
HGPRT deficient cells, this pathway is also blocked, so the cells die. The fused hybrids, 
however, have the intact HGPRT gene obtained from the fused antibody secreting cells, so 
they can grow in the media containing the de novo synthesis pathway blocking drug. The 
unfused mAb secreting cells are mortal and die in tissue culture after a few days. A 
summary of this selection can be seen in figure 11.
The cell fusion process was originally mediated by Sendai virus. Now, however, it 
is easier to use polyethylene glycol (PEG) mediated cell fusion. Polyethylene glycol is 
commercially available and inexpensive to use. It is usually used in a final concentration of 
40 - 50% as below 30% little cell fusion occurs, and above 50% the PEG become toxic to 
the cells (Goding 1986, Harlow & Lane 1988). This method of fusion is still not very 
efficient, with only about 1% of the starting cells becoming fused, with only about 1 in 10-^  
of those forming viable hybridomas (Harlow and Lane 1988). This means that a lot of 
hybridoma colonies need to be screened in order to guarantee obtaining the required amount 
of mAb - secreting hybridoma cells. Hybridoma screening is the most labour intensive part 
of the whole procedure.
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F igure II :  Schem atic d iagram  o f  the procedure used  for the selection  o f  
hybridom a cellsThe myeloma cells are HGPRT deficient and can not grow in the HAT media. The spleen cells contain an intact HGPRT gene but are mortal and so die after a few days. The hybridoma cells have the HGPRT gene from the spleen cells and their immortality from the myeloma cells, so 
they survive in the HAT media.
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The hybridoma clones are usually plated into 96 well microtitre plates. Due to the 
low plating efficiency of the hybridoma clones, this process is usually done in the presence 
of feeder cells such as macrophages. Although the cells attach to the surface of the wells, 
they are not adhesive. The advantage of using hybridoma clones as a way of making mAbs 
is that they secrete the antigen specific mAbs into the tissue culture media in which they are 
grown. This allows easy screening for positive clones. The most popular way of screening 
for positive hybridoma colonies is by antibody capture, usually ELISA. The antigen with 
which the animals were immunised is immobilised on the surface of a microtitre plate. The 
growth media, containing the mAbs, is incubated with the antigen and the mAbs allowed to 
bind. A labelled anti-I g mAb is then used to probe for antibody-anti gen complexes.
Once the positive mAbs have been detected, the hybridoma clones need to be 
subcloned. This is to ensure that the antigen specific mAbs are homologous and were 
secreted from a colony which originated from a single cell. The clones are subcloned by the 
limiting dilution of the hybridoma cell suspension. As with the original round of screening, 
the subcloned colonies need to be screened to eliminate any cells which do not secrete 
antigen specific mAbs. Limiting dilution is not the only method available for subcloning the 
hybridoma clones, but it is the most commonly used as it is quick, convenient and allows 
the direct testing of the tissue culture supernatants. Other methods, such as cloning by 
growth into soft agar, are time consuming and require additional practical steps.
There are two ways of expanding the growth of the hybridoma clones. One is by 
expansion in tissue culture and the other is by injection of the hybridoma clones into the 
peritoneal cavity of same strain mice. Hybridomas grown in tissue culture media produce 
up to 10 ugmT ^  of specific mAbs, whereas hybridomas grown in the ascitic fluid produce 
about 5 - 2 0  rngml'E Although the ascitic fluid method of expansion produces vast 
quantities of mAbs, the mAb containing solutions will also contain other proteins and small 
amounts of host immunoglobulins and so is not suitable for some practical applications.
The protocol described is highly efficient for the production of antigen specific 
mAbs. However, it is time consuming and requires the sacrifice of at least two animals for 
each fusion. The mAbs obtained from this system are highly specific, with binding
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affinities which vary from relatively low affinity (e.g. lO^M) to exceedingly high (e.g. 
IQi^M). The desired affinity of a mAb to its antigen can be selected during the screening 
process. This method of isolating antigen specific mAbs is currently the most popular 
method used. A summary of the stages involved in the whole process can be seen in figure 
12 .
2 .1 .2  P hage D isp lay
Phage display utilises recombinant gene technology to mimic the natural immune 
response. This technique involves the alteration of the pairing between heavy and light 
chain variable domains (Vh and Vl respectively) using V gene libraries.
Initially the Vh and V l genes were amplified, using degenerate primers, by the 
Polymerase Chain Reaction (PGR) from hybridoma clones. The resulting variable pairs 
were manipulated and cloned into a bacterial expression vector to create more stable 
hybridoma clones (McCafferty etal 1990, Winter & Milstein 1991). The soluble antibody 
fragments produced from these pairings were then secreted from the bacteria and screened. 
This method was eventually adapted to include genes directly amplified from the B cells of 
immunised animals.
The screening of the bacteria however, was time consuming as each positive 
bacterial colony had to be individually grown, screened and characterised. To overcome 
this, McCafferty etal (1990) displayed the Vy and V l antibody fragments on the surface of 
the Fd bacteriophage, which allowed the phage particles to be screened by antigen affinity 
chromatography. Rare phage particles (one in 10^) can be isolated in this way. If multiple 
rounds of affinity screening are performed then mAbs of differing affinities can be 
produced. From the first round, a number of antigen binding activities can be detected, but 
few bind with high affinity. After the second round of affinity screening, the binding 
affinities are enriched with strong binders, at the expense of the weak binders.
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Figure 12 : The experimental protocol of the production of antibody 
producing hybridoma clones
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There are two ways of displaying the Vh and V l antibody fragments of the surface 
of bacteriophage Fd, and both involve the fusion of the antibody fragments to the N 
terminus of one of the coat proteins. McCafferty etal fused the Vh and V l fragments to the 
gene III protein product. There are approximately four copies of this protein found within 
the virus particle. However, for cell attachment, a single native copy is required. The 
fusion of the Vh and V l fragments to this coat protein allows the antibody fragments to be 
selected on the basis of affinity. Clackson etal (1991) and Sdderlind et d  (1992) used a 
different coat protein, the Gene VIII gene product. There are estimated to be approximately 
2000 copies of this coat protein in a virus particle. This system is not efficient for the 
selection of antibody fragments on the basis of affinity but is useful for the selection of 
multiple fragments of low affinity which when combined have a high affinity for a specific 
antigen (multivalency). Antibodies displayed on the surface of the phage particles provide a 
faster and more efficient method of selection than bacterial screening.
Phage display technology is a powerful selection system which still needs a source 
of rearranged and affinity matured immunoglobulin genes (Sdderlind et al 1992), which 
can only be obtained from immunised or seropositive animals. If artificial combinatorial 
libraries are used, e.g. the expression of Vh and V l gene libraries in a phagemid vector 
where they can be randomly combined, the size of the libraries becomes restrictive. Only 
10"^  clones are available using this method, which is a small proportion of the natural 
antibody repertoire available (10^^).
One way of overcoming the size of the library, and the use of immunised animals, 
is to use in vitro site specific recombination. Geoffrey etal (1994) developed a system of 
using both phagemid and plasmid technology and the site specific recombination sites 
found within E. coli. Their method involves E. coli being transformed with a plasmid 
encoding a repertoire of V l genes (about 10  ^clones). These transformed bacteria are then 
infected with a phagemid encoding a repertoire of Vh genes (about 10^ clones). For 
recombination to occur, both the plasmid and the phagemid need distinct replicons and alt 
sites. The plasmid also needs to be transformed into a bacterial strain which is susceptible 
to phage infection, and which is capable of expressing the heat-inducible Int recombinase.
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Once recombination occurs, the number of clones available are equivalent to the natural 
immune system. In addition, the produced recombined vector is stable and capable of 
infecting other phagemid susceptible bacteria for the construction of multi-combinatorial 
antibody libraries.
Phage display is a highly versatile process. The antibodies produced can be used in 
the cloning and rescue of hybridomas, and for the screening of other large combinatorial 
libraries (McCafferty etal 1990). It can be also used to change and refine the properties of 
other proteins or peptides which can then be selected by display on the surface of phage 
particles (Clackson Éff a/ 1991, Courtney etal 1995). The main advantage to this method of 
producing antigen specific mAbs over the traditional method is that the selection process. 
As selection can be performed using an affinity column, this allows a more specific mode 
of selection, and allows the selection of lower affinity mAbs. The main disadvantage to 
using phage display for the production of mAbs is when large scale production of mAbs 
for further study are required. The bacteriophage are not as efficient as hybridoma cells at 
producing large amounts of mAb.
2.2 Monoclonal antibody purification
Most mAbs are secreted into a growth media where other proteins are present. In 
order to ensure that there are no unwanted protein - protein cross-reactions when using the 
antibodies in various immunological techniques, the mAbs need to be purified. The method 
of purification depends on the species of animal in which the mAbs were raised, the class 
and subclass of the immunoglobulin from which the mAb is composed and the methods 
used to expand the growth of the hybridomas e.g. ascitic fluids or tissue culture media. The 
homogeneity of the mAbs makes them easier to purify than polyclonal antibodies, and as 
such standard purification protocols can be used (Goding 1986. Harlow & Lane 1988). 
This section of the introduction describes some of the most common ways of purifying 
mAbs.
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2.2 .1  A ffin ity  C h rom atograp h y
The immobilisation of the antigen, to which the mAb was raised, on Sepharose / |
agarose beads is the simplest way of affinity purifying a mAb. Monoclonal antibodies bind j
to the affinity column between pH 4.0 - 7.0, and in a salt concentration of less than 1 M i
(Perry & Kirby 1990, Cusack & Bey non 1993). The elution of the purified mAbs from the 
affinity columns is dependant upon the affinity of the mAb for its antigen. Those mAbs I
with low affinity elute from the column by increasing or decreasing the buffer pH, or by ]
increasing the buffer salt concentration. The high affinity mAbs are more difficult to elute |
from the affinity column, needing denaturing conditions such as 8 M urea or 6 M guanidine 1
hydrochloride (Harlow & Lane 1988, Perry & Kirby 1990). |
Sometimes the harsh conditions used for the elution of the mAbs from the antigen I
affinity column does not make this an ideal way of purifying mAbs. If the mAb comprises 
of immunoglobulin G (IgG), then an alternative method is available.
In section 1.1 (iv) of the Introduction, a method was described for the purification 
of recombinant proteins tagged with either Staphylococcal Protein A or Streptococcal 
Protein G. The affinity column used for the purification of the tagged proteins was an IgG 
affinity column. This can also work in reverse. Protein A or Protein G affinity columns can 
be used for the purification of mAbs containing the IgG subtypes. One problem with this is 
the different binding affinities that the IgG subtypes have for the two bacterial proteins 
(Harlow & Lane 1988). A summary of the variation in binding to Protein A / Protein G 
exhibited by the IgG subtypes can be seen in Table 3.
The binding of the IgG containing mAbs to Protein A or Protein G can be enhanced 
by the physiological conditions of the affinity column. Those subtypes which have a 
relatively high affinity for Protein A can bind under physiological conditions. However, 
mAbs with a relatively low affinity for the bacterial proteins require high salt conditions if 
mAb binding is to occur. The high salt concentration acts to strengthen the hydrophobic 
interactions needed for mAb binding to the bacterial proteins, and therefore, increases the 
strength of binding. Elution of the purified mAbs is achieved by lowering the pH of the
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wash buffer. Purification using this method produces highly pure mAbs (Goding 1986. 
Harlow & Lane 1988, Perry & Kirby 1990, Cusack & Beynon 1993).
Species Affinity for Protein A Affinity for Protein G
human IgGl H—1—1—h + + + +
human IgG2 + + + + H—1—1—H
human IgG3 _j—1—1—1_
human IgG4 H—1—1—h 4—1—1—h
rat IgGl 4-
rat IgG2a + + + +
rat IgG2b 4-4-
rat IgG2c + 4*4'
mouse IgGl + 4—1—1—h
mouse IgG2a + + + + 4-4-4-4-
mouse IgG2b + + + 4-4-4-
mouse IgG3 H—l- 4-4-4-
T ab le 3 : T he P rote in  A an d  P ro te in  G a ffin ities  fo r  v a r io u s  m o n o c lo n a l  
an tib od y  typ es.
key: ++++ - high affinity; + - low affinity; - no binding. (Harlow and Lane 1988)
An alternative method of affinity purifying mAbs is by the immobilisation of anti­
immunoglobulin (anti-Ig) antibodies. The anti-Ig antibodies are covalently bound to 
activated beads (e.g. cyanogen bromide activated Sepharose beads) and the mAb containing 
solution is applied to the column. Elution is obtained by washing the column with a buffer 
of low pH followed by a buffer of high pH (Cusack & Beynon 1993).
The affinity purification of mAbs is recommended for the purification of mAbs 
which are found in low amounts, such as those found in tissue culture media. The highly 
specific nature of affinity chromatography purifies the mAbs efficiently, and without loss 
of the mAb molecules.
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2 .2 .2  A m m onium  su lp h ate  p rec ip ita tion
The precipitation of immunoglobulins using this method is one of the most 
commonly used methods of non-specifically purifying mAbs. It is more commonly used 
for the purification of the high concentrations of mAbs found in ascitic fluid or serum 
(Harris 1993). The concentration of ammonium sulphate used is species dependent. Rabbit 
mAbs precipitate in a 40% saturated ammonium sulphate solution whereas mouse mAbs 
need a 45-50% saturated ammonium sulphate solution before precipitation occurs. To 
overcome these differences, immunoglobulins are precipitated in a standard 50% saturated 
ammonium sulphate solution (Harris 1993).
An advantage of using immunoglobulin precipitation as a method of mAb 
purification is that unlike Protein A / Protein G affinity chromatography, ammonium 
sulphate precipitation is not immunoglobulin specific. A disadvantage to using this method, 
however, is that other high-molecular weight molecules (e.g. proteins) will also precipitate 
out of solution under these conditions, contaminating the mAb solution. Therefore, the 
anunoniura sulphate precipitation of mAbs is usually used as a single step in an overall 
purification protocol.
2.2 .3  Ion - exch an ge ch rom atograp h y
This purification method works on the principle that antibodies have a more basic 
isoelectric point than serum proteins (Scopes 1996). For example, in anion exchange 
chromatography, if the salt concentration of the buffer is raised then the mAbs will be the 
first molecules to be eluted. This property of mAbs has been exploited in two ways. First 
by keeping the pH below the isoelectric point so that the mAb molecules will not bind to an 
anion exchange column (e.g. DEAE-Sepharose) but the serum proteins will. Secondly, by 
keeping the buffer above the pH of the isoelectric point of the mAbs so that they will bind 
to an anion exchange column. By raising the pH of the buffer, the mAbs elute first, leaving 
the other serum proteins bound (Harris 1993, Scopes 1996).
Like ammonium sulphate precipitation there are likely to be serum proteins with a 
similar isoelectric point to the immunoglobulins, and so ion exchange chromatography can
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also not be used for the single step purification of mAbs. When ammonium sulphate 
precipitation is followed by ion - exchange chromatography, highly pure mAbs are 
obtained (Harris 1993).
2.4 Conclusions
Monoclonal antibodies are being used for an ever growing number of practical and 
clinical applications, in both medical and molecular biological research, and as such, have 
become an important tool in biological and immunological techniques.
With their ability to be labelled in numerous ways, their uses have become 
boundless. Monoclonal antibodies can be radiolabelled; labelled with enzymes such as 
horseradish peroxidase, alkaline phosphatase or (3-galactosidase; labelled with biotin; or 
labelled with fluorochromes (Harlow & Lane 1988). All of these labelling techniques have 
allowed mAbs to be used for the detection of many proteins, carbohydrates or nucleic 
acidsT in many different expression systems. Owing to this, much of the information 
currently known about a number of biological processes would not have been determined if 
not for mAbs.
3. HUMAN IMMUNODEFICIENCY VIRUS (HIV)
Since their discovery in the 1980’s, the human immunodeficiency viruses type 1 
and 2 (HIV-2 & HIV-2) have become two of the most studied viruses in medical and 
molecular biological research. The first of the HIV types to be discovered was HIV-1 in 
Los Angeles in the United States of America in 1981. HIV-2 was isolated later in 1986 in 
West Africa and has been shown to be less pathogenic than HIV-1. Also, individuals 
infected with HIV-2 tend to develop AIDS later than those individuals infected with HIV-1 
(Hirsch & Curran 1996). Both of these viruses cause the same depletion of circulating 
helper T lymphocytes, and cause a similar spectrum of opportunistic illnesses in an infected 
individual (e.g. Pneumocystis carinii pneumonia, Kaposis sarcoma, mucosal candidiasis
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and disseminated cytomegalovirus infection). One of the major undertakings involving 
HIV-1 and HIV-2 is the development of a protecting vaccine against HIV infection. To 
achieve this, the structure of the virus and its life cycle need to be fully understood (Hirsch 
& Curran 1996).
The human immunodeficiency viruses, and the related simian immunodeficiency 
viruses (SIV), are members of the lentivirus genus of the Retroviridae viral family. They 
are single stranded positive sense RNA viruses which have enveloped virions. The genetic 
material of the virus consists of two identical strands of positive sense RNA closely 
associated to the nucleocapsid protein, derived from the gag gene. Like most eukaryotic 
RNA strands, the genome is capped at its 5 ’ end and polyadenylated at the 3’ end. There is 
also evidence of the internal méthylation of selected adenine residues within the RNA 
sequences (Luciw 1996).
The virions are spherical in shape and are approximately 110 nm in diameter. The 
virion consists of a lipid bilayer envelope surrounding a cone shaped nucleocapsid core 
(figure 13a). The envelope is composed of the lipid membrane from the host cell from 
which the virus budded, and viral envelope glycoprotein “spikes’’. Each virion particle has 
approximately 72 spikes, which are composed of the two envelope glycoproteins. Each 
spike is 9 - 10 nm long and has a bulbous tip with a diameter of 14 - 15 nm. The spikes are 
used for the attachment of the virus to the cellular receptor of the next target cell to be 
infected (see section 3.2 env). Within the virion shell is the nucleocapsid which contains 
the genetic material of the virus. The nucleocapsid structure is conical in shape and at its 
longest runs the length of the virion. Its width varies from 4 0 -6 0  nm at its widest point to 
20 nm at its narrowest point (Luciw 1996).
3.1 Life Cycle
The infectious life cycle of HIV and SIV can be divided into two distinct phases 
(figure 14). Phase one involves the attachment of the virus to the target cell, uncoating and 
entry of the nucleocapsid into the cytoplasm of the cell (figure 14 (i)). Once in the cell the
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Figure 13 : Schematic representation of the structure of the virus particle (a) and 
the genomic organisation (b) of HIV-2 and SIVThere are small differences between the genomic organisation of HIV-2 I SIV and HIV-1. In the HIV-1 genome, the long terminal repeats (LTR’s) are smaller than those in the HIV-2 I  SIV genomes and the HIV-1 genome does not contain the gene vpx but instead has the gene vpu .
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F igure 14: An overview  o f the life  cycle o f  the the hum an and sim ian  
im m u n od efic ien cy  v iru ses.The life cycle of retroviruses involves a number of processes including (i) targeting of the virus to the cellular receptor and viral entry; (ii) uncoating of the viral particle and reverse transcription; (iii) proviral DNA synthesis and integration into the host genome; (iv) viral mRNA and protein synthesis; (v) viral capsid assembly; (vi) targeting of the envelope glycoproteins and the assembled capsid to the cell membrane; (vii) viral budding through the cell membrane; and (viii) cleavage and maturation of the viral proteins to form the infectious viral particle.
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nucleocapsid disperses, exposing the virai RNA, which is then used as a template for the 
synthesis of, first negative sense DNA and then double stranded (ds) DNA by reverse 
transcription (ii). The dsDNA is then transported to the nucleus where it can either by used 
as a template for the synthesis of viral mRNA or genomic viral RNA, or it can integrate into 
the genome of the cell as a provirus and lay dormant for many years (iii). This first phase 
of the virus replicative life cycle occurs using only those proteins which are present in the 
virion. No viral gene expression is needed (Luciw 1996).
Phase two of the life cycle involves the synthesis and processing of the viral 
genome, viral mRNA’s and finally viral proteins (iv). This is accomplished using the host 
cell’s transcription / translation machinery. Once all viral proteins have been synthesised, 
the new virions begin to assemble (v). The two viral RNA strands are encapsidated by the 
gag gene products, the Nucleocapsid, Matrix, and Capsid proteins. Also found within the 
capsid are the viral Protease, Polymerase and Reverse Transcriptase proteins, and within 
the nucleocapsids of HIV-2 and SIV, the accessory proteins Vpr and Vpx. Simultaneously 
with the formation of the nucleocapsid, is the targeting and accumulation of the envelope 
glycoproteins at the plasma membrane (vi). The completed nucleocapsid migrates to the 
inner surface of the cell membrane where it buds out of the cell, through the plasma 
membrane which becomes integrates as part of the virion envelope (vii). Once out of the 
cell, the viral proteins undergo proteolytic cleavage to produce the fully infectious viral 
proteins (viii), allowing the virus particles to infect other cells, and start the cycle again 
(Luciw 1996).
3.2 Genomic Organisation
The genomic organisation of HIV and SIV is similar to most other members of the 
Retrovirus family (figure 13b). They have the three genes common to all retroviruses, gag, 
pol and env, which encode the viral particle proteins, enzymatic proteins and envelope 
proteins. However, in addition to these three genes are a number of other genes. Other 
Retroviruses have accessory genes, e.g. the tax and rex genes of human T-cell lymphoma
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viruses and B-ceü lymphoma viruses, but no retrovirus has the same number as HIV and 
SIV. Both the HIV and SIV group of viruses have six additional genes, one is a 
transactivator protein which increases proviral replication (tat), one is a regulator of virus 
expression and gene splicing {rev) and the other four are known as accessory proteins. The 
function for some accessory gene products has yet to be determined (Luciw 1996). The 
functions of all HIV/SIV genes are discussed in more detail.
The gag gene encodes the structural capsid proteins which are used to package the 
viral RNA genome into mature virion particles. It is translated late in the life cycle and its 
production is Rev - dependent (see rev). The gag gene is translated as a Pr55§^S 
polyprotein, which then undergoes cleavage by the viral protease into p l7  matrix (MA), 
p24 capsid (CA), p2, p7 nucleocapsid (NC) and the C terminal p6 protein (Luciw 1996).
The MA protein is produced from the 5 ’ end of the gag gene and resolves at 17 - 18 
kDa when analysed by SDS-PAGE. The protein is localised between the virion capsid and 
the envelope of the mature virus particles, and within an infected cell, targets to the cell 
membrane (Luciw 1996). The methionine at the start of the protein is cleaved soon after 
translation and a my ri Stic acid moiety is added, by the cellular enzyme N my ri sty I 
transferase, to the glycine which is now the N terminal amino acid. If this glycine is 
removed then myristylation does not occur. Myristylation is important for the targeting of 
the protein to the cell membrane, as are the first 31 amino acids (Luciw 1996). In addition 
to myristylation, MA is also phosphorylated on serine residues. The purpose of this post- 
translational modification is not known, but it appears to have no effect of protein function.
The MA protein is thought to be involved in viral infectivity. If deletions are made 
in the first two thirds of the MA protein then Pr55?^» polyprotein processing and capsid 
formation are unaffected. However, the incorporation of the Env glycoproteins into the 
virion particles is impaired and the virus particles are not infectious. This suggests an 
interaction with one of the Env glycoprotein subunits, possibly gp41 (Bukrinsky et al
1993).
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The MA protein also functions during the early stages of viral infection. For this 
protein function, an intact C terminus is required. Within the C terminus are a number of 
basic amino acids which act as a nuclear localisation signal to direct the viral pre-initiation 
complex to the cell nucleus (Luciw 1996). If this signal is removed or mutated, the virus 
can integrate and replicate but only in cells undergoing cell division, not in growth arrested 
cells (Bukrinsky a/ 1993).
The capsid (CA) protein is produced from the central portion of the gag gene. When 
resolved by SDS PAGE, the protein appears to be 24 - 27 kDa in size. Capsid protein is the 
major subunit of the viral capsid shell. Within its structure are a large amount of 
hydrophobic residues and like MA, CA is also phosphorylated on serine residues. The role 
for this phosphorylation is unknown (Coffin etal 1996, Luciw 1996).
Within the C terminus of CA is a region of 20 amino acids known as the Major 
Homology Region. This region is conserved in the CA proteins of many diverse 
Retroviruses. Mutations to this area affect virion particle assembly, and deletions to this 
area affect the formation of precursor nucleocapsid. The Major Homology Region is 
thought to be important for viral particle assembly and the infectivity of the virus, not only 
in HIV-1 & 2 and SIV but also in Mason-Pfizer Monkey Virus (Reicin etal 1995).
The N terminus is not well defined, but deletions to this area inhibit virus 
replication. Mutant viruses, with an N terminal deletion in CA, assembled into particles and 
were released as wild type but were not infectious. This lack of viral replication may be due 
to the N terminus of the protein being involved in the interaction with cyclophilins A and B . 
This interaction is unique to HIV-1 and SIVchimpanzee (SIVcpz), no other primate 
lentiviruses have this interaction (Braaten graZ 1996, Thall etal 1994).
The cyclophilins are peptidyl-prolyl isomerases which catalyse a rate limiting step in 
protein folding, and protect the cell from heat shock. Both cyclophilin A and B are 
incorporated into the virions of HIV-1 (and SIVcpz), but not the virions of other primate 
lentiviruses (Franke etal 1994). A proline rich region of 25 amino acids found in the centre 
of the protein is required for cyclophilin binding and incorporation (Franke e ta l 1994), 
specifically aGly-Pro motif (Colgan era/ 1996, Reimer etal 1997). If this Proline residue
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is mutated then the cyclophilin A - CA interaction is blocked, and cyclophilin A is not 
incorporated into the virions (Franke etal 1994), The multimerisation of the CA protein is 
also a required for cyclophilin binding and incorporation, as is the interaction of CA with 
genomic RNA. The incorporation of the genomic RNA is necessary for cyclophilin 
incorporation.
The interaction of CA and the cyclophilins can be blocked by the 
immunosuppressant cyclosporine A or its non-immunosuppressant analogue SDZ NIM 
811 (Thall etal 1994. Franke & Luban 1995, Steinkasserer etal 1995, Franke etal 1995). 
If the interaction is blocked then HIV-1 replication is inhibited, nuclear localisation is 
prevented and proviral integration is inhibited. In contrast, these two drugs had no effect on 
the replication of the viruses SIVmac and HIV-2. These results suggest that the inclusion of 
the cyclophilins into the virion particle is essential for HIV-1 and SIVcpz replication.
The p2 protein is found between the CA and nucleocapsid (NC) proteins of the 
Pr55§^§ polyprotein. The location of this protein is conserved in all primate lentiviruses, 
but not the sequence and length. A deletion of this domain from the Pr55s^s polyprotein 
results in the release of particles which are less infectious than the wild type. When the 
rates of cleavage for the CA-p2 and p2-NC cleavage sites were studied in vitro, the 
cleavage at the CA-p2 site was significantly slower (approximately 40 times slower) than 
that observed at the p2-NC site. This gave a potential function for p2 in the control of the 
sequential processing in vitro, and in infected cells, of the Pr55§^g polyprotein cleavage 
products (Pettit etal 1994).
p2 has an alternative function when still fused to the CA protein. If the CA-p2 
fusion from HIV-1 was substituted for the CA-p2 proteins in SIVmac and HIV-2, then a 
sensitivity to SDZ NIM 811 was conferred, and cyclophilin A was packaged into the 
virions (Dorfman & Gottlinger 1996). This supports the evidence for p2 having a role in 
virion assembly (Pettit etal 1994).
The NC protein is found at the C terminus of the gag gene, and is formed from two 
rounds of protease processing. First a protein of 15 kDa is produced from the processing 
of the Pr55§^§ poly protein. This 15 kDa protein is then cleaved again to form the p7 NC
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protein and the C terminal p6 protein (see later). NC is a basic, hydrophilic protein which 
binds to the viral RNA genome. Each molecule of NC covers 4-6 nucleotides on the RNA 
strand. The main function of NC may be to condense the viral RNA for packaging into the 
mature capsids during virion morphogenesis. Nucleocapsid is not required for the 
production of virion particles (Luciw 1996).
Within the NC structure of HIV-1, there is a central globular domain flanked by 
flexible N and C termini. Within the central globular domain there are two copies of the 
Cys-His motif: Cys-X2-Cys-X4-His-Cys. Within SIV and HIV-2 there is only a single 
copy of this motif. The Cys-His motif is similar to the metal binding domains of many 
proteins which interact with nucleic acids, and a zinc ion has been found within mature 
virion particles. The first Cys-His motif has been shown to be required for RNA 
packaging, but the second is dispensible (Luciw 1996).
The NC protein has been shown to interact with the major packaging site, psi, on 
viral RNA. The binding of NC to the psi sites on two genomic RNA molecules may have 
an influence on the formation and stability of the dimeric form of the viral RNA genome. In 
a similar vein, NC has also been implicated to be involved in the annealing of the tRNAL s 
primer to viral RNA (Luciw 1996).
In addition to the protein functions mentioned, there is preliminary evidence to 
show that NC is involved in the uncoating of the virus during entry, and has an influence 
on the reverse transcription process which occurs in the preinitiation complex (Colgan et al 
1996).
The C terminal p6 protein is the least understood of the proteolytic products of the 
Pr55§^§ polyprotein. It is thought to be involved in the mediation of viral budding from 
infected cells (Reicin etal 1995).
A complete summary of the proteolytic processing of the Pr55S‘^ ? polyprotein is 
shown in figure 15.
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The cleavage of Pr55g^g polyprotein by the viral protease produces the mature structural proteins required for the assembly of the virion particles.
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This gene encodes the enzymatic proteins. Protease, Reverse Transcriptase 
(including RNaseH activity) and Integrase, needed for viral infection (Luciw 1996). These 
proteins are translated as the Prl60 Gag-Pol polyprotein from mRNA, formed by 
frameshifting of the RNA polymerase at the 3' end of gag. Once translated the polyprotein 
is cleaved by the viral protease into its protein constituents. There are four protease 
cleavage sites in the Gag polyprotein and seven protease cleavage sites in the Gag-Pol 
polyprotein (Hirsch & Curran 1996, Luciw 1996).
The first cleavage of the polyprotein releases the Protease protein. It is an 
autocatalytic cleavage that occurs in trans. The Protease protein is about 10 kDa in size, and 
is related to cellular aspartate proteases. The viral protease needs dimérisation for function 
activity, whereas the other aspartate proteases function as monomers. The dimérisation of 
the protease is also essential for viral replication. The active site has been shown by X-ray 
crystallography to be able to accommodate a substrate seven amino acids long. However, 
the cleavage sites can be variable, and are determined by both the primary sequence and 
conformational structure of the protein. A loose specificity for a specific primary sequence 
has been elucidated which involves a hydrophobic residue four amino acids upstream of the 
cleavage site (usually a tyrosine or a phenylalanine) and a proline residue three amino acids 
downstream of the cleavage site. All of the information obtained on the method of action 
and the structure of the pro tease, and its targets, has helped in the development of protease 
inhibitors for the treatment of infected patients (Hirsch & Curran 1996, Luciw 1996).
The Reverse Transcriptase (RT) protein contains two enzymatic activities : the RNA 
dependent DNA polymerase activity, and an RNaseH activity. This protein is cleaved from 
the Prl60 Gag-Pol polyprotein by Protease as a protein with a molecular weight of 66 kDa. 
The enzyme dimerises soon after protease cleavage to form a homodimer. One of the 66 
kDa subunits is then C terminally cleaved, again by Protease, to form the mature RT 
heterodimer consisting of a 66 kDa subunit and a 51 kDa subunit. The p66-p66 homodimer 
is catalytically active as is the mature p66-p51 heterodimer, but a p51-p51 homodimer has 
no catalytic activity (Luciw 1996). Reverse transcriptase acts to synthesise the dsDNA
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provirus from an RNA template. For this, it needs a primer sequence, which the RNaseH 
activity provides. The RNaseH then digests the RNA part of the RNA-DNA hybrid 
produced so that the full length viral DNA can be synthesised. Both of these enzymatic 
activities are needed for viral replication.
Reverse transcriptase also plays a large part in the diversity of the HIV and SIV 
viruses due to its high error rate. This is attributed to the protein having no 3 ’ - 5' 
exonuclease activity to proof-read for mutations. The error rate of RT in HIV types I & 2 
and SIV is 1 error per 1700 - 4000 nucleotides, and even for Lentiviruses this error rate is 
very high. The errors that occur can be due to misincorporation of a nucleotide to give a 
single base mutation, slippage along the strands at repetitive sequences to give deletions or 
insertions, or frameshifts caused by a misalignment of the template primer. All of these 
processes cause the genetic sequence, and sometimes the amino acid sequence, of the virus 
to be constantly changing (Hirsch & Curran 1996, Luciw 1996).
Integrase is a protein 32 kDa in size which mediates the insertion (and excision) of 
the viral provirus into (and out of) the host cell’s genome. For this it has both DNA 
cleavage and DNA ligation activities. This protein is processed by the Protease from the 
Prl60 Gag-Pol polyprotein, and it also acts as a dimer (Luciw 1996). The dimérisation of 
the protein is essential for integrase activity and also incorporation of the protein into the 
viral particles. Integrase also appears to be required for viral replication in some cell lines. 
Within its structure are two conserved Histidine residues and two conserved cysteine 
residues which are thought to be involved in DNA binding as they can form a secondary 
structure similar to the metal binding domain of some DNA binding proteins. It is not 
known what the recognition sequences are within the host cell genome but the integrase 
protein recognises the 6 - 9 nucleotides att sequences found at either end of the linear viral 
DNA (Hirsch & Curran 1996, Luciw 1996).
A complete summary of the proteolytic processing observed for the Gag-Pol 
precursor can be seen in figure 16.
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env
The env gene encodes the envelope glycoproteins found on the surface of the virion 
particle and the plasma membrane of infected cells. The function of the envelope 
glycoproteins (env gp) is the attachment of the virus particle to target cell membrane 
receptors, and to facilitate the entry of the virus particles into the cells by the fusion of the 
virus membrane to the plasma membrane of the targeted cell. The most commonly targeted 
cellular receptor is the CD4 receptor found on the surface of CD4+ T lymphocytes, 
monocytes, macrophages and dendritic cells (Luciw 1996). However, recent research has 
shown that the CD4 molecule alone is insufficient for the promotion of viral fusion. In 
addition to CD4, co-receptors have been discovered which are necessary for viral entry. 
These co-receptors are members of the seven - transmembrane - spanning receptor family 
fusin (Moore et al 1997). In T-lymphocyte - tropic virus strains the co-receptor is 
principally CXCR4 (Chen etal 1997, Moore etal 1997), and for macrophage - tropic virus 
strains the co-receptor is principally CCR5 (Yang etal 1997, Moore etal 1997). This is a 
potential area for further study as it was also determined that the co-receptor function of 
these proteins is inhibited by their natural a  - and p- chemokine ligands (Moore etal 1997).
The env gene is transcribed and translated as a polyprotein of unknown size. The 
gene product undergoes extensive glycosylation which occurs soon after translation and 
which creates the glycoprotein gpl60. This large glycoprotein is then cleaved by the viral 
Protease to give the N terminal glycoprotein gpl20 (gpl20), and the C terminal 
glycoprotein 41 (gp41; Luciw 1996).
Glycoprotein 120 is known as the surface (SU) protein. This is a highly 
glycosylated hydrophilic protein which is found on the external surface of the virion 
membrane and the plasma membrane of infected cells. It is non-covalently attached to gp41 
and it contains the domain for binding to the CD4 receptor. This domain is highly 
conserved and requires the conservation of both the primary sequence (e.g. the 
conservation of amino acids in non-contiguous regions) and the conformational structure 
(e.g. discontinuous epitopes; Luciw 1996, Fox etal 1997). The overall sequence of gpl20 
falls into five variable regions with interspersed conserved regions. These regions are
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prone to attack by neutralising antibodies, with the most targeted being the V3 loop region. 
The V3 region is important for the cytopathicity and cell tropism of the virus and if it is 
mutated, viral infectivity is abolished. As expected there is no sequence homology between 
the V3 loops of HIV-1 and HIV-2. This region is less important for SIV infection (Rizvi 
1992, Fox etal 1997).
Another function of gpl20 is the down-regulation of CD4 from the surface of cells. 
This protein acts in conjunction with, but independently of the other viral proteins, Nef, 
and in HIV-1, Vpu. The exact mechanism of gpl20 induced CD4 down regulation is 
unknown, but gpl20 is thought to bind to CD4 within the golgi apparatus to prevent its 
transport to the cell surface (Sanfridson etal 1994, Luciw 1996).
Glycoprotein 41 is known as the transmembrane (TM) protein and it has three main 
structural motifs. An N terminal hydrophobic region required for the fusion of the viral and 
cellular lipid membranes during virus particle entry. A second, more C terminal, 
hydrophobic region which anchors the protein in the viral membrane or plasma membrane 
of infected cells. The third region is found between these two regions, and outside of the 
cellular / viral membrane. It is a highly conserved hydrophilic region which is thought to be 
involved in protein - protein interactions with other viral proteins, but not necessarily only 
gpl20. Glycoprotein 41 is thought to be directly involved in the budding of the virus from 
the infected cell as well as viral entry (Luciw 1996).
The env glycoproteins of HIV-1, HIV-2 and SIV are all similar. As the envelope 
glycoproteins are exposed to attack from an infected hosts immune system, the virus has 
introduced a high degree of variation into the env gene nucleotide sequence (Luciw 1996). 
Within HIV-1 and HIV-2, there are a number of subtypes or clades, determined by the 
variations which have been observed in the env gene. To date, there are nine clades for 
HIV-1 and five clades for HIV-2. Within each clade there is also intrasubtype 
diversification. This viral diversification is due, in the most part, to recombination between 
the different subtypes found in an individual, or to host transfer. The more hosts the virus 
comes into contact with, the higher the potential diversification (Daniel et al 1992, Cranage 
etal 1995, Luciw 1996).
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Tat is a 10 - 12 kDa protein which is produced from a series of multiply spliced 
mRNA moieties, and is one of the earliest proteins to be produced in the viral cell cycle. It 
is a /7*a«j-activator protein which is found in all Lentiviruses. It is a powerful stimulator of 
long terminal repeat (LTR) directed gene expression, and it is essential for viral growth. Tat 
has been localised to the nucleus, specifically the nucleolus, of infected cells (Kao et al 
1991, Luciw 1996).
Within the structure of the protein there are three essential domains. One is an acidic 
N terminus containing two glutamate residues and one aspartate residue. These residues are 
found on a single face of an amphipathic a-helix, and are essential for Tat’s /ra/w-activation 
function (Steffy & Wong-Staal 1991). The second domain consists of a stretch of seven 
cysteine residues. This domain is thought to be involved in the zinc ion mediated 
dimérisation of Tat. All seven residues, bar one, are essential for Tat function and cannot 
be mutated (Steffy & Wong-Staal 1991). The final domain is found in the C terminus and 
consists of a number of basic amino acid residues. This domain has the ability to act as a 
nuclear localisation signal and is thought to be the part of the protein which interacts with 
the trans-acting response element (TAR) RNA motif (Steffy & Wong-Staal 1991, Luciw 
1996).
The TAR element is an RNA element which is located in the 5 ’ LTR, in a region 
which is transcribed. In HIV-1 and HIV-2, TAR has been mapped to the nucleotides +1 to 
+ 111, although only nucleotides +1 to +42 are essential for a Tat response by forming a 
hair-pin loop secondary structure. The position of the TAR element cannot be moved from 
its current position or altered (e.g. inverted) if Tat function is to be maintained (Steffy & 
Wong-Staal 1991). Within the TAR structure there are two areas that specifically can not be 
altered. One is the sequence CUGGG at position +30 to +34 and the other is the 
trinucleotide bulge found at the base of the hairpin. If any of these structures are altered 
then Tat function is abolished. An alteration in any of the other parts of TAR (as long as the 
secondary structure is not effected) decreases the effect of Tat, but does not abolish its 
activity.
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The TAR element of SIV is slightly different. It is longer and has been mapped to 
sequences +l to +124 (Viglianti etal 1992). Instead of a single hair-pin stem loop, SIV 
TAR forms three. The first loop is similar in sequence and structure to that formed in both 
HIV-1 and HIV-2. In fact they are partially functionally interchangeable, with only a slight 
decrease in HIV or SIV Tat efficiency (Viglianti etal 1992).
The mechanism of action of Tat has been well studied but is far from being 
completely understood. It is thought that it acts at both transcriptional and post- 
transcriptional levels. At the transcriptional level Tat acts as an anti-terminator of RNA 
elongation and also as a promoter of the rate of transcription initiation (Steffy & Wong- 
Staal 1991, Kao etal 1991, Brother etal 1996). This has been supported by the fact that in 
the absence of Tat the rate of initiation is lower than that seen in cells where Tat is present, 
and viral transcripts are prematurely terminated after 60 nucleotides (figure 17),
The mechanism of Tat dependent RNA elongation is not full understood, but Tat’s 
ability to bind to a number of host factors is thought to be involved. One possible 
explanation could be due to a direct interaction between Tat and the TATA binding protein 
(TBP) subunit of Transcription Factor HD (TFIID). The direct effect of Tat on TFHD is 
unknown, but Tat has been shown to stabilise the interaction of TFIID to another 
transcription factor, TFIIA, on the HIV TATA box. TFIIA is necessary for the initiation of 
HIV and SIV transcription (Kashanchi etal 1996). Another explanation is concerned with 
the interaction of Tat to a functional TF1ÏH containing complex. Once Tat binds to this 
complex, it phosphorylates the C terminal domain of RNA polymerase II, thereby 
enhancing the polymerases ability to move further down the DNA, and produce longer 
RNA transcripts (Parada etal 1996).
As stated earlier. Tat also appears to act on a post-transcriptional level by stabilising 
the TAR containing mRNA and allowing it to be translated more efficiently (Kao et al 
1991, Steffy & Wong-Staal 1991). Another interesting function of Tat is it’s ability to 
/7*afT5-activate the gene expression of cellular genes as well as viral genes. One gene whose 
expression has been conclusively proved to be rruÂW-activated by Tat is that which encodes 
Tumour Necrosis Factor (TNF). Within TNF mRNA is a TAR-like secondary structure.
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Figure 17 : Possib le m echan ism  o f  T at induced gene expressionWithout the binding of fat to the Rev response element (RRL), the RNA polymerase stalls and falls off the DNA after transeribing approximately 60  nucleotides. When l at is present, it binds to the RRH and in some way promotes the association of transcription factors to the l A 1A box of the promoter region, promoting the elongation of mRNA synthesis.
This structure could be the reason why Tat can enhance the expression of this gene 
(Brother et al 1996). Tumour Necrosis Factor is found in increasing concentrations in 
infected individuals and has the ability to activate HIV-1 gene expression, and also to 
rescue Tat defective HIV-1 proviruses. Tumour necrosis factor has been shown to effect 
the vascular, immune and central nervous systems of an infected individual. This is a 
potential example of the exploitation of cellular proteins by the virus to increase its own 
gene expression and infectivity, and to induce the onset of disease (Brother etal 1996). In 
addition to this. Tat has been implicated to be involved in T cell death by inducing 
apoptosis, either directly or indirectly.
rev
Viral genes are expressed either early or late in the viral life cycle. Those which are 
expressed early in the life cycle are the non-structural genes tat, rev and nef. These are 
produced as small multiple spliced mRNA moieties of 1 - 2 kb (Luciw 1996). The late 
genes are the structural genes {gag and env), the accessory genes {vif, vpr, vpx and vpu) 
and the pol gene. These genes are produced as singly spliced 4 kb mRNA moieties (Luciw
1996). In addition to the production of mRNA for protein production, the virus also needs 
to produce genomic RNA from the DNA provirus. This is produced as an unspliced 9 kb 
mRNA moiety (Steffy & Wong-Staal 1991, Unger etal 1991). The Rev protein controls 
the differential expression of the viral proteins at the post-translational level by allowing the 
accumulation and utilisation of unspliced and singly spliced viral mRNA (Steffy & Wong- 
Staal 1991).
Rev is a 19 kDa phosphoprotein which is localised to the nucleolus of infected 
cells. There are two motifs within the protein structure which are critical for protein 
function. The first is a short stretch of basic arginine amino acids, situated in the N 
terminus of Rev. These amino acids are important for nuclear localisation and for the 
sequence specific binding of Rev to the cis -acting Rev response element (RRE) RNA motif 
(Steffy & Wong-Staal 1991). The second motif is a leucine rich region found in the C 
terminus. This motif is believed to be a nuclear export signal. The nuclear export signal has
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also been found in the other Lentiviruses Visna Virus and Equine Infectious Anaemia Virus 
(Meyer et al 1996). Within the protein there are two serine residues which are 
phosphorylated, but this phosphorylation does not appear to be necessary for protein 
activity.
The RRE is a 200 nucleotide sequence found within the env gene. It’s sequence 
allows the formation of a complex secondary structure of five stem loops and it is this 
secondary structure which is important for Rev binding. The second stem loop is the most 
important for Rev responsiveness, and if altered abolishes Rev function (Unger etal 1991). 
However, if an RNA structure of similar sequence is substituted, then Rev function is 
restored. The Rev / RRE function can also be replaced in viTi'o by the cis - acting 
constitutive transport element from both the Simian type D Retrovirus and Mason-Pfizer 
Monkey Virus (Rizvi etal 1996). Rev interacts with the RRE as a multimer but it is not 
known if this multimerisation is essential for Rev function (Steffy & Wong-Staal 1991).
Rev also functions to stabilise the transport of RRE containing mRNA molecules 
from the nucleus. This is supported by evidence of decreasing levels of gag, pol and env 
mRNA transcripts in the cytoplasm when Rev is absent. This is also supported by the 
presence of the RRE in unspliced and singly spliced mRNA transcripts (Steffy & Wong- 
Staal 1991, O’Reilly e ta l 1995). As with all viral proteins, the full function, and the 
mechanism of function, of Rev has not been fully determined.
m i
Nef is one of the least understood proteins of the lentiviruses. It is found in all 
primate lentiviruses, though Nef of HIV-2 / SÏV is slightly larger than that of HIV-1. Nef 
is formed from the multiply spliced early mRNA transcripts which are produced in a Rev - 
independent manner. If Nef is deleted, a number of contradictory observations have been 
made which have not been explained. For example, Huang etal {1995) observed that if Nef 
was deleted, then there was a low level of viraemia and a lack of disease progression in 
Rhesus Macaques. However, to contradict this. Miller et al ( 1995) observed that Nef
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deficient viruses were more infectious and had an increased infectivity to a wild type 
control virus.
Nef is a 23 - 27 kDa protein which is found in the cytosol and associated with the 
inner surface of the cell membrane. Like the Pr55§^“ polyprotein. Nef is also myristylated 
on a glycine residue once the first methionine amino acid is removed. Removal of the 
glycine residue abolished myristylation and the attachment of Nef to the cell membrane 
(Luciw 1996). In addition to myristylation, Nef is also phosphorylated on serine and 
threonine residues. In HIV-1 the phosphorylated residues are a threonine at position 15, a 
serine between positions 1 - 35 and a threonine between positions 36 - 86 (Bodéus eta l
1995). The kinase thought to be responsible for this phosphorylation is Protein Kinase C 
(Coates & Harris 1995, Luciw 1996).
In the centre of Nef is a conserved leucine zipper like motif which has a core of 
hydrophobic residues. Within the C terminus of Nef is a highly acidic region stretching for 
over 40 amino acid residues. Within this structure there are two predicted a-helices which 
are separated by a p-linker sequence. This has homology to the activation domains of acidic 
transcriptional activation factors, suggesting that Nef may be part of a class of non-DNA 
binding leucine zipper acidic transcription activation factors (Samuel etal 1991). This has 
now been supported by the discovery that Nef can bind RNA in vitro (Echarri etal 1996). 
The Nef proteins from HIV-1 & -2 and SIV all have this activity.
Within the N terminus of Nef is an acidic region followed by, in HIV-1, many 
repeats of the proline rich motif Pro Xa Xa Pro. HIV-2 and SIV have only a single copy of 
this repeat. This proline rich region is found in proteins which interact with the Src- 
homology region-3 (SH3) domain of cellular proteins which are involved in the mediation 
of signal transduction. The binding of Nef to SH3-containing proteins is specific, e.g. Nef 
has been shown to bind to the cellular proteins Hck and Lyn but not to others of similar 
sequence and structure such as Lck (Saksela etal 1995).
The functions of Nef have yet to be fully understood, but to date at least two 
activities have been described. One is the down regulation of surface CD4 and the other is 
the promotion of viral growth. The effect of Nef on the down regulation of surface CD4
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occurs in lymphoid and non-lymphoid cells. As the levels of CD4 mRNA are not effected. 
Nef must exert its effect post-translationally. The steady state level of CD4 in Nef 
expressing cells is significantly reduced compared to control cells. One hypothesis on Nef 
mode of action is that it promotes the degradation of newly synthesised CD4. As the 
biosynthesis and oligosaccharide processing of CD4 is normal then the effect of Nef must 
occur later in the biosynthetic pathway, possibly in an acidic compartment (Sanfridson etal
1994). It is thought that Nef induces the sorting of CD4 into a cellular compartment where 
it can be degraded. For the down-regulation of CD4, the Nef protein needs to be 
myristylated (Saksela era/ 1995). There are many reasons why the virus would want to 
down-regulate CD4, and with there being three viral proteins which have this function 
(Env, Nef and Vpu), it implies that this is an important prerequisite for viral infection. All 
three proteins act independently of each other, possibly as a fail-safe system so if one 
protein is inactivated there are still two others to complete the task.
For the promotion of viral growth the PxxP motif needs to be active. This sequence 
is dispensible for CD4 down regulation implying that the two functions of Nef are entirely 
separate (Saksela etal 1995). The promotion of viral growth could be due to the interaction 
of Nef to a number of cellular proteins via the PxxP motif. Nef binding proteins have been 
found in both the cytosol and to be membrane associated. Again the myristylation of the 
glycine residue is necessary for the binding of Nef to the membrane associated proteins, 
however the un-myristylated form can still bind to the cytosolic proteins (Harris & Coates 
1993).
Nef may also effect viral growth by having an effect on the initiation of reverse 
transcriptase, Nef defective viruses were shown, in several cell types, to be limited in their 
ability to perform reverse transcription once internalised. This activity could be fully 
rescued if Nef was given in trans. The Nef proteins of HIV-2 and SIVmac could only 
partially rescue Nef defective HIV-1 viruses suggesting that the stimulation of the synthesis 
of the DNA pro virus is partially species specific (Aiken and Traso 1995).
The full function of Nef is unknown, but one suggestion is that Nef may have 
multiple functions within the viral life cycle. This has become more accepted due to the
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discovery of a cleavage derivative of Nef ( a protein of 18 kDa) in virus particles 
(Bukovsky etal 1997). However, as Nef has shown no specific interaction with a virion 
component, Nef may simply be packaged because of its association with the cell membrane 
(Bukovsky etal 1997).
n £
Vif is one of the accessory proteins found only within the Lentivirus genus of the 
Retroviridae family, and is found within all Lentiviruses except the Equine Infectious 
Anaemia Virus. The vz/gene is transcribed late in the viral cell cycle as singly spliced 
mRNA. Its production, like all late genes, is dependent on the function of Rev. The Vif 
protein is a non-glycosylated protein of 23 kDa. It has been shown that 90% of the Vif 
protein produced associates with the cytoplasmic membranes of an infected cell, with the 
other 10% lying within the cytosol (Simon eta l 1997). However, Vif is not an integral 
membrane protein. Within the structure of Vif there are a number of conserved cysteine 
residues, the number of cysteines vary, depending on the virus. For example, within HIV- 
1 there are 2 conserved cysteine residues and within HIV-2 and SIV there are 4 or 5 
conserved cysteine residues. These cysteines are essential for Vif protein function.
The function of Vif, and indeed all accessory proteins, has yet to be completely 
determined. One of the first observations made was that in the H9 CD4+ T-cell line there 
was a 1000 fold reduction in viral infectivity. This gave rise to the theory that Vif was 
involved in virion maturation in a natural infection (Sova etal 1995).
One of the difficulties in the determination Vif function was the different 
phenotypes exhibited by Vif deletion mutant viruses in different cell lines. In some cell 
lines such as the H9 T cell line. Peripheral Blood Lymphocytes (PBL) and Macrophages, 
the Vif deficient mutant virus would not replicate. These cell lines were deemed non- 
permissive. In other cell lines, such as HeLa and COS cell lines, the Vif deficient mutant 
viruses would replicate. These cell lines were deemed permissive. To complicate matters 
further, there are now semi-permissive cell lines (e.g. SupTl & some GEM) where partial 
viral replication is observed (Sova e ta l 1995, Borman e ta l 1995). For the purpose of
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studying the function of Vif, only the infection of non-permissive cell lines by viruses 
containing deletion mutants have been studied.
Vif deletion mutants in non-permissive cell lines have an abnormally shaped virion. 
Instead of the cone shaped virion, it now appears condensed. Initially it was shown that the 
quantity of the Gag, Pol and Env polyproteins within the virion were altered (Borman et al 
1995, Simm etal 1995), but this has since been disproved (Fouchier etal 1996, Bouyac et 
al 1997, Simon etal 1997 & Kotler etal 1997). The presence of an abnormal virion in Vif 
deficient viruses has led to the theory that Vif is involved in the formation of the virus 
particles. This theory has been strengthened by the discovery that the Vif protein has been 
shown, using double fluorescent labelling, to colocalise with the Gag pol y protein at the 
cellular membrane as virion assembly and budding takes place (Simon etal 1997).
However, there is also evidence that the Vif protein may have another function 
which occurs earlier in the virus life cycle. Camaur and Trono (1996) have shown that the 
Vif protein is present in virus particles. It has been estimated that there are between 7 and 
80 molecules of Vif protein present within the virion, significantly less than the amounts 
present in infected cells. This is unusual as virion - associated proteins tend to be found in 
higher concentrations within the virion than in the infected cell. This discovery implies that 
the Vif protein is needed in the early phase of the life cycle, before gene expression is 
initiated. One possible function of Vif is the stabilisation of the preinitiation (nucleoprotein) 
complex immediately after viral entry. In Vif deficient mutants, proviral DNA and genomic 
RNA can not be detected. One explanation is that the preinitiation complexes are 
disassembling prematurely, leaving the exposed DNA and RNA open for degradation 
(Borman etal 1995, Simon etal 1996). This is not seen in viruses where Vif is intact.
The involvement of Vif in the assembly of virus particles has also come a step 
closer to being proved. The Vif protein is not present in the virions of Vif deficient viruses, 
hence the abnormally shaped viral cores.
The actual function of the Vif protein has yet to be fully determined but it has been 
implicated in the assembly and stabilisation of the viral core, the stabilisation of the viral
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preinitiation complex, and recently in the regulation of the viral protease (Kotler a / 1997), 
although more work needs to be done to confirm this.
vgr
The vpr gene is a produced late in the viral life cycle as a single spliced mRNA. Vpr 
is a 15 kDa virion - associated protein which accumulates late in infection (Luciw 1996). 
Vpr deficient mutants have no effect on the replication of HIV-1, HIV-2 and SIV. It is 
localised to cytoplasmic membranes and to the nucleus, inferring that it has a role in the 
targeting of the preinitiation complex to the infected cell’s nucleus (Lang etal 1993, Luciw
1996). Its structure has three distinguishing features, a single conserved cysteine residue, 
the potential for an amphipathic a-helix in the N terminus and an arginine rich region in the 
C terminus (Luciw 1996).
The Vpr protein has been shown to bind to the Gag polyprotein, an interaction 
which is necessary for Vpr incorporation into the virion. For this interaction to occur the 
Gag polyprotein does not need to be processed but an intact p6 protein domain is required 
(Lavallee e ra /1994). The acidic amino acids and the leucine residues within the N terminus 
region are also necessary for this interaction to occur. Any mutations to the leucine residues 
abolishes the incorporation of Vpr into the virion and seriously effects the stability of the 
protein (Mahalingham era/ 1995, 1995a).
Vpr is thought, therefore, to have a number of functions including; the targeting of 
the viral preinitiation complex to the nucleus (Luciw 1996); the promotion of maximal viral 
replication; for the persistence of a high level of viral infection; the progression of disease 
(Lang etal 1993); and the reactivation of the HIV provirus from latently infected T and B 
cell lines (Levy etal 1995, Rogel etal 1995). The complete function of the Vpr protein has 
not been fully determined or understood.
vpx
The vpx gene is highly homologous to the vpr gene (Luciw 1996). Only HIV-2 and 
some SIV strains (e.g. SIVmac) have this gene. It is produced as singly spliced mRNA late
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in the virus life cycle. Vpx is a 14 - 16 kDa virion - associated protein. Like Vpr it has a 
predicted amphipathic a-helix as its N terminal. Within the cell, it is found on the inner 
surface of the cellular membrane (Yu etal 1991, Luciw 1996). For virion incorporation, 
Vpx needs the Pr55?“§ pol y protein or the CA protein. Its presence in the virus particle 
implies that it has a function early in the viral life cycle, before gene expression occurs ( Yu 
etal 1993). Within the virus particle, most of the Vpx protein is localised to the outside of 
the virus core indicating an involvement in viral entry (Yu etal 1993). Vpx is also thought 
to be needed for efficient viral replication.
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vpu is a protein of about 15 kDa which is produced late in the virus life cycle from 
a singly spliced mRNA. It is found only in HIV-1 and SIVcpz, Within the N terminus there 
are 27 hydrophobic residues, with the rest of the protein being hydrophilic. This makes it a 
potential type I integral membrane protein. Vpu is localised to the cellular membrane, and 
has two phosphorylation sites, Ser-52 and Ser-56, where it is phosphorylated by casein 
kinase II (Luciw 1996).
The function of Vpu is one of the best understood of the accessory proteins. It has 
two distinct functions, to facilitate the budding of the virus particles from the infected cell 
(Bour eta l 1996) and the down modulation of the cellular receptor CD4 from the cell 
surface (Luciw 1996). Unlike the Env glycoprotein which binds to the CD4 receptor in the 
endoplasmic reticulum (ER), Vpu causes the rapid and selective degradation of CD4 within 
the ER. It causes a reduction in the life span of the CD4 receptor from 6 hours to 12 
minutes. The down modulation of CD4 receptors is dependent on the phosphorylation of 
Vpu, whereas the mediation of the release of viral particles is only partially dependent on 
protein phosphorylation.
The down modulation of CD4 receptors by Vpu occurs independently of the mode 
of action of the Env glycoprotein and the Nef protein. However, the action of all three 
proteins are needed for the clearance of all CD4 molecules from the cell surface (Chen et al 
1996, Fujita etal 1996).
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A complete summary of the localisation within an infected call and the virion 
particle, and the known functions of all viral proteins is shown in table 4.
3.3 Problems for the development of a vaccine to HIV
Over recent years, the development of a vaccine to HIV has progressed slowly, and 
with little success. Much of information on the method of transmission of HIV, the 
progress of the immunodeficiency disease and the molecular basis of HIV has been 
determined, and yet no vaccine is available. Some of the main difficulties encountered 
when designing a vaccine to HIV are discussed in more detail.
The first problem is the ability of the HIV DNA provirus to integrate into the 
genome of a host cell where it can lie dormant for many years. This makes the provirus 
invisible to the immune system. Also, with HIV being able to pass directly from cell to cell, 
viral transmission can occur without the virus ever being detected by either neutralising 
antibodies or cytotoxic T cells (Tijhaar 1997). To overcome this, a method must be found 
to target integrated proviral containing cells without harming normal uninfected cells (Sabin 
1992).
In addition to proviral integration, HIV and SIV have a high mutation rate due to the 
inaccuracy of reverse transcriptase (RT) during DNA synthesis. This inaccuracy is caused 
by RT having no proofreading activity to correct any mistakes. Owing to this, the genomic 
sequence of HIV and SIV, and the amino acid sequence of the viral proteins, constantly 
change, with the most variable region being the V3 region of gpl20. In addition, HIV-1 
and HIV-2 have a number of subtypes. If using the variability of the env gene to determine 
viral sub-type, for HIV-1 there are nine, and for HIV-2 there are five. A major problem is 
that these subtypes are non- or minimally cross-neutralising (Daniel etal 1992, Cranage et 
al 1995). As this constant changing can not be prevented, an ideal vaccine needs be able to 
be modified or mutate at a similar rate.
Another problem is the location of the initial infection. Most HIV infected 
individuals contracted the virus through the rectal mucous membrane, where the virus can
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Gene Gene Product Location within 
viral particle
Cellular location Protein Function
MA viral matrix cell membrane 
associated
(i) viral particle assembly:
(ii) nuclear localisation of 
the pre-initiation complex: 
(ill) viral infectivity
CA viral capsid cytosolic (i) virus particle assembly:
(ii) incorporation of 
cyclophilin A into HIV-1 
virion particle
p2 unknown unknown (i) control of the rate of 
proteolysis of the gag 
precursor
(ii) virion particle 
assembly and 
incorporation of 
cyclophilin A into virion 
particles
NC nucleocapsid cytosolic (i) packaging and 
condensation of the viral 
genomic RNA into virion 
particles
(ii) possibly virus 
uncoating
p6 unknown viral envelope (?) viral budding
pol Protease nucleocapsid cytosol maturation of viral 
proteins
Reverse
transcriptase
nucleocapsid nucleus synthesis of proviral DNA
Integrase nucleocapsid nucleus intergation and excision of 
the proviral DNA from the 
host cell genome
env Gpl20 envelope extracellular to 
cell membrane
(i) attachment of virus 
particle to CD4 cellular 
receptor
(ii) surface CD4 down 
regulation
Gp41 envelope integral cell 
membrane protein
Entry and budding of 
mature virus particles
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M Tat not vinon associated
nucleolus (i) stimulation of LTR 
directed gene expression 
by promotion of the 
elongation of mRNA 
synthesis
(ii) stabilisation of TAR 
containing mRNA for 
translation
rev Rev not virion associated
nucleolus (i) promotion of mRNA 
splicing
(ii) nuclear export of 
mRNA
Nef not vinon 
associated 
(cleavage product 
found in matrix)
cellular and cell 
membrane 
associated
(i) down regulation of 
surface CD4
(ii) promotion of viral 
growth
Vif matrix cell membrane associated 
although a small 
proportion found 
in cytosol
assembly of virus particle
vpr Vpr nucleocapsid nucleus and cell 
membrane 
associated
targeting of pre-initiation 
complex to nucleus
vpx Vpx matrix inner surface of 
cell membrane
viral entry and replication
vpu Vpu not virion 
associated
perinuclear region 
of the cell 
membrane
(i) facilitate budding of 
virus
(ii) down regulation of 
surface CD4
T ab le 4 : A sum m ary o f the ce llu lar  and v ira l loca lisa tion , an d  the fu n ction  o f  the  
vira l p roteins o f  the hum an im m u n od efic ien cy  virus (H IV ).
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penetrate into the surrounding tissues (e.g. dendritic cells) where the virus can replicate. In 
addition, a number of HIV infected individuals have been found to have HIV proviral DNA 
within the cells of the colon (Joag et at 1996). To prevent viral replication in this initial 
stage of infection, an effective immune response is necessary. However, most current 
vaccine strategies do not induce a protective mucosal immune response (Joag et al 1996. 
Tijhaar 1997).
The final problem encountered when trying to control the replication of HIV and 
SIV, is that they selectively target T helper cells, a cell type which has an important role in 
the immune system. One interesting observation made was that if the immune response of a 
newly infected animal was studied, then a strong humoral and cellular response was 
elicited. This initial immune response, however, did not have the ability to totally eradicate 
the viral infection before it became persistent. In many cases where an individual became 
infected, i.e. by blood transmission or in utero transmission from a mother to the child, 
neutralising antibodies were present which recognised viral proteins, and yet infection still 
occurred. This makes the design of a vaccine more difficult as it is not known what type of 
immune response is needed before protection is obtained. One recent observation is that if a 
T rI type helper T cell response is elicited, rather than a Tr2 type helper T cell response 
then the infection can be prevented. However, if Ty2 type helper T cell response is elicited, 
then infection is not prevented to the same extent (Clerici & Shearer 1993, Ahlers et al
1997). The direction of the initial immune response towards a TrI type helper T cell 
response could aid in the development of a vaccine which gives protection to a cell - 
associated HIV infection.
3.4 SIV infection of Rhesus macaques as a vaccine model for HIV
The infection of Rhesus macaques {Macacamullata) with SIVmac is one of the 
most commonly used animal models for the study of HIV pathogenesis and the testing of 
potential vaccines. Although HIV-1 has been shown to infect chimpanzees and the gibbon, 
these animals do not succumb to an AIDS-like immunodeficiency disease (Tijhaar 1997).
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This makes it impossible to observe the pathogenesis of the disease and to test any potential 
vaccines which are developed.
SIVmac was discovered by Daniel et al in 1985 in captive macaques at the New 
England Primate Research Centre (McClure 1991). As yet no Asian macaques in the wild 
have been found to be infected with SIVmac, and is thought that SIVmac is a derivative of 
the SIV found in Sooty Mangabeys (SIVsmm). When comparing SIVmac to HIV-1, they 
were found to share morphological, biological, serological and molecular properties.
The genomic organisation of SIVmac is similar to HIV-1, but more so to HIV-2. In 
addition there is strong sequence homology. For the whole genomic sequence, SIVmac has 
75% homology to HIV-2 and 40% homology to HIV-1. Like HIV-1 and HIV-2, SIVmac 
also has the ability to undergo genetic variation. When looking at the microscopic 
morphology of SIVmac, it is impossible to distinguish SIVmac from HIV-1 or HIV-2. 
SIVmac has a restricted tropism to CD4+ cells in vitro and has been shown to exhibit 
similar cytopathic effects such as the formation of syncytia. Finally, and most important of 
all, SIVmac is highly virulent and causes a disease in the Rhesus macaque similar to AIDS 
in humans. This is known as simian AIDS or SAIDS (McClure 1991, Joag eta l 1996). 
With the macaques succumbing to an AIDS like disease, it allows the study of viral 
pathogenesis and the testing of potential vaccines for effectivity.
All of the properties described make the infection of macaques by SIVmac an ideal 
model for the study of vaccines against HIV-1 and HIV-2.
4. Objectives of the work
Many of the vaccines developed against HIV and SIV have made use of the 
structural proteins and envelope glycoproteins for the production of an immune response. 
Their location within the viral particle, and their function, make them natural targets for the 
host’s immune system. However, although a vaccine incorporating these proteins does 
produce a strong immune response, to date no protection has been attained. The emphasis 
of vaccine design has therefore turned towards using other viral proteins, such as the
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accessory proteins or the enzymatic proteins, in a vaccine in order to obtain an immune 
response capable of protecting the host from an infectious viral challenge. A number of 
vaccines have been devised which incorporate viral accessory proteins. For example, the 
use of live attenuated virus vaccines (Kestler etal 1990, Daniel etal 1992, Cranage et al
1997), DNA vaccines (Lu etal 1996, Tijhaar 1997) and multiple epitope vaccines (Hanke 
1993, Kent etal 1996). The current vaccine methods favoured by our research group are 
DNA vaccines and multiple epitope vaccines, both of which utilise recombinant DNA 
technology.
The multiple subunit vaccine favoured by the research group are solid matrix 
antibody antigen (SMAA) complexes. A SMAA complex is composed of a antibody- 
antigen complex immobilised on a solid matrix support, usually agarose beads. In view of 
the method in which SMAA complexes are constructed, they can be homogenous (i.e. 
contain many molecules of a single antigenic epitope) or heterogenous (i.e. contain many 
antigenic epitopes; Hanke 1993). This allows the presentation of a number of viral proteins 
withina single multiple epitope vaccine.
For the construction of SMAA complexes, a two step purification system was 
devised. Viral genes were cloned into an expression vector which, when expressed, tagged 
the recombinant protein produced at both termini. The affinity tags most commonly used 
were the hexahistidine tag and the oligopeptide Pk tag, devised by the research group 
(Southern et d  1991, Randall e ta l 1993). A monoclonal antibody was available which 
recognised the Pk tag. The Pk tag - mAb interaction was used as the final step of the 
purification protocol, and as the first stage in the production of the SMAA complexes.
The mAb which recognises the Pk tag binds with an unusually high affinity such 
that denaturing conditions are required to separate them. In order to utilise the two step 
purification system for the purification of Pk tagged recombinant proteins, which are not 
required for incorporation into SMAA complexes, the mAb-Pk tag interaction needed to be 
studied more closely.
The aims of this project were the efficient purification of Histidine and Pk tagged 
recombinant non-glycosylated SIV proteins for incorporation into a multiple epitope
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vaccine other than SMAA complexes. In order to achieve this, a range of mAbs which 
recognised the Pk tag were developed and characterised. In addition, the Pk tag was also 
modified to allow further study of the mAh - Pk tag interaction. Using the newly developed 
anti-Pk mAbs and the modified Pk tag, the original two step purification protocol was 
modified to allow Pk tagged recombinant protein purification from an affinity column.
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Materials And Methods
1. P la sm id s
Plasmid pQ9cPk was derived from the plasmid pQE-9 (Qiagen, Hybaid, Middlesex. 
U.K.). Plasmid pUBS 501 is derived from the pFDX500 (Brinkmann e td  1989). Plasmid 
pBluescript is copyright of Stratagene (Cambridge, U.K.).
2. R ecom bin ant DN A preparation
DNA was isolated from bacterial cells using the lithium chloride alkaline lysis method 
devised by Griff etal (1990). Pelleted cells were resuspended in ice cold GTE (50 mM 
glucose, 25 mM Tris-HCl, pH 8.0, 10 mM EOT A), and lysed with a freshly prepared 
solution of 0.2 M NaOH, 1% SDS. Cell debris was precipitated using a solution of KCl 
(29.4g potassium acetate plus 11.5ml glacial acetic acid in 100ml). The mixture was 
centrifuged at 4000rpm for 10 min and the supernatant removed. DNA was precipitated by 
the addition of 1 volume of propan-2-ol, and pelleted by centrifigation at 7000rpm for 30 
min. After the DNA was resuspended in TE (10 mM Tris-HCl, pH 7.5, 1 mM EDTA), 
4.4M LiCl was added and left on ice to precipitate any RNA present. The mixture was 
centrifuged at 4000rpmfor 15 min and the supernatant removed. DNA was precipitated by 
the addition of 2.5 volumes of ethanol and centrifuged at 7000rpm for 30 min. The pelleted 
DNA was resuspended in TE and 4 units of RNase (Boehringer Mannheim, Lewes, East 
Sussex) were added. After the addition of 10% SDS, the mixture was heated to 70°C for 
10 min before extraction with 1 volume of phenol:chloroform:isoamyI alcohol (100:96:4) 
and precipitation with NaAc and ethanol. The pelleted DNA was then resuspended in TE or 
water to an approximate solution of Img/ml.
3. D N A  link ers and P rim ers
nefFOR 5’ C TAG CTG AAT TCC GCC TTC TTC TAA CCT CTT CCT C-3 ’ 
nefBACK 5’ GTG CAG TGA TCA ATG GGT GGA GCT ATT TCC ATG AGG-3’
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plTFOR 5 ’ C TAG CTG AAT TCC GTA ATT TCC TCC TCT GCC GCT AGA TGG-3’ 
plSBACK 5’ GTG CAG GGA TCC ATG GCA GAA GCC CTG AAA GAG GCC-3’
pGEXc-Pk(I4A) FORWARD : 5'AATT CCA GGA AAG CCG GCC CCA AAC CCT 
TTG CTG GGA TTG GAC TCC ACC TGA-3'
pGEXc - Pk(I4A) BACK : 5'AATT TCA GGT GGA GTC CAA TCC CAG CAA AGG 
GTT TGG GGC CGG CTT TCC TGG-3'
pGEXc - Pk(L8A) FORWARD : 5'AATT CCA GGA AAG CCG ATC CCA AAC CCT 
GCG CTG GGA TTG GAC TCC ACC TGA-3'
pGEXc - Pk(L8A) BACK : 5' AATT TCA GGT GGA GTC CAA TCC CAG CGC AGG 
GTT TGG GAT CGG CTT TCC TGG-3'
pGEXc - P k (L llA ) FORWARD : 5' AATT CCA GGA AAG CCG ATC CCA AAC CCT 
TTG CTG GGA GCG GAC TCC ACC TGA-3'
pGEXc - P k (L llA ) BACK : 5' AATT TCA GGT GGA GTC CGC TCC CAG CAA 
AGG GTT TGG GAT CGG CTT TCC TGG-3'
For sequencing :
pQ9gagPk : 5' AGG ACC CAG CTG TGG ATC T-3'
4. D N A  D igestion s
Restriction enzymes used for recombinant DNA work were purchased from New England 
Biolabs (NEB, Bishop’s Stortford, Herts) or Promega (Southampton), and used according 
to manufacturers recommendations.
5. A garose G el E lectrop h oresis
DNA samples were analysed by horizontal agarose gel electrophoresis. The agarose 
(Flowgen instruments Ltd., Lichfield, Staffordshire, U.K.) was reconstituted in TBE 
(90mM Tris-borate, 2mM EDTA pH8.0) buffer to a final percentage of 1% (w/v). The size 
of the gel was 10 x 10 x 0.5 cm. The DNA samples were mixed 1:5 (v/v) with X6 loading
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buffer ( 15% Ficoll, 0.25% Broraophenol blue - type 400) and then loaded into the wells. 
The DNA was separated at 65 - 85 volts for varying lengths of time, and was stained with 
1 /fg.mh^ ethidium bromide in the gel and buffer and visualised using an Ultra Violet (UV) 
trans-illuminator.
6. R ecovery  o f  DN A from  agarose  gels
The relevant band of DNA, visualised on a UV transilluminator, was excised from the 
agarose gel. The DNA was isolated from the gel using the Qiaquick Gel Extraction Kit 
(Qiagen ), according to the manufacturers recommendations.
7. D N A  liga tion s
50-100ng of cut plasmid vector was mixed with 100-200ng of DNA insert in a total of 
50/4 ligation buffer containing 20U T4 DNA Ligase (Promega). The mixture was 
incubated at 37°C for I hour. The ligation mix was used directly in the transformation of 
competent bacterial cells
S. C om petent B acteria  T ransform ation s
20 - 25/4 of the ligation mix was combined with 50 - 100/4 of E. coli competent cells, XLl 
Blue strain (Stratagene), and stored on ice for 1 hour. The bacteria were heat shocked by 
heating at 42°C for 90 seconds before returning the mixture to ice for a further 90 seconds. 
1 ml Luria broth (LB) was added and the transformation mix placed in a 37°C incubator for 
1 hour. The bacteria were plated onto L-agar plates containing the relevant antibiotic(s) for 
selection.
9. C om petent B acteria  P reparation
Escherichiacoli strain XLl-Blue were made competent using the MgCl2 / CaCl2 method. A 
50 ml culture was grown to an OD^oo = 0 4. The culture was placed on ice and split 
between two 30ml Corex tubes. The cells were pelleted by centrifugation at 5000rpm for 5 
min. The pellets were resuspended in 5 ml sterile O.IM MgCG and placed on ice for 2 min.
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The suspensions were centrifuged again at 5000rpm for 10 min and the pellets resuspended 
in 1 ml sterile O.IM CaC^. The freshly made cells were left for at least 30 min before use.
10. H y b r id isa tio n
60-70 colonies were streaked onto an agar plate and incubate at 37°C overnight. The 
following day a nitrocellulose filter was placed onto the plate for 5 min. The cells which 
had stuck to the nitrocellulose filters were lysed by moistening the filters with lysis buffer 
(0.5M NaOH, 1.5M NaCl), and the NaOH was neutralised by the addition of 0.5M 
Tris/HCl pH 7.5, 1.5M NaCl. The filters were dried and the DNA crosslinked to the filter 
by exposure to UV light. The filters were washed with X3 Sodium chloride /sodium citrate 
(SSC), 1% SDS at 65°C for 1 hour, and then incubated with pre-hybridisation buffer (6X 
SSC, 5X Denhardt's solution, 0.05% sodium pyrophosphate, 0.5% SDS) at 37°C for 1 
hour. The filters were then mixed incubated in hybridisation buffer (6X SSC, IX 
Denhardt's, 0.05% sodium pyrophosphate) containing the radioactive probe at 65°C 
overnight. The DNA template used was dependent upon the hybridisation performed. The 
filters were washed in reducing salt concentrations of SSC/0.05% sodium pyrophosphate, 
and exposed to a phosphorimaging plate for varying lengths of time. Any radioactive signal 
obtained was visualised using a Fujix Bas 1000 Phosphorimager (Fuji).
11. R ad io lab ellin g  o f  probes for  h yb rid isation
The radioactive probe was made using the T 7 Q u i c k P r i m e ™  Kit (Boehringer Mannheim) to 
manufacturers recommendations.
12. Indu ction  o f  pQ 9ne’/P k  and p Q 9gagP k  G ene E xp ression
Cultures of LB containing the relevant antibiotic(s) were inoculated with the bacteria 
containing either pQ9«e/Pk or pQ9ga^Pk and incubated at 37°C overnight. The overnight 
cultures were used as the inoculum for a larger LB cultures, which were incubated at 37°C 
until an OD^oo = 0.4 - 0.6 was reached. Gene expression was induced by the addition of 
IPTG to a final concentration of 1 mM, unless otherwise specified, and the bacterial
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cultures left at 37°C for varying lengths of time. Samples were taken and the cells pelleted. 
The pellets were resuspended in Sodium Dodecyl Sulphate - Polyacrylamide gel 
electrophoresis (SDS-PAGE) loading buffer and analysed by SDS-PAGE.
13. SD S-P A G E  and Im m u n ob lot an alysis
Samples were diluted 3 :1 in SDS-PAGE loading buffer (X4 concentration : 20% glycerol, 
200 mM Tris/HCl pH 7.0, 20% 2-mercaptoethanol, 8% sodium dodecyl sulphate (SDS), 
Bromophenol blue type 400) and boiled for 15 min before loading onto a polyacrylamide 
gel (PAG). The polypeptides were separated on a polyacrylamide gel cross-linked by bis 
-acrylamide and TEMED, in the Bio-rad mini gel system. The polypeptides were either 
stained by Cooraassie Brilliant Blue or transferred to nitrocellulose filters (BDH Laboratory 
Supplies, Poole Dorset, U.K.) using a semi-dry gel electroblotter. The filters were blocked 
in 5% Marvel (Premier Beverages, Adbaston, Staffordshire, U.K.) and incubated with 
monoclonal antibodies in 5% blocking solution ( 5% Marvel, 0.1% Tween 20, 0.14 mM 
NaCl,~"0.02 mM Tris/HCl pH 7.6). The bound antibodies were detected by incubation with 
a horseradish peroxidase (HRP) conjugated anti - mouse Ig mAb (Scottish Antibody 
Production Unit, Carluke, Lanarkshire, U.K.) and enhanced chemiluminescence (ECL).
14. E xp ression  and  N ick el a ffin ity  p u rifica tion  o f  H is-N ef-P k
/î^/gene expression was induced with 1 mM IPTG at 37°C for 1 hour. The bacteria were 
pelleted and the pellet resuspended in TBS buffer (0.3 M Tris HCl, pH 8.0, 0.02 M NaCl). 
Lysozyme was added to a final concentration of 1 m g.m l'f and incubated on ice for 15 
min. Triton X-100 was added to a final concentration of 1% (v/v), the lysates were 
sonicated and centrifuged at 12000 rpm for 30 min. The supernatant was removed and 
incubated with Ni^+-NTA beads for one hour. The resulting heterogeneous mixture was 
used to pack a column. The column was washed with 10 volumes of TBS and the 
recombinant protein eluted with TBS containing 250 mM imidazole. Protein elution was 
detected by spotting a Ipl sample from each fraction collected onto nitrocellulose filters and
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staining with napthalene black. To confirm the purification of His-Nef-Pk, samples were 
analysed on 12,5% SDS-polyacrylamide gels (PAG's).
15. Im m unisation  sch ed u le  for d evelop m ent o f an  im m une resp on se  to the  
PIcth peptide
Six BALB/c mice were injected intraperitoneally with lOpg of a branched peptide 
containing the Pk tag and a Th cell epitope (see figure 28). After 3 - 4  weeks the 
immunisation was repeated. Over the following 21 days samples of blood were taken from 
the mice, by making a small incision in the tail, and the specific serum antibody responses 
studied by ELISA. After the 21 days, the immune response in two of the mice was boosted 
by an intravenous injection into the tail vein. Two to three days later the mice were 
sacrificed by cervical dislocation, and their spleens removed.
16. D evelop m en t o f  m on oclon a l an tib od y  secreting  hybridom a clon es
The two freshly removed spleens were washed with PBS before the tissue was broken up 
by grinding over sterile wire gauze. The cell suspension obtained was centrifuged at 1500 
rpm for 15 min, and the majority of the supernatant removed by pouring. To lyse any red 
blood cells, 0.83% ammonium chloride was added and left to stand for 3 - 5  min. A layer 
of new bom calf serum (NBCS) was carefully added to the bottom of the tube, centrifuged 
at 1500 rpm for 5 min and the supernatant removed. The cells were washed with PBS and 
centrifuged at 1500 rpm for 5 min to remove the NBCS. This process was repeated three 
times. As the splenocytes were being washed, the SP2/0 myeloma cells were prepared by 
pelleting and washing with PBS, and a 50% solution of polyethylene glycol (PEG) 
prepared.
For the fusion, the splenocyte and SP2/0 cells were mixed together in a ratio of 3:1 
(splenocytes : SP2/0), and centrifuged at 1500 rpm for 15 min. All of the supernatant wa 
removed before the 0.5 ml of the 50% PEG solution was added. After a short 45 second 
centrifugation, the cells were once again resuspended in the PEG solution and protein free 
hybridoma media (PFHM) was added over a period of 2 -3  min. The cells were pelleted by
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centrifugation at 1500 rpm for 15 min before being resuspended in PFHM (+/- foetal call 
serum) + HAT media supplement to an approximate concentration of 2 - 4 x 10^ SP2/0 
cells (not including splenocytes) per 100 ml of PFHM. 100 pi of the fused cells suspension 
was plated into each well of a microtitre plate containing macrophages (one week prior to 
the fusion, forty 96 well microtitre plates were seeded with macrophages from BALB/c 
mice) and incubated at 37°C in a humidified incubator in the presence of 5% carbon dioxide 
(COo).
17. Screen ing  o f  m on oclon a l antib ody  secre tin g  hybridom a c lones
Inamunlon-4ELISA plates (Dynatech Laboratories Inc., Chantilly, Virginia, U.S.A.) were 
coated with PBS containing 1% gluteraldehyde and incubated at 37°C for 5 hours. The 
plates were washed with PBS, coated with PBS containing 50 pg of the P k ^  peptide, and 
incubated at 4°C overnight. The wells were blocked with PBS + 10% (w/v) Marvel at 37°C 
for 1 hour, and incubated at 37°C for 1 hour, with tissue culture supernatant taken from 
wells m which the hybridoma colonies were confluent. After washing with PBS, positive 
binding was detected using a HRP conjugated anti mouse I g mAb and a solution of TMB 
(3,3’,5,5’- tetramethylbenzidine; Kirkegaard & Perry Laboratories Inc, Gaithersburg, MD 
20879).
18. Im m u n oflu orescen ce  a n a ly sis
BALB/c cells stably expressing the SV5 phospho (P) protein were plated onto 
immunofluorescence slides, with the expression repressor tetracycline removed, and 
incubated at 37°C overnight. The slides were washed with PBS and fixed for 10 min in 
PBS containing 5% formaldehyde and 2% sucrose. After washing with PBS containing 
1% calf serum and 0.1% azide, the cells were permeabilised by incubating in a solution of 
PBS containing 0.5% NP-40, 10% sucrose and 1% calf serum for 10 min. After further 
washing with PBS +1%  calf serum, the wells were incubated with mAb containing tissue 
culture supernantant for 1 hour at room temperature. After washing, the wells were 
incubated, for 1 hour at room temperature, with a Texas Red conjugated anti-mouse Ig
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mAb. and DAPI (4,6-diamino-2-phenyiindole) for DNA staining. After washing, the slides 
were incubated once again in the fixing solution, before mounting in the anti fading agent 
AF-KCitifluor Products, Canterbury, Kent, U.K.).
19. Iso typ in g  o f  anti-Pk^n m on oclon a l an tib od ies
The isotypes of the anti-PkTu mAbs were determined using a isotyping kit for mouse mAbs 
from Serotec (Oxford, U.K.), using the retailers test procedure.
20. S P O T ’s an a lysis
Membranes containing synthesised peptides (Genosys Biotechnologies, Cambridge, U.K.) 
were blocked for 1 hour at room temperature with the commercially available Blocking 
solution (Genosys Biotechnologies, Cat. No. SU-07-250). The membranes were then 
incubated for 1 hour at room temperature with tissue culture supernatant containing the anti- 
Pk mAbs. After washing, a positive result was developed by incubating the membranes 
with a HRP conjugated anti- mouse Ig mAb and ECL. Once a result was obtained, the 
membranes were regenerated by a 30 min incubation of a solution of 8 M urea, 1% SDS 
and 0.1% (5-mercaptoethanol, followed by a 30 min incubation with a solution of Ethanol, 
water and acetic acid in a ratio of 5:5:1. Finally the membranes were rinsed in PBS +1%  
Tween 20 and stored at 4°C in blocking solution.
21. C ovalent coupling  o f  the Pk^H peptide to a CM S sensor chip
The Pk-m peptide was concentrated on the carboxylated dextran matrix by an ion exchange 
effect at pH below the isoelectric point of the peptide, and covalently coupled via primary 
amine groups. The immobilisation run was performed at a flow of 5pl.min-^ in HBS, pH 
7.4 (10 mM Hepes, 0.15 M NaCl, 3.4 mM EDTA, 0.05% surfactant 20). The 
carboxylated matrix was activated with 30 - 35 p,l of a mixture of N-hydroxysuccinimide 
(NHS) and N-ethyl-N’-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). After 
washing with HBS, PkxH peptide (50jil) at a concentration of 50 pg.mF^ in HBS buffer 
was injected. Unreacted groups were blocked by the injection of30f.il of 1 M ethanolamine
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hydrochloride / NaOH, pH 8.5, followed by 15 pi of 50 mM NaOH to remove covalently 
bound peptide.
22 B iosen sor  ana lys is o f  the in teraction  betw een  the an ti-P k  m A bs and the  
Pk^H peptide
All experiments were carried out on the BIALite (BIACORE AB, Stevenage, Herts, U.K.) 
system. The five anti-Pk mAbs at concentrations ranging from 1.4 nmol to 140 nmol in 
HBS was allowed to interact with sensor surface on which the Pk™ peptide was 
immobilised. The runs were performed at 37°C at a flow rate of 5pl.min"^ during 8 min (40 
pi injection), and a sensorgram recorded all time points and resonance units (RU). After the 
run, the surface of the sensor chip was regenerated using 0.2 M glycine pH 2.8 over 6 min 
(30 pi injection) and 50 mM HCl over 6 min (30 pi injection).
The apparent association and dissociation rate constants and the Equilibrium rate 
constant were calculated according to equilibrium reaction kinetics using BIAevaluation 
software (BIACORE AB). For a full review see Altschuh etal 1992.
23. D o t B lo t ana lys is !
Nitrocellulose filters were incubated with 100 pg.mh^ of His-Nef-Pk or SV5 P protein in |
PBS for 1 hour at room temperature. After blocking with 5% Marvel in PBS the I
nitrocellulose sheets were sandwiched between 84-well Terasaki plates, with 13 pi of anti-
iPk mAb containing tissue culture supernatant per well. After this 1 hour incubation at room ]
temperature, the filters were cut into lengthwise strips so that each strip contained an area ]
which had been incubated with each of the anti-Pk mAbs. Each nitrocellulose strip was I
then incubated for 1 hour at room temperature, with mixing, with one of a number of I
elution buffers. After this time, the strips were washed with PBS before being developed I
!using a HRP conjugated anti-mouse Ig mAb and ECL. |
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24. D e te rm in a tio n  o f  c o n d itio n s  o f  reco m b in a n t p r o te in  e lu t io n  u s in g  
E L ISA  an a lysis
ELISA plates were coated with PBS containing 100 mg.ml'^ of one of the four GST fusion 
proteins and stored at 4°C overnight. The plates were blocked with PBS containing 10% 
Marvel, at 37°C for 1 hour. Each row of wells was then incubated at 37°C for 1 hour with 
a different anti-Pk mAb. After washing with PBS, each column of wells was then washed 
a number of times with a different elution buffer, ensuring that each mAb was subjected to 
the same conditions. The wells were washed again with PBS before being developed with 
a HRP conjugated anti- mouse Ig mAb and TMB. After a set time, usually 5 min after the 
addition of TMB, the reaction was stopped by the addition of 1 M phosphoric acid.
25. C ou p lin g  o f  a n ti-P k  m o n o c lo n a l a n tib o d ies  to  p r o te in  G  S ep h a ro se  
b ea d s
Previously swelled PrG-Sepharose beads (Sigma-Aldrich,Co. Ltd., Poole Dorset, U.K.) 
were incubated with supernatant containing one of the five anti-Pk mAb for 2 hours at 
room temperature. After two washes with 0.2 M borate / 3 M NaCl, pH 9.0, the beads 
were then incubated for 30 min with the borate / NaCl buffer containing 0.02 M 
dimethylpimelidate, the coupling agent. After a further two washes with the borate / NaCl 
buffer, and a single wash with 200 mM ethanolamine, pH8.0, the beads were incubated for 
an hour with 200 mM ethanolamine. The coupled beads were then subjected to two washes 
with phosphate buffered saline (PBS), two washes with 0.2 M glycine pH 2.5 and then a 
further two washes with PBS. The mAb coupled beads were then stored in PBS + 0.1% 
sodium azide.
26. B atch  pu rifica tion  o f  P k  tagged  recom binant proteins
100 jLil of anti-Pk monoclonal antibody coupled Protein G Sepharose bead slurry were 
washed with PBS incubated with one of the GST fusion proteins for 1 hour at room 
temperature. The beads were then washed with PBS before aliquoting into 20pl samples, 
which were washed 3 - 4  times with one of a number of elution buffers. The aliquots were
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washed with PBS before being resuspended in SDS-PAGE loading buffer and analysed on 
a 10% SDS-PAG. The PAG's were stained with Coomassie Brilliant blue type R-250
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RESULTS
1. CLONING, EXPRESSION AND PURIFICATION OF 
RECOMBINANT SIV PROTEINS
Previously in our laboratory, recombinant Simian Immunodeficiency Virus (SIV) 
proteins have been used for the production of multiple epitope subunit vaccines against 
SIV. The recombinant SIV proteins which were incorporated into the subunit vaccines 
were tagged at both ends with small oligopeptide tags, an N terminal Histidine (His) tag 
and a C terminal Pk tag. Together, these two tags allow tagged recombinant proteins to be 
detected and efficiently affinity purified (Hanke et al 1994). Section 1 of the Results 
describes the production and purification of two nonglycosylated SIV proteins, termed Nef 
and Pr55§^g.
1.1 The construction of ^09nef Pk
All the nonglycosylated SIV genes, derived from the SIVmac251 clone BK28, had 
previously been cloned into the expression vector pQ9cPk (figure 18; Hanke etal 1994). 
When expressed, the recombinant proteins were tagged with a His tag and a Pk tag. The 
His tag consisted of 12 amino acids, six of which were histidine residues. The expressed 
His tag has a size of 1.4 kilodaltons (kDa). The Pk tag is a peptide of 14 amino acids which 
when expressed has a size of 2 kDa (see section 1.1 of the Introduction for more details).
New Medical Research Council (MRC) directives on vaccine development stated 
that all vaccines for SIV were to be derived from the infectious J5 molecular clone of 
SIVmac32H. The difference in the primary sequence between the J5 and BK28 molecular 
clones lies exclusively in the last 1.2kb of their genomes. This involves changes to the C
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BamHI
PstI6-Histag EcoRI
IPTG inducible 
promoter ^ ;ktag /H in d lll
pQ9cPk
amp
F igure 18 : p lasm id m ap o f the expression vector wh ich produces 
tagged recom b inant proteins
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termini of the env and rev genes, the whole of the nef gQnQ and all of the 3' long terminal 
repeat (LTR; Rud eta l 1994). For future vaccine studies, the nef gene from the J5 jImolecular clone was cloned into the pQ9cPk expression vector to facilitate the purification j
of the J5 Nef protein. j
1The Mg/gene was amplified by the Polymerase Chain Reaction (PGR) from the J5 j
ISIV molecular clone genomic sequence, using the oligonucleotide primers NefFOR and |
Nef BACK (see Material and Methods). The oligonucleotide primers were designed to |
produce an amplified insert with and £o?Rl compatible restriction sites at the 5 ’ and |
3 ’ ends respectively. The amplified Mg/gene was initially ligated into Bamlil and ÆcoRI |
restriction sites of the expression vector pBluescript to facilitate cloning. The nef insert was j
then excised from pBluescript and ligated into the pQ9cPk expression vector. Figure 19 J
shows the digestion pattern of pQ9Mg/Pk when cut with the restriction endonucleases i1BamWl a n d  EcoRI, w h i c h  c o n f i r m e d  that M g / h a d  b e e n  c l o n e d .  ’
i
]1.2 Expression and purification of His-Nef-Pk '
IThe recombinant Nef protein was expressed as a fusion protein with a His tag at the N ]
Iterminus and the oligopeptide Pk tag at the C terminus (His-Nef-Pk). Both tags have been 1
1shown to have little effect on the immunogenicity of the recombinant proteins they are I
fused to (Takacs & Gerard 1991; Randall etal 1993; Randall etal 1994). This ensures that |
any significant immune response elicited by a multiple epitope subunit vaccine which i
contains recombinant fusion proteins, is due for the most part to the proteins and not the j
oligopeptide tags. {
!
I
1.2.1 O p tim isation  o f  exp ress ion  o f  p Q 9 « e /P k
To confirm that recombinant Nef was produced from pQ9Mg/Pk, E. coli were j
1transformed with the plasmid and expressed by induction at 37“C with 1 mM isopropyl- j
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pQ9Pk
Mg/insert
F igure 19 : The restriction pattern obtained when digesting pQ 9ng/Pk with the 
restriction enzym es Bam H I and EcoRÏ.
pQ9/ig/Pk was digested with the restriction enzymes BamHI and EcoRI at 37°C for 1 hour. The 
mixture was loaded onto a 1% agarose - TBE gel. The DNA was visualised using ethidium 
bromide and UV light
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p-D-thiogalactopyranoside (IPTG), for 2 hours. Total cell lysate (TCL) samples were 
loaded onto a 12% polyacrylamide gel (PAG) and electrophoresed. After transfer to 
nitrocellulose filters, the separated proteins were probed with the anti-Pk mAh SV5-P-k. 
Detection was by enhanced chemi-luminescence (ECL). The result can be seen in figure 20, 
lane a. This confirmed that the Mg/gene had been cloned and that recombinant His-Nef-Pk 
was being produced.
To ensure that sufficient amounts of recombinant protein were produced for protein 
purification and vaccine production, a number of experimental conditions were investigated 
to determine the optimal conditions for the expression of nef.
In many cases, unexpectedly low protein yields have been obtained even with the 
optimisation of the transcription and translation signals. This is especially true for many 
eukaryotic genes which are expressed from prokaryotic systems (Brinkman et al 1989; 
Gutierrez et al 1996). One of the main differences between the genetic sequences of 
eukaryotic and prokaryotic genes is the usage of codons. Some codons which eukaryotes 
target as “major” (i.e. are the most frequently used within many eukaryotic genes), 
prokaryotes target as “minor” (i.e. are the least used codons in prokaryotic genes; 
Brinkman etal 1989: Gutierrez etal 1996). As prokaryotes only have surplus amounts of 
the tRNA molecules which are frequently used in host cell gene expression, the supply of 
charged tRNA’s molecules corresponding to the major eukaryotic codons may be limited 
(Gutierrez etal 1996). If the eukaryotic genes to be expressed contain a large percentage of 
codons which the bacterial expression system determine as "minor", or if many of these 
codons run concurrently within the gene, translation could stall owing to an exhaustion of 
the tRNA supply. This in turn causes a reduction in the amount of full length recombinant 
protein produced (Chen etal 1990; Gutierrez etal 1996).
An example of codons considered by eukaryotes to be major, and prokaryotes to be 
minor, are the arginine codons AGG and AGA (Chen etal 1990; Schenk etal 1995). These 
two codons are considered to be the most minor in E. coli. and yet in many
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N e f
F igure 20 : A W estern B lot show ing the relative am ounts o f H is-Nef-Pk  
recom b inant protein which was produced when various conditions were tried
5ml cultures of E. coli previously transformed with pQ9ne/Pk +/- pUBS520, were grown at 37°C 
until an OD600 of 0.5 - 0.7 was reached. The cultures were induced with 1 mM IPTG for 2 hours. 
1 ml samples were removed and the cells pelleted. The pelleted cells were resuspended in SDS- 
PAGE loading buffer and loaded on to a 12.5% SDS-PAG. The separated proteins were transferred 
to nitrocellulose filters and probed with the anti-Pk mAh SV5-P-k. The blots were developed by 
ECL and visualised on photographic film, 
key : a - pQ9ne/Pk alone; b - pQ9ne/Pk + pUBS520.
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eukaryotic genes, such as HIV gp40, a high percentage of the AGG/AGA arginine codons 
are found. When these genes are expressed in E. coli, the amount of protein obtained is 
very small (Brinkman etal 1989). With SIV and HIV being genetically similar, SIV genes 
may also use codons which would make them susceptible to the production of low protein 
yields in prokaryotes.
To determine whether this was the case. Exoli strain XL 1 Blue bacteria were 
transformed with the expression vector pUBS520. This plasmid contains the dnaY (or 
argU) gene which encodes the tRNAAOA a g g  molecules (Brinkman etal 1989; Schenk etal 
1995). Bacteria containing pUBS520 were made competent and transformed with 
pQ9Mg/Pk to produce double transformants. Bacterial cultures containing both plasmids 
were induced with 1 mM IPTG at 37°C for 2 hours and samples taken for TCL analysis by 
Western blotting (figure 20).
When a comparison of the cultures induced in the presence or absence of the extra 
tRNA molecules was made, approximately a fivefold increase in the amount of protein 
produced was observed in those cultures where the extra tRNA molecules had been present 
(figure 20, lanes a & b). In addition, there were a number of other protein bands in the 
TCL sample where the extra tRNA molecules had been present, which were not observed 
in the sample where the extra tRNA molecules were absent. These bands were thought to 
be degradation and aggregation products of recombinant His-Nef-Pk, due to the large 
amounts of protein being produced.
In addition to the nef gene, other nonglycosylated SIV genes had been cloned into 
the pQ9cPk expression vector and the conditions for the optimisation of gene expression 
determined (Hanke etal 1994). However, at that time, the use of the extra tRNA molecules 
to increase protein production had not been tested.
The expression of the other nonglycosylated SIV genes was performed using 
identical conditions to those used for His-Nef-Pk and the results can be seen in figure 21. 
For some genes the presence of the extra arginine tRNA molecules did not effect the 
amount of protein produced, e.g. rev (lanes Ic & Id) and Npol ( le  & If). For others the 
effect was negligible, only increasing protein production 1 or 2 fold, e.g. rt (lanes la  & lb)
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F igure 21 : W estern blot analysis showing a com parison between the levels o f protein
produced from  bacteria transform ed w ith pQ 9SIVPk and p 0 9 SIV Pk plus pU BS520.
Small scale cultures of bacteria containing either pOQSIVPk or p09SIVPk + pUBS520 were 
induced with 1 mM IPTG, harvested and the pellets obtained resuspended in SDS-PAGE loading 
buffer. Samples were then loaded onto a 12.5% SDS-PAG. The separated polyproteins were 
transferred onto nitrocellulose filters, and the filters probed with the mAh SV5-P-k. The protein 
bands were visualised by ECL.
Key; la  - RT; lb  - RT + tRNA’s; Ic - Rev; Id - Rev + tRNA’s; le - Npol; If - Npol + tRNA’s; Ig - 
Nuc; Ih - Nuc 4- tRNA’s; 2a - Vif; 2b - Vif +  tRNA’s; 2c - Vpx; 2d - Vpx -t- tRNA’s; 2e - Vpr; 2f - 
Vpr + tRNA’s; 2g - Tat; 2h - Tat + tRNA’s; 2j - Prot; 2k - Prot + tRNA’s
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and y //(lanes 2a & 2b) However, nuc showed an approximate tenfold increase in protein 
production when the extra arginine tRNA molecules were present (lanes Ig & Ih).
The length of induction can also effect the levels of protein produced. The longer 
the induction, the more time bacterial proteases have to degrade the recombinant proteins 
once maximal translation has been reached. For the nef gene of the SIV molecular clone 
BK28, the optimal length of induction was 30 min (Hanke etal 1994). After this time, the 
levels of recombinant protein produced did not increase. For the newly cloned J5 nef gene, 
it was important to determine if this was also the case.
Small scale bacterial cultures previously transformed with both pQ9«ejT*k and 
pUBS520 were induced with 1 mM IPTG at 37°C, and samples taken at 0, 30, 60, 120 
and 180 minutes. The TCL samples were separated by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS - PAGE) and analysed by Western blotting (figure 
22i).
When comparing the levels of protein obtained at each time point, it was observed 
that the protein yield increased with time [figure 22 (i)]. However, it was also clear that the 
longer the time of induction, more degradation products were obtained (compare 30 min 
and 180 min lanes). It was also observed that recombinant protein was produced when 
IPTG had not been present (see 0 min lane). This may have been due to insufficient 
repression of the promoter by the L ad  repressor protein. However, as the growth of the 
bacteria was unaffected by this "background" expression, steps to rectify it were 
unnecessary.
Initially, Mé/was induced with 1 mM IPTG. This concentration of IPTG may have 
been far in excess of what was necessary to achieve maximal induction. Small scale 
bacterial cultures containing pQ9né/Pk and pUBS520 were induced at 37°C for 2 hours 
with the following final concentrations of IPTG : 1 mM, 0.5 mM, 0.25 mM, 0.1 mM and 
25 ]aM . Total cell lysate samples for each IPTG concentration were separated by SDS - 
PAGE and analysed by Western blotting [figure 22 (ii)]. A comparison was made of the 
amount of protein obtained for each IPTG concentration. All final concentrations of IPTG
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ii. changing IPTG concentration
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Figure 22 : W estern blot analysis o f bacterial total cell lysates containing the H is-Nef- 
Pk fusion protein
Bacterial cultures were previously transformed with pQ9ne^k and pUBS520. These were then 
induced with IPTG, harvested and resuspended in SDS-PAGE loading buffer. Samples were 
loaded onto a 12.5% SDS-polyacrylamide gel. Once transferred to nitrocellulose filters, the blots 
were probed with the mAh SV5-P-k and developed by ECL.
Key : i. timed inductions with samples taken at 30, 60, 120 and 180 minutes; ii. inductions using 
various concentrations of ITPG; 1 mM, 0.5 mM, 0.25 mM, 0.1 mM & 25 pM.
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gave the same yields of protein. For ail subsequent inductions, a concentration of 25 piM 
IPTG was used.
From the preceding data, it was determined that the optimal induction of nef gene 
expression occurred in the presence of the dnaY gene product, at 3 T C  for 30 min, and 
with a final concentration of 25 pM of IPTG. These optimal conditions were applied to all 
subsequent inductions.
1.2 .2  P u r ifica tio n  o f  H is-N ef-P k
The expressed recombinant Nef protein was tagged at the N terminus by a His tag 
and at the C terminus by the oligopeptide Pk tag. These two tags together provided the 
basis of a two step affinity purification protocol which ensured that only full length 
recombinant proteins were purified (Randall ef a/ 1993; Randall etal 1994). This two step 
purification protocol was initially developed for the production of antibody - antigen 
complexes, specifically solid matrix antibody antigen (SMAA) complexes, to be used for 
immunisation purposes.
The first step in the purification protocol involved the histidines within the His tag. 
The His tag can bind reversibly to nickel (Hochuli e ta l 1987), even when the nickel is 
immobilised on agarose beads (e.g. a Ni^+ - NT A resin). The use of a nickel affinity 
column ensured that only His tagged recombinant proteins bound, and that non-tagged 
proteins were washed through. Elution from the nickel column was achieved by 
competition with relatively high concentrations of imidazole, e.g. 250 mM (see section 
1.1.1a of the Introduction for more details).
The second part of the two step purification protocol uses the mAb SV5-P-k, which 
recognises the Pk tag, immobilised on Sepharose - Protein A beads. When the eluant from 
the nickel affinity purification step was passed through the immuno-affinity column, only 
full length recombinant proteins containing both the N terminal His tag and the C terminal 
Pk tag were retained. Elution of recombinant proteins from this column is difficult because 
SV5-P-k binds to the Pk tag with a high affinity (Randall etal 1993; Randall etal 1994). 
This makes the two step purification protocol ideal for the production of antibody - antigen
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complexes which can then be used as SMAA complexes. However, as this experiment did 
not require antibody - antigen complexes, the immuno-affinity purification step was not 
used to purify His-Nef-Pk recombinant protein.
Bacterial cultures expressing His-Nef-Pk were optimally induced with IPTG, as 
described in section 1.2.1. The cells were lysed using lysozyme and Triton-XlOO, 
sonicated and centrifuged. The soluble protein fraction was mixed at room temperature with 
Ni^+-NTA beads and the resulting heterologous mixture was used to pack a column. After 
washing with PBS, the bound proteins were eluted with a solution containing 250 mM 
imidazole. Samples were taken at each stage of this procedure and analysed by Western 
blotting (figure 23). As can be seen in lane c, His-Nef-Pk recombinant protein was eluted 
from the nickel affinity column. However, when comparing to the TCL sample shown 
(lane a), not all of the protein which was bound to the column was eluted. This was 
confirmed when studying a sample of the nickel beads after protein elution (lane d). From 
this analysis, it was estimated that approximately 70% of the bound protein was eluted.
1.3 The Construction of p 09m g Pk
Previously, the genetic sequences for the structural proteins p l5 , p l7  and p27 had 
been cloned into the expression vector pQ9cPk (Hanke etal 1994). In order to simplify the 
purification of the structural proteins, the gag gene was cloned into the expression vector 
pQ9cPk. The gag gene encodes the Pr55§^§ polyprotein from which the structural proteins 
are derived. This meant that in order to obtain purified structural proteins, only a single 
recombinant protein needed to be synthesised and purified, instead of three.
The gag sequence was amplified by PGR from the SIVmac32H J5 molecular clone 
using the primers 17F0R and 15BACK (see Materials and Methods). The oligonucleotide 
primers were designed such that 17FOR contained a BamHI compatible restriction site and 
15BACK contained an EcoRI compatible restriction site. This created an amplified insert 
with a 5 ’ BamHI compatible restriction site and a 3 ’ EcoRI compatible restriction site. To 
aid cloning, the insert was ligated into the BamHI and EcoRI restriction sites of the vector
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a c d
F igure 23 : W estern blot analysis o f the protein fractions collected during the Nickel 
chelate purification o f His-Nef-Pk.
500 ml bacterial cultures which had previously been transformed with pQ9«e/Pk & pUBS520, 
were induced at 37°C for 30 min with 25 pM IPTG. The cells were lysed and centrifuged, and the 
soluble protein fraction incubated with Ni-NTA beads for 1 hour. After washing with PBS the 
bound protein was eluted with 250 mM imidazole. Samples were collected at each step of the 
procedure and loaded onto a 12.5% PAG. The separated proteins were transferred to nitrocellu­
lose filters and probed with the mAh SV5-P-k
a - total cell lysate; b - nickel beads before elution; c - eluted recombinant protein; d - nickel beads 
after elution
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pBluescript. However, when excising the gag insert from pBluescript, it was noticed that 
the insert contained an internal BamHI site. This made it impossible for the second ligation 
into pQ9cPk to be carried out in a single step. The transfer of the gag gene from 
pBluescript to pQ9cPk was, therefore, carried out in two stages. Initially, the 3 ’ BamHI /
EcaRI fragment was ligated into the relevant restriction sites of pQ9cPk, and then using a 
partial digest from the pBluescript expression vector, the 5’ BamHI / BamHI fragment was 
ligated into the BamHI restriction site of pQ9cPk, and in front of the previously ligated 3 ’ 
fragment. However, when sequencing was performed to verify the orientation of the 5' 
insert, it was discovered that the insert had been ligated in the incorrect orientation (see 
figure 24). To rectify this, the second step of the ligation was repeated. To ensure the 
correct orientation of the insert, the plasmid vector was dephosphorylated prior to the 
ligation of the insert. Restriction digestion of the gene confirmed that the gene had been 
cloned (see figure 25), and sequencing of the gag gene confirmed the orientation (data not
1shown). II
1.4 Expression and purification of the His-Pr55g^g-Pk polvprotein j
iI
As with n e f the recombinant protein produced from the gag gene was tagged at the 
N terminus with a His tag and the C terminus with the Pk tag. This protein was known as 
His-Pr55§^§-Pk.
1,4.1 O p tim isation  o f  the exp ression  o f  p Q 9gogP k
In order to confirm the orientation of the BamHI / BamHI insert and to ensure that 
recombinant protein was being produced from the pQ9gagPk expression vector, E. coli 
were transformed with pQ9gagPk. Expression was induced with 1 mM IPTG, at 37“C for 
3 hours. Total cell lysate samples were loaded onto a 12% PAG and analysed by Western 
blotting. The nitrocellulose filters were probed with the anti-Pk mAb SV5-P-k, and 
detection was by ECL (figure 26).
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1.
G A T c
11.
5 ’ - G ATATTGC AGG A AC A ACTAGTTC AGTAG ATG A AC A A ATCC AGTGG ATGT
3’ - CTATAACGTCCTTGTTGATCAAGTCATCTACTTGTTTAGGTCACCTACA
A AG AC A AC AG A ACCCC ATACC AGTAGGC A AC ATTTAC AGG AG ATGG ATCC -3 ’
TTCTGTTGTCTTGGGGTATGGTCATCCGTTGTAAATGTCCTC TACCTAGG - 5’
F igure 24 : a sequencing gel (i) and correspond ing DNA sequence (ii) showing that 
initial attem pts to clone gag resulted in the 5 ’ BamHI /  Bam HI insert being ligated in 
tbe incorrect orientation.
The nucleotides shown in bold indicate those shown on the sequencing gel. The nucleotides 
underlined correspond to the BamHI restriction site
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BamHI/EcaRI insert 
BamHI/BamHI insert
Figure 24 : The restriction pattern obtained when d igesting pQ 9gagPk with the 
restriction enzym es Bam H I and EcdRl.
pQ9gagPk was digested with the restriction enzymes BamHI and EcoRI at 37°C for 1 hour. The 
mixture was loaded onto a 1% agarose - TBE gel. The DNA was visualised using ethidium 
bromide and UV light.
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As can be seen recombinant protein was produced, and because the protein 
produced was of the correct size, it was determined that the 5' BaiwHI / BamHI insert had 
been ligated into the plasmid vector in the correct orientation.
As with His-Nef-Pk, a number of experimental conditions were tested to determine 
optimal conditions for the induction of gag. From the experiments performed, it was 
determined that optimal gene expression was obtained when pQ9gagPk was induced with 1 
mM IPTG, at 26°C, for 3 hours. The presence of extra tRNA molecules had no effect on 
protein yield.
1 .4 .2  P u r ifica tio n  o f  H is-P r55g^g-P k
The induction culture volume was increased, and gene expression induced using 
the conditions described in section 1.4.1. The pelleted cells were lysed with lysozyme and 
Triton X-100, sonicated and centrifuged. The soluble protein fraction was removed for 
further analysis.
The soluble protein fraction thought to contain His-Pr55S^g-Pk was mixed with 
Ni2+_NTA beads for 1 hour and the heterologous mixture used to pack a column. As with 
His-Nef-Pk, 250 mM imidazole was used for elution. Unfortunately, no protein elution 
was detected (data not shown). One unusual observation made was that protein was 
detected binding to the column, but once elution was attempted, this protein was no longer 
detectable. The reason for this was unclear, and has not yet been explained.
As insufficient protein was obtained from this purification step for either 
immunisation studies, or the second purification step, it may therefore be more efficient to 
express and purify the structural proteins individually rather than to try and obtain sufficient 
expression and purification from the whole gag gene.
1.5 Conclusions
The purified His-Nef-Pk was used, in collaboration with E. Tijhaar, to produce 
anti-sera in rabbits. Figure 27 shows a Western blot in which untagged SIV Nef was
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F igure 26 : W estern blot analysis showing the production o f His-Pr55gagPk after the 
induction o f pQ9^agPk
Small cultures of E. coli which had previously been transformed with pQ9gagPk were induced 
with 1 mM IPTG at 37°C. Samples were taken after 0, 1 and 2 hours. The pelleted cells were 
resuspended in SDS-PAGE loading buffer and loaded onto a 12.5% PAG. After transfer to a 
nitrocellulose filter, the proteins were probed with the anti-Pk mAh SV5-P-k and visualised by 
ECL.
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Figure 27 : W estern blot showing the detection o f untagged recom b inant SIV N ef by 
the developed N ef anti-sera
Bacteria containing the expression vector pQ9n /^7Pk were induced with 1 mM IPTG at 37°C for 1 
hour. Samples were taken and the cells pelleted. The pelleted cells were resuspended in SDS- 
PAGE loading buffer and loaded onto a 12.5% PAG. After transfer to a nitrocellulose filter, the 
protein was probed with the Nef anti-sera. Protein was detected using and anti-rabbit conjugate as 
the secondary antibody and ECL.
Key : a - uninduced sample; b - sample induced with IPTG.
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probed with the rabbit anti-sera obtained. Both the purified His-Nef-Pk, and the Nef anti­
sera, that were generated in this project have been used for a number of different purposes 
by a variety of research groups. Samples of purified protein and Nef anti-sera have been 
sent to the Medical Research Council to be used for a number of purposes.
The purified Nef has been used to generate mAbs to Nef (K. Kent, personal 
communication), and as an antigen in T lymphocyte proliferation assays to produce an 
immune response in SIV infected macaques.
In addition, the recombinant Nef was incorporated into multivalent SMAA 
complexes for immunisation / protection studies. Unfortunately, although the animals made 
an antibody and cell mediated immune response to the recombinant SIV proteins within the 
vaccine, they were not protected upon challenge (J. Stott, personal communication).
2. DEVELOPMENT, SCREENING AND 
CHARACTERISATION OF MONOCLONAL ANTIBODIES 
RAISED TO THE Pk TAG
The failure to induce protective immunity in macaques was disappointing. 
However, it was felt that perhaps recombinant proteins presented with a different adjuvant 
may be more successful. The problem was that the two tag purification system developed 
was only capable of producing antibody - antigen complexes because of the high affinity of 
the SV5-P-k monoclonal antibody for its tag. Consequently, it was decided to develop a 
number of monoclonal antibodies with differing binding affinities to the Pk tag, in the 
expectation that the resulting mAbs may be used in immuno-affinity column 
chromatography. This would enable Pk tagged recombinant proteins to be used for a 
number of procedures, for which SV5-P-k had been unsuitable. This section of the Results 
chapter describes the generation of additional mAbs to the Pk tag, their characterisation, 
and initial attempts to further develop the Pk tag for purification purposes.
1 0 0
2.1 Immunisation, development and screening of mAb-secreting 
hvbridomas
2.1 .1  Im m u n isa tion  sch ed u le  for the develop m en t o f  an a n t i-P k ^  im m une  
resp on se  Six BALB/c mice were primed by injection with lOpg of a peptide 
containing the Pk tag. If a peptide as small as the Pk tag is to generate an immune response, 
without the aid of a carrier protein, it must contain a helper T cell epitope (McLean et al 
1992). A peptide complex was constructed which contained the Pk tag amino acid sequence 
fused to a class II restricted T (helper T) cell epitope, derived from sperm whale 
myoglobin. This peptide was designated the Pk^H peptide (figure 28). The complex was 
constructed with a branched structure of eight peptide molecules surrounding a lysine core. 
The branched nature of the peptide enhances the immune response signal produced by the 
immunised animal (McLean etal\992\ Marsden etal 1992). The helper T cell epitope fused 
to the Pk tag sequence, was known to be active in BALB/c mice (McLean etal 1992, Tam 
1988).
Glv. Lvs. Pro. He. Pro. Asn. Pro. Leu. Leu. GIv. Leu. Asp. Ser. Thr. Asn. Lys. Ala.
Glu. Leu. Phe. Arg. Lys. Asp. He. Ala. Ala. Lys. Tyr. Lys. Glu
F igu re  28 : the am ino  a c id  seq u en ce  o f  the Pk™  p ep tid e  u sed  for  the  
im m u n isation  o f  B A L B /c m ice.
The amino acid sequence of the original Pk tag is shown underlined.____________________
The soluble peptide was injected intraperitoneally. After 3 - 4  weeks, the mice were 
injected intraperitoneally a second time with the PkxH peptide and over the next 21 days, 
blood samples were taken and the specific serum antibody responses observed. After 21 
days, the immune response was boosted by an intravenous injection into the tail vein. 
Three to four days later, the two mice were sacrificed and their spleens removed.
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2.1 .2  D evelopm ent and care o f  an ti-P k ,ii m Ab secre ting  hybridom a clon es
The monoclonal antibody-secreting hybridomas were made in the classical way by 
the fusion of splenocytes, from the immunised mice, to SP2/0 melanoma cells. SP2/0 
melanoma cells were used for a number of reasons: they grow rapidly and are relatively 
easy to maintain: they do not constitutively produce any globulin chains; and they do not 
have the purine salvage enzyme hypoxanthine guanosine phosphoribosyl transferase 
(HGPRT; see section 2.1.1 of the Introduction for further details). In the now standard 
protocol, adapted from that devised by Kohler and Milstein in 1975, the fused cells are 
grown in the presence of foetal calf serum (PCS). To obtain mAbs with few contaminating 
proteins, the PCS must be removed. This is carried out by “weaning” the hybridoma cells 
from the PCS at a later stage in the protocol. To evaluate to effect of PCS on the growth 
and development of mAb secreting hybridoma clones, and also to remove the weaning 
stage in the protocol, half of the fused cells were grown in Protein Free Hybridoma Media 
(PFHM), and half in PFHM containing 10% PCS. Each fused cell suspension was plated 
into 96 well microtitre plates.
A comparison was made between those plates with hybridoma colonies grown in 
the presence of PCS and those where PCS was absent. The following characteristics were 
observed. As expected, the presence of PCS caused the hybridoma cells to grow at a faster 
rate and to form larger colonies than the cells grown in media without PCS. However, 
when studying the individual wells in more detail it was noted that there was more cell 
debris present within wells where PCS was present. This could have been due to the PCS 
used, or to the PCS having a detrimental effect on the macrophage feeder cells present. 
When a comparison was made of the relative number of hybridoma clones visible in both 
sets of plates, at the time of counting, there were more hybridoma colonies visible in, and 
therefore, potentially more colonies screened from, the 96 well plates where PCS was 
present in the media. A comparison of the number of hybridoma clones screened for each 
condition can be seen in table 5.
1 0 2
Average number of 
wells per plate 
containing 
hvbridoma colonies
Potential number of 
wells available for 
screening
Total number of 
wells screened
with FCS 58.3 1340 407
without FCS 38.6 598 423
T ab le  5 : a num erical com p arison  betw een  hybridom a c lon es grow n  in  the  
presen ce and absence o f  foeta l c a lf  serum .
More hybridoma clones were screened from those plates where FCS was absent 
due to a fungal infection contaminating the plates where FCS had been present. The plates 
without FCS eventually succumbed to the fungal infection 2 -3 weeks after those where 
FCS had been present.
2.1 .3  Screen in g  o f  the hybridom a  clon es produced  for anti-Pk-rn m A bs
The hybridoma clones secreted mAbs into the tissue culture media in which they 
were grown. To select anti-Pk^ mAb positive clones, 70% of the tissue culture media from 
wells containing confluent hybridoma colonies was removed, and screened by Enzyme- 
linked Immunosorbent Assay (ELISA). The ELISA plates were coated with the Fk^H 
peptide antigen. Those colonies which screened positive were transferred to 24 well plates 
and allowed to expand. The tissue culture media was screened again, to confirm that the 
clones were continuously secreting anti-PktH mAbs, before the clones were sub-cloned. 
Sub-cloning was performed in order to ensure that the hybridoma clones secreting the anti- 
Pk™ mAbs originated from a single hybridoma cell, and were therefore homogeneous. 
From this fusion, 24 anti-Pk™ mAb secreting hybridoma clones were produced. They were 
numbered according to the order in which they were screened.
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2.2 Characterisation of anti-Pk-m monoclonal antibodies
The 24 positive hybridoma clones obtained were grown in large culture volumes 
and the growth media, into which the mAbs were secreted, collected. The media containing 
the secreted mAbs were subjected to a number of tests in order to define the characteristics 
of each mAb.
2.2 .1  E L ISA  analysis o f  the an ti-P kn i m Abs
The hybridoma colonies had originally been screened by ELISA where the plates 
had been coated with the Pk™ peptide antigen used to immunise the mice. From this 
analysis, 24 hybridoma clones which secreted anti-Pk™ mAbs were obtained. The next 
step was to determine whether the ‘new’ mAbs would recognise either the Pk tag when 
fused to recombinant proteins, or the native P and V proteins of SV5, from which the Pk 
tag was derived (Randall etal 1987: Southern etal 1991). ELISA plates were coated with 
either purified His-Nef-Pk. or BALB/c cell extracts containing the P and V proteins of 
SV5. and probed with each of the mAbs. The secondary antibody used for detection was 
an anti- mouse Ig HRP conjugate. The results are shown in table 6.
The results of the ELISA studies were disappointing. It appeared that of the 24 
mAbs, only four (No's 2, 46, 196, & 337) recognised both the native P and V proteins and 
the His-Nef-Pk recombinant protein. There were three additional mAbs (no's 287, 523, & 
727) which showed weak binding to extracts of P and V expressing cells, but no binding to 
His-Nef-Pk. The reason for this may have been that these three mAbs recognised a cross­
reacting epitope within the BALB/c cell extracts rather than the Pk epitope itself.
To ascertain whether this was the case, the V gene, which had previously been 
cloned into a bacterial expression vector pETl 1C, was expressed in E. coli and the protein 
produced used to coat ELISA plates. Again the V protein was not purified and the cell 
lysate was used to coat the ELISA plates. No mAb binding was shown. This confirmed 
that mAbs no 287,523, & 727 cross-reacted with an epitope within BALB/c cells.
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Clone
Number
PkxH
peptide
N e f -P k P protein 
(balb/c 
expressed)
V protein 
(balb/c 
expressed)
V protein
(E. coli 
expressed)
SV5-P-k +•+■+ +++ +++ +++ +++
1 -K4-I- - - - -
2 +++ +++ +4—h +++ +++
3 +++ - — —
36 4—H- - - - -
46 ■+■++ +4—h 4—h+ +++ +++
146 ++4- - - - _
187 4-4-+ - - - -
196 +++ +++ +++ +++ 4—h+
287 +++ - ++ ++ -
337 +++ +++ +++ +++ +++
467 +++ - - - -
523 +++ - ++ ++ -
534 +++ - - - -
537 +++ - - - -
551 +++ - - -
579 _!_++ - - - -
622 +++ - - - -
638 +++ - - - -
652 +++ - - - -
727 +++ - ++ 4—h -
757 +++ - - _
759 +++ - - - -
768 +4—h - - - -
812 +++ - - -
SV5-HN-4a - - - - -
table 6 : A sum m ary o f  the E L ISA  data obtained on the recognition o f all 24  
anft-PkxH m A b’s to various Pk epitope containing recom b inant proteins.
ELISA plates were coated with either His-Nef-Pk, SV5-Pprotein or SV5-V protein. Each of 
these plates was then probed with the anti-Pk™ mAb’s developed. The binding patterns of all 
the mAb’s was shown by the relative colour change when the assay was developed by TMB. 
Key +++ strongly positive reaction; ++ weakly positive reaction; - no reaction
105
2 .2 .2  Iso ty p in g
The isotype of an antibody is the antigenic determinant of the constant - region of 
the immunoglobulins within the antibody. These determinants define each heavy-chain 
class and subclass and each light-chain type. The class and sub-class of an antibody defines 
its properties and to a certain degree its method of action.
A range of anti-isotype antibodies are commercially available for the determination 
of the class, and sub-class, of mAbs. In this study, an isotyping kit from Serotec was used 
to isotype mAbs in tissue culture supernatants, and was based on the principle of red blood 
cell agglutination. Sheep anti-isotype antibodies were coupled to red blood cells. When the 
anti-isotype antibody came into contact with a mAb of the relevant isotype, the red blood 
cells agglutinated and formed a lattice. When the antibody coated red blood cells were 
added to a supernatant containing a class of antibody which the antibody did not recognise, 
no agglutination was observed. The red blood cells settled to the bottom of the well, 
forming a small circle or “button” . The isotyping results for the 24 anti-Pk mAbs are 
shown in table 7.
Most of the antibodies were from the IgG class of immunoglobulins. This was not 
surprising as IgG is the most common immunoglobulin produced. The fact that four were 
IgA was slightly surprising, because although IgA is found in high concentrations in 
external secretions, it is found in relatively small concentrations in serum.
2.2 .3  Im m u n ob lo ttin g  o f  H is-N ef-P k
To confirm that only four of the 24 anti-PkjH mAbs recognised the Pk tag (or the 
epitope within the P/V proteins), all 24 mAbs were used to probe an immunoblot of His- 
Nef-Pk.
A sample of purified His-Nef-Pk recombinant protein was electrophoresed on a 
12.5% PAG and transferred to nitrocellulose filters. The filters were cut into strips and 
each strip probed with one of the 24 mAbs. SV5-P-k was used as a positive control, and 
the mAb SV5-HN-4a (a mAb which recognises the SV5 HN protein) was used as a 
negative control. The secondary antibody was an anti-mouse Ig HRP conjugated mAb, and
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Clone
Number
Isotype Clone
Number
Isotype
SV5-P-k IgG2a 534 IgGl
1 IgGl 537 IgGl
2 IgGl 551 IgGl
3 IgGl 579 IgM
36 IgGl 622 IgGl
46 IgGl 638 IgA
146 IgGl 652 IgGl
187 IgGl 727 IgGl
196 IgGl 757 IgA
287 IgGl 759 IgA
337 IgGl 768 IgGl
467 IgGl 812 IgA
523 IgGl
T able 7 : T he iso types o f  the n ew ly  d evelop ed  anti-PkTH m o n o c lo n a l an tib od ies
The isotype of the mAh’s were defined using the Serotec isotyping kit. lOOpl samples of each 
mAb-containing supernatant were incubated with lOOjd of each of the anti-isotype red blood cell 
conjugated mAh’s. The resulting mixtures were left to stand for 1 hour to allow agglutination to 
occur, or the red blood cells to settle to the bottom of the wells. The results were observed by 
studying the bottom of the wells from underneath.
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detection was by ECL (figure 29). Lanes 1 and 10 are the positive and negative controls 
respectively. This immunoblot shows the binding of three of the four mAbs which had 
recognised the Pk tag in all previous characterisation experiments (figure 29, lanes 3, 6 & 
8). The immunoblot also shows that one of the mAbs which cross-reacted with a balb/c 
cellular epitope, did not recognise the Pk tag when it was fused to a recombinant protein 
(figure 29, lane 7).
2.2 .4 . Im m u n oflu orescen ce  stu d ies  in a SV5 P hosph o (P) p rotein  
exp ressin g  c e ll line
Within our research group, a number of cell lines which express the P and V 
proteins of SV5 have been developed. Gene expression, within this system, is controlled 
by the tetracycline transactivator protein (tTa). The tetracycline transactivator protein 
consists of the TetR protein fused to the transcriptional activator domain of Herpes Simplex 
Virus (HSV; Gossen & Bujard 1992). The tetracycline transactivator protein stimulates 
transcription from the mammalian promoter controlling the gene of interest, for example the 
P or V genes of SV5, when it combines with upstream tet operators. The presence of 
tetracycline reversibly represses gene expression (Gossen & Bujard 1992). There is also a 
reverse phenotype to the system described, where the addition of tetracycline, or a 
tetracycline derivative, stimulates the binding of the reverse tTa (rtTa) to the operator 
(Gossen etal 1995). In this case tetracycline needs to be present for transcription to occur. 
For the purposes of the immunofluorescence data presented here, a BALB/c P expressing 
cell line with transcription activated by the removal of tetracycline was used.
BALB/c P expressing cells were washed with phosphate buffered saline (PBS) to 
remove the tetracycline, and plated onto immunofluorescence slides. The slides were placed 
at 37°C overnight to allow for the accumulation of the expressed P protein. After fixing and 
permeabilisation, each well of the slide was incubated with one of the mAbs to be tested. 
For detection, the secondary antibody was an anti-mouse Texas Red conjugate and the 
fluorescence was visualised under green light (figure 30).
1 0 8
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F igure 29 : W estern blot analysis o f His-Nef-Pk
Nickel purified His-Nef-Pk was loaded onto a 12.5% SDS-PAG. The fusion protein was trans­
ferred onto a nitrocellulose filter, and the filter cut into strips. Each strip was probed with a 
different anti-PkxH mAb. Detection was by ECL.
Key : 1 - SV5-P-k; 2 - 36; 3 - 46; 4 - 146; 5 - 187; 6 - 196; 7 - 287; 8 - 337; 9 - 467; 10 - SV5- 
HN-4a
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a. b.
c. d.
Figure 30 : Immunofluorescence assay showing the four different results obtained for 
the anti-Pku. mAh’s.
BALB/c cells were plated onto immunofluorescence slides in the absence of the gene expression 
repressor tetracycline and incubated over night at 37°C. This allows the P protein which is expressed 
to accumulate within the cells. After fixing and permeabilisation, the cells were incubated with the 
a n ti-P k iH  mAb’s. Detection was using a Texas Red conjugated anti mouse Ig mAb as a secondary 
probe.
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Of the 24 mAbs tested by immunofluorescence, four exhibited strong fluorescence 
equivalent to that shown by mAb SV5-P-R (figure 30b). They were the four mAbs which 
had shown strong binding in the ELISA assays described in section 2.2.1 (i.e. no’s 2, 46. 
196 & 337). In addition there were three other mAbs which showed weak fluorescence 
(figure 2.2c). They were the three which had given a positive result to only the P and V 
proteins only in the ELISA experiments described in section 2.2.1 (no’s 287, 523 & 727). 
The other 17 mAbs did not give any fluorescence at all. A complete summary of this data 
can be seen in Table 8.
2.3 Conclusions
From the experiments described in this section, the following conclusions were 
drawn. From the ELISA studies and the immunoblots, of the 24 anti-Pk™ mAbs 
developed, only four (no’s 2, 46, 196, & 337) recognised the Pk tag when it was fused to 
a recombinant protein. In the ELISA studies and immunofluorescence assays it was 
observed that there were three other mAbs (no’s 287, 523 & 727) which showed weak 
binding to BALB/c extracts containing the P and V proteins. On closer examination, it 
transpired that these three mAbs were cross-reacting to a cellular epitope within the BALB/c 
cell extracts. From all of the experiments, it became clear that the remaining 17 mAbs only 
recognised the Pk^ H peptide antigen with which the mice had been immunised.
Although the results were disappointing, the fusion process had created hybridoma 
clones which produced a further four mAbs which recognised the Pk tag, now termed anti- 
Pk mAbs. Further analysis was necessary to determine whether these four mAbs could be 
used for the affinity purification of Pk tagged recombinant proteins.
I l l
Clone Number Fluorescence
Intensity
Clone Number Fluorescence
Intensity
SV5-P-k 4-++ 534
1 537
2 H—h+ 551
3 579
36 622
46 4—(—(- 638
146 652
187 - 727
196 -I”++ 757
287 -H- 759
337 +++ 768
467 812
523 +•+• SV5-HN-4a -
table 8 : a sum m ary showing the levels o f  fluorescence ob tained for each m A h  
when used to probe for SV5 P protein in  a BALB/c cell line.
BALB/c cells were grown overnight on an immunofluorescence slide to allow the 
accumulation of P protein. The cells were then fixed, permeabilised and incubated with each 
of the anti-Pk mAb’s. The levels of fluorescence were visualised under green light and the 
relative amounts compared to SV5-P-k.
Key +++ levels of fluorescence equivalent to SV5-P-k; ++ distinct fluorescence visible but 
much weaker than SV5-P-k; - no fluorescence visible.
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3. BINDING AFFINITY STUDIES FOR ANTI - Pk 
MONOCLONAL ANTIBODIES
The four anti-Pk mAbs (described in section 2 of the Results) were further 
characterised, as was SV5-P-k, and all five were renamed. Section 3 details the 
determination of the binding epitopes and binding affinities of the four anti-Pk mAbs and 
SV5-P-k. Section 3 also details preliminary data on buffer conditions, which may be useful 
for the elution of Pk tagged recombinant proteins from mAb coupled affinity columns.
3.1 Determination of antibody binding epitopes
The five mAbs which were used for further characterisation studies were renamed :
SV5-P-k - SV5-Pkl
2 SV5-Pk2
46 SV5-Pk3
196 SV5-Pk4
337 SV5-Pk5
To determine the binding epitopes, SPOT’s technology (Genosys) was used. 
SPOT’s is a technique where a number of different peptides can be synthesised in a format 
which is suitable for the systematic analysis of antibody epitopes. This involved a method 
where peptides, of known sequence, were synthesised onto derivatised cellulose sheets and 
then assayed for antibody binding (Geysen etal 1984). As well as epitope mapping, this 
technology has been used for a number of other applications; e.g. peptide combinatorial 
library studies; the study of protein - protein interactions; phosphorylation studies; and 
enzyme - substrate interactions (Boldicke etal 1988; Scott & Smith 1990).
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A number of peptides were synthesised by SPOT technology. Their sequences 
were derived from the Pk tag 14 amino acid sequence (figure 31). The peptides in the first 
membrane were essentially N terminal deletions (figure 31a). However, in the event that 
the binding epitopes of the mAbs mapped across the C terminus of the Pk tag, and into the 
helper T cell epitope, those amino acids found in the helper T cell epitope were added to the 
C terminus of the Pk tag sequence as an amino acid was deleted from the N terminus of the 
peptide. This meant that the N terminal deletion peptides remained the same length. The 
second membrane contained C terminal deletions (figure 3 lb).
Both membranes were incubated with each of the five mAbs in turn. The results 
were developed by ECL, and visualised on photographic film. A positive result, i.e. one 
where the antibody binds to the reduced peptide, is shown by a distinct dark ’spot’ on an 
autoradiograph (figure 32). The results obtained for each mAb are discussed in turn. 
SV5-PkI - this mAb recognised and bound to the first five peptides (figure 32a) of the N 
terminal deletions. This showed that for mAb binding to occur, the proline at position 5 
(pro-5) needed to be present. When studying the C terminal deletions, SV5-Pkl recognised 
and bound to the first five peptides strongly, and to the sixth and seventh peptides weakly 
(figure 32b). This suggested that the removal of the leucine at position 11 (leu-11) and the 
glycine at position 10 (gly-10) reduced the binding efficiency of the mAb, but only with the 
removal of the leucine at position 9 (leu-9) was mAb binding abolished.
SV5-Pk2 - this mAb bound to the first four of the N terminal deletion peptides (figure 32a), 
and the first eight of the C terminal deletion peptides (figure 32b). This indicated that the 
removal of the isoleucine at position 4 (ile-4) abolished mAb binding, as did the removal of 
the leucine at position 8 (leu-8).
SV5-Pk3 - recognised the first five N terminal deletion peptides (figure 32a), and the first 
four C terminal deletion peptides strongly. SV5-Pk3 also recognised the fifth C terminal 
deletion peptide weakly (figure 32b). This demonstrated that for mAb binding to occur. 
pro-5 needed to be present within the tag. The results obtained for the C terminal deletions 
suggested that the removal of the aspartate residue at position 12 (asp-12) reduced the 
binding of the mAb to the tag, but binding was not abolished until leu-11 was removed.
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b.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
gly. lys. pro. île. pro. asn. pro. leu. leu. gly. leu. asp. ser. tlir
1 gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser
2 lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser.thr
3 pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser.thr.asn
4 ile.pro.asn.pro.leu.leu.gly.leu.asp.ser.thr.asn.lys
5 pro.asn.pro.leu.leu.gly.leu.asp.ser.thr.asn.lys.ala
6 asn.pro.leu.leu.gly.leu.asp.ser.thr.asn.lys.ala.leu
7 pro.leu.leu.gly.leu.asp.ser.thr.asn.lys.ala.leu. g lu
8 leu.leu.gly.leu.asp.ser.thr.asn.lys.ala.leu. g lu .le u
9 leu.gly.leu.asp.ser.thr.asn.lys.ala.leu. g lu .le u .p h e
10 gly.leu.asp.ser.thr.asn.lys.ala.leu. g lu .le u .p h e .a r g
11 leu.asp.ser.thr.asn.lys.ala.leu. g lu .le u .p h e .a r g .ly s
1 lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser.thr
2 lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser
3 gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser
4 gly.iys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp
5 gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu
6 gly.lys.pro.ile.pro.asn.pro.leu.leu.gly
7 gly.lys.pro.ile.pro.asn.pro.leu.leu
8 gly.lys.pro.ile.pro.asn.pro.leu
9 gly.lys.pro.ile.pro.asn.pro
10 giy.lys.pro.ile.pro.asn
11 gly.lys.pro.ile.pro
12 gly.lys.pro.ile
F igu re 31 ; T he am ino ac id sequences o f  the peptides w ith in  the S P O T ’s 
m em branes
The amino acids highlighted in Bold indicate those NOT derived from the Pk tag. 
a. N terminal deletions: b. C terminal deletions.
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a.
SV5-Pkl
SV5-Pk2
SV5-Pk3
SV5-Pk4
SV5-Pk5
No 287
1 2 3 4 5 6 7 8 9 10 11 12
b .
SV5-Pkl
SV5-Pk2
SV5-Pk3
SV5-Pk4
SV5-Pk5
1 2 3 4 5 6 7 8 9 10 11 12
Figure 32 : Autorad iographs showing the results o f the SPO T tests.
The SPOT membranes were probed with each of the 5 anti-Pk mAb’s and mAb No287. These 
mAb’s were probed with an horse radish peroxidase conjugated anti-mouse Ig mAb and a positive 
result was detected by ECL.
Key : a. N terminal deletions; b. C terminal deletions
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SV5~Pk4 - bound to the first five N terminal deletion peptides (figure 32a), and to the first 
eight C terminal deletion peptides (figure 32b). These results showed that for mAb binding 
to occur, pro-5 and leu-8 needed to be intact.
SV5-Pk5 - bound to the first three N terminal deletion peptides strongly and to the fourth 
and fifth peptides weakly (figure 32a). This suggested that the deletion of the proline as 
position 3 (pro-3) and ile-4 reduced mAb binding, but the removal of pro-5 abolished mAb 
binding. When studying the C terminal deletion peptides, it was observed that SV5-Pk5 
bound to the first five peptides (figure 32b). This showed that the removal of leu-11 
abolished mAb binding.
When the information obtained from both the N and C terminal deletion membranes 
was combined, the minimum binding epitope for each mAb antibody was determined. 
These are shown in figure 33.
Pk tag
Thr
SV5-Pkl
SV5-Pk2
SV5-Pk3
SV5-Pk4
SV5-Pk5
Gly. Lys. Pro. lie. Pro. Asn. Pro. Leu. Leu. Gly. Leu. Asp. Ser.
Pro. Asn. Pro. Leu. Leu 
lie. Pro. Asn. Pro. Leu
Pro. Asn. Pro. Leu. Leu. Gly. Leu 
Pro. Asn. Pro. Leu. Leu. Gly 
Pro. lie. Pro. Asn. Pro. Leu. Leu. Gly. Leu
figure 33 : m in im um  bind ing ep itopes o f  the an ti-P k  m Abs.
The minimum binding epitopes are the amino acids within the Pk tag sequence which were 
found to be essential for the binding of the mAbs to the Pk tag. The above figure also shows 
the position of the minimum binding epitopes relative to the Pk tag sequence.____________
To confirm that the mAbs which had shown weak immunofluorescence in SV5 P 
and V expressing BALB/c cells, and which had given a positive result in the P and V 
protein ELISA tests, were recognising an epitope other than the Pk tag, mAb no. 287 (a 
mAb which had not been renamed) was also incubated with the N and C terminal deletion
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membranes (figure 32a). The mAb only showed a positive result for the last four peptides 
of the N terminal deletion series, and did not give a positive result to any of the C terminal 
deletion peptides. From this data, it was deduced that the amino acid sequence this mAb 
was recognising was l e u .p h e .a r g . lys. a sequence which was part of the T helper cell 
epitope which had been added to the Pk tag for immunisation purposes.
3.2 Immunofluorescence studies showing inAb cross reacting to HeLa cells
An interesting observation of SV5-PkI was made prior to this work. The mAb 
SV5-Pkl showed a specific cross reaction with a cellular epitope within naive HeLa cells 
when immunofluorescence studies were performed. This cross reaction was found to be 
confined to the cytoplasmic side of the nuclear membrane, possibly the Golgi stack or 
rough endoplasmic reticulum (RER) (figure 34a). When looking for the same specific 
fluorescence in other cell lines e.g. naive Vero cells, this specific binding was not found 
(figure 34b). This confirmed that the specificity of this fluorescence was confined to HeLa 
cells. As there were similarities between the new anti-Pk mAbs and SV5-Pkl, experiments 
were carried out to see if they also showed this specific cross reaction in HeLa cells.
Naive HeLa cells were incubated, after permeabilisation. with each of the mAbs. 
SV5-Pkl was used as a positive control and the anti - HN mAb, SV5-HN-4a, as a negative 
control. At the same time, HeLa cells were infected with SV5 and fixed. Simian virus 5 
was used for the immunofluorescence studies as the viral P and V proteins are known to 
contain the epitope which is recognised by the anti-Pk mAbs. The infected cells also 
provided a positive control, to ensure the mAbs had gained entry into the permeabilised 
cells. For detection the secondary antibody was an anti - mouse Ig Texas Red conjugate 
and the fluorescence was visualised under green light.
SV5-Pk2 (figure 35c) and SV5-Pk3 (data not shown) appeared to cross react with 
the naive HeLa cells. The cross-reaction was confined to the cytoplasm surrounding the 
nucleus as it was for SV5-Pkl (compare figure 35a & 35c). The fluorescence observed in 
cells incubated with SV5-Pk2 and SV5-Pk3 was not as strong as the fluorescence obtained
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k
d.
F igure 34 : Im m unofluorescence assay showing the cross reaction exhibited in H eLa  
cells by SV 5-Pkl
Naive HeLa and Vero cells were plated onto immunofluorescence slides and incubated at 37°C over­
night to allow the cells to adhere. After fixing and permeabilisation the cells were incubated with 
tissue culture supernatant containing SV5-Pkl. Immunofluorescence was detected using a solution 
of Texas Red conjugated anti mouse Ig mAb and DAPI.
Key : a. - HeLa cells showing background immunofluorescence; b. - DAPI staining of the HeLa cells;
c. - Vero cells stained with Texas Red (negative control); d. DAPI staining of Vero cells
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a. b.
d.
F igure 35 : Im m unofluorescence assay showing the cross reaction exhibited in the 
H eLa cell line by the newly isolated anti-Pk m A h’s.
Naive HeLa cells were plated onto immunofluorescence slides and incubated at 37°C overnight to 
allow the cells to adhere. At the same time naive HeLa cells were infected with the W3 strain of 
SV5, and incubated at 37°C overnight. After fixing and permeabilisation, the cells were incubated 
with tissue culture supernatant containing the anti-Pk mAb’s. Immunofluorescence was detected 
using a solution of Texas Red conjugated anti mouse Ig mAb.
Key : a. - SV5-PkI, uninfected; b. - SVSPkl + SV5 infection; c. - SV5-Pk2, uninfected; d. - 
SV5-Pk2 + SV5 infection; e. SV5-Pk4, uninfected; f. - SV5-Pk4 + SV5 infection
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for SV5-Pkl (compare figure 35a & 35c). SV5-Pk4 (figure 35e) and SV5-Pk5 (data not 
shown) did not show any cross reaction with the naive HeLa cells. To confirm that the 
fluorescence observed was restricted to HeLa cells, the mAbs were also incubated with 
naive Vero and BALB/c cells. No fluorescence was obtained (data not shown).
The infected cells also emphasised that the fluorescence obtained when probing for 
the SV5 P/V proteins was so strong, that any background fluorescence obtained with SV5- 
Pkl, SV5-Pk2 and SV5-Pk3 in HeLa cells was masked (figure 35b, d & f).
3,3 Analysis of the mAb - Antigen interaction by Biosensor technology
Biomolecular interaction analysis (BIA) is a relatively new technique in the field of 
biomolecular research. It is a technology which is used for the monitoring of molecular 
interactions in “real time” without the use of labels. It is a fast and non-invasive method of 
detecting the affinity and kinetics of an interaction and can be used for the study of the 
interactions of proteins, peptides, nucleic acids, carbohydrates, lipids and low molecular 
weight molecules such as pharmaceuticals (Foote & Milstein 1991; Altschuh e ta l 1992; 
Borrebaeckera/ 1992; Gruen etal 1993).
Detection is based on the principle of Surface Plasmon Resonance (SPR). This is 
described as “an optical phenomenon arising in thin metal films under conditions of total 
internal reflection” (figure 36). Surface plasmon resonance detects the changes in the 
refractive index of a solution close to the surface of a sensor chip. As the refractive index is 
directly related to the concentration of a solute at the surface layer, a number of questions 
can be addressed. In the case of the monoclonal antibodies to be tested; how fast do they 
associate and dissociate from the peptide antigen tag; and how strongly do they interact 
with the peptide antigen tag?
To perform the analysis, the ligand is immobilised on the surface of a gold covered 
sensor chip. The sensor chip forms one wall of the micro-flow cell (figure 37) where the 
interactions are monitored. The analyte is then injected over the surface of the sensor chip 
in a controlled flow. The flow is controlled by micro-fluidics using a miniaturised
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Figure 36 : The prin c ip les o f  surface p lasm on resonance (SPR ).
The SPR angle is sensitive to the mass concentration of molecules close to the sensor chip 
surface. As this concentration changes, the SPR angle shifts and prcxiuccs a response. A 
response of KXX) resonance units (RU) corresponds to a change in surface concentration of 
1 ng.mm-2.
micro-valvc
Integrated m icro- 
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Figure 37 : A m icroflu id ics flow  chart.
A diagrammatic vertical section through the flow cell shows how the cell is formed by 
the IFC pressing against the sensor chip.
integrated micro-fluidics cartridge (IFC). The IFC controls the delivery of samples and 
buffers to the sensor chip through micro-computer controlled pneumatic microvalves. A 
change in solute concentration at the surface of the sensor chip caused by an interaction 
between the two interactants is detected as an SPR signal and expressed in resonance units 
(RU). A continuous display of RU against time is known as a sensorgram (figure 38). A 
change in response of 1000 RU corresponds to a change in sensor chip surface 
concentration of Ing/mm^ (Biosensor Handbook. Pharmacia). Once the experiment is 
completed the sensor chip must be regenerated so it can be used for the next reaction. The 
method of regeneration is dependent upon the strength of the interaction between the two 
interactants used in the experiment.
The Pk-TH peptide tag was covalently immobilised on a CM5 sensor chip by amine 
coupling. The sensor chip is composed of three layers; glass, gold and carboxymethylated 
(CM) dextran. After the PkpH tag was covalently coupled to the CM dextran layer of the 
sensor chip, each mAb was passed over the chip in the flow buffer and the change in the 
RU studied on the sensorgram (figure 38). A number of different concentrations of each 
mAb were tested to allow for discrepancies in the association and dissociation phases. After 
the binding injection was completed, a period of dissociation must occur. This is for the 
determination of the apparent dissociation rate constant, which is important for the 
determination of the apparent rate association constant and the Equilibrium constant. A time 
period of about 400s is usually sufficient for the calculation of the apparent rate dissociation 
constant. Once the interaction has been left for a suitable length of time to allow for 
dissociation, the sensor chip was regenerated to be used again for another mAb - Pk^n tag 
interaction.
The apparent association (ka) and dissociation (k<j) rate constants, and the 
Equilibrium rate dissociation constants (Kd) were calculated using a simple mathematical 
model (see materials and methods; Table 9).
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Monoclonal
Antibody
association constant 
ka
dissociation constant 
k d
Kd for Pk peptide
SV5-Pkl 2.98 X 106 7.03 X 10-5 23.6 pmol
SV5-Pk2 3.73 X 106 2.27 X 10-4 60.9 pmol
SV5-Pk3 5.08 X 106 2.26 X 10-4 44.5 pmol
SV5-Pk4 3.54 X 106 1.73 X 10-4 48.9 pmol
SV5-Pk5 3.4 X 106 2.13 X 10-4 62.6 pmol
T ab le 9 : the average ap p aren t assoc ia tion  / d issoc ia tion  con stan ts an d  the  
eq u ilib riu m  d issoc ia tion  con stan ts ob ta in ed  for the b ind ing  o f  the Hve anti- 
Pk m A bs to the Pk^n p eptid e.
The main aim of developing more mAbs was to obtain antibodies which had lower 
binding affinities for the Pk tag and which could be used for the affinity purification of 
tagged recombinant proteins. The Biosensor studies gave the first indications of how the 
binding affinities of the four mAbs developed differed from SVS-Pkl.
There was little difference between the association rate constants obtained for the 
five anti-Pk mAbs. However, the dissociation rates constants of the four newly developed 
mAbs showed a 10 fold difference to the dissociation constant obtained for SV5-Pkl. Of 
the four newly developed anti-Pk mAbs, SV5-Pk4 showed the quickest dissociation from 
the PkTH tag, and the largest dissimilarity to SV5-Pkl.
The Biosensor data has shown that there were small differences in the Equilibrium 
constants obtained for all five mAbs. The Equilibrium constant obtained for SV5-Pkl 
showed that of the five anti-Pk mAbs, it still had the strongest affinity for the Pk tag. 
However, the other four mAbs did not appear to have binding affinities which were 
sufficiently low enough to allow easy elution of tagged recombinant proteins from affinity 
columns.
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3.4 Preliminary analysis of conditions which cause the dissociation of 
tagged recombinant proteins from the anti-Pk monoclonal antibodies
The Biosensor binding affinity studies in section 3.3, showed that although the four 
new mAbs developed had strong binding affinities, they did not bind as strongly as SVS- 
Pkl. However, the affinity of a mAb for its antigen does not necessarily determine the 
difficulty with which the immunocomplex will be dissociated. In immuno-affinity 
chromatography the ease with which an antigen can be eluted can also be determined by the 
rate of dissociation. As the newly developed mAbs had faster dissociation rates, it was 
decided to compare the conditions required for the elution of the mAbs from tagged 
recombinant proteins.
An efficient way of investigating a large number of elution conditions was by Dot 
blotting, a cross between Western blotting and ELISA’s. In this assay, nitrocellulose filters 
were incubated with bacterial TCL containing the SV5 P protein. The protein bound to the 
nitrocellulose filters, allowing the coated filters to be probed with the anti-Pk mAbs. By 
using 84 wellTerasaki plates (see Materials and Methods), all five anti-Pk mAbs could be 
assayed simultaneously. The series of dots which are developed on the autoradiograph (see 
figure 39) represent an area of the nitrocellulose filter which had been incubated with an 
anti-Pk mAb. Once the filters had been incubated with the anti-Pk mAbs, they were cut into 
strips and each strip incubated with a different elution buffer. A number of different elution 
buffers were tested in order to find relatively mild combinations which would elute the 
mAbs from Pk tagged recombinant proteins. The strips were incubated with an HRP 
conjugated secondary antibody, and developed in the same way as a Western blot. From 
these experiments, an efficient elution buffer is one which shows the least detected mAb 
binding when compared to the PBS positive control (figure 39i, ii, iii, lane a).
Initially relatively mild, standard conditions for mAb elution were tested e.g by 
varying the pH (figure 39i), the salt concentration of the elution buffer (figure 39ii) and by 
the addition of various detergents (figure 39iii).
1 2 6
F igure 39 : Dot blot analysis o f SV5 Phospho (P) protein coated filters.
Nitrocellulose filters were coated with S V5-P protein. The filters were probed with the 5 anti-Pk mAh’s, 
and the anti-P protein mAh SV5-Pe as a positive control, using an 84 well Terasaki plate to create the 
“dot’s”. The filters were cut into strips and each strip washed with a different elution buffer. Detection 
of mAb binding was by ECL.
1. Filter strips were washed with elution buffers at different pH. a.PBS; b. pH2; c. pH4; d. pH6; e. pH8; 
f.pHlO; g.pH12
ii. Filter strips were washed with elution buffers containing different NaCl concentrations, a. PBS; b. 
2.5 M; c. 3 M; d. 3.5 M; e. 4 M; f. 4.5 M; g. 5 M
iii.. Filter strips were washed with elution buffers containing different salt concentrations and different 
detergents, a. PBS; b. 0.5 M NaCl + SDS; c. 2 M NaCl +SDS; d. 5 M NaCl + SDS; e. 0.5 M NaCl + 
NP40; f. 2 M NaCl + NP40; g. 5 M NaCl +NP40
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Only the most extreme pH’s such as pH2 (figure 39i, lane b) or pH12 (figure 39i, 
lane g) appeared to affect the binding of the anti-Pk mAbs. Although a decrease in mAb 
binding was seen at pH 10 for mAbs SV5-Pk2 and SV5-Pk3 (figure 39i, lane f). With the 
effective pH’s being so extreme, it was unlikely that a change in pH alone would be useful 
as an elution buffer. Another disadvantage to using very high or very low pH is that the 
extreme pH could denature the recombinant protein being purified.
A number of salt concentrations and detergents were tested together to see if these 
combinations would effect antibody binding, as salt concentration alone had no effect 
(figure 39ii), even with concentrations as high as 5 M (lane g). Initially the detergents 
Tween 20, Triton X-100, sodium dodecyl sulphate (SDS), and Nonidet p40 (NP40) were 
tested in combinations with relatively high (5 M), medium (2 M) and low (0.5 M) sodium 
chloride concentrations. Of those tested, only the SDS and NP40 results are shown (figure 
39iii). Of all detergents tested, only SDS showed an effect on antibody binding (lane b) and 
then only under relatively low salt conditions. Although this appeared promising, SDS is 
not ideal for use in an elution buffer as it is extremely difficult to remove completely from a 
column.
Having experimented with changes in pH, salt concentration and the addition of 
detergents, it became clear that mild elution conditions were not sufficient to elute the P 
protein or tagged recombinant proteins from the newly developed anti-Pk mAbs (see figure 
39). To analyse fully conditions which could be used for protein elution, a number of other 
elution buffers were used : 0.2 M glycine at various pH’s (pH 2.8, 10.1 & 11.5): 
chaotropic ions [3.5 M magnesium chloride (MgCl2); 3.5 M sodium thiocyanate 
(NaSCN)l; other ionic detergents (0.1% sodium deoxycholate); mild denaturing conditions 
(0.1 M diethylamine pH 11), ethylene glycol pH 11.5 (1%, 10% & 50%), and as a last 
resort strong denaturing conditions such as 6 M guanidine hydrochloride, 8 M Urea and 20 
mM hydrochloric acid (HCl). All of these elution buffers were tested on nitrocellulose 
filters coated with His-Nef-Pk (figure 40).
From figure 40 it was observed that the anti-Pk mAbs SV5-PK3 and SV5-Pk4 did 
not bind well to the filters. This is a result of the poor quality of tissue culture media
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Figure 40 : Dot blot analysis o f H is-Nef-Pk coated nitrocellulose filter.
Nitrocellulose filters were coated with purified His-Nef-Pk and probed with the five anti-Pk mAh’s, 
with SV5-HN-4a as a negative control. The filters were cut into strips, and each strip was incubated 
with a
different elution buffer. Dectection of mAb binding was by ECL.
Key: a & h - phosphate buffered saline; b - 0.1 M glycine pH 2.8; c - 0.1 M glycine pH 10.1 ; d - 
0.1 M glycine pH 11.5; e - 3.5 M magnesium chloride; f - 3.5 M sodium thiocyanate; ; g - 0.1% 
sodium deoxycholate; j - 1% ethylene glycol; k - 10% ethylene glycol; 1-0.1 M diethylamine; m - 
0.05% sodium acetate pH 4.0; n - 20mM hydrochloric acid; p - 0.1 % sodium dodecyl sulphate
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available for use in this experiment. The results stated in this section for these two anti-Pk 
mAbs are, therefore, from subsequent experiments where the data is not shown. Of all the 
conditions tested, glycine pH 2.8 (figures 40. lane b), diethylamine (figures 40. lane 1) and 
hydrochloric acid (figures 40. lane n) gave the most significant effect on antibody binding 
for all five anti-Pk mAbs. Glycine pH 2.8 significantly reduced the binding of SV5-Pk5 to 
His-Nef-Pk (lane b), but only gave a slight decrease in the binding of SV5-Pk2 to His-Nef- 
Pk (lane b). In addition, unlike the other anti-Pk mAbs, SV5-Pk2 binding was not 
abolished by diethyiamine (lane 1) and hydrochloric acid (lane n), only significantly 
reduced. The binding of SV5-Pk4 and SV5-Pk5 was reduced by the elution buffer glycine 
pH 11.5 (figures 40, lane d). The strong denaturing conditions, 6 M guanidine 
hydrochloride and 8 M urea, completely removed mAb binding (data not shown), but this 
may have been due to the removal of the bound protein from the nitrocellulose filters rather 
than the antibody from the protein.
4. CONSTRUCTION OF MODIFIED Pk TAGS
From the experiments described in Section 3, it was apparent that the four new anti- 
Pk mAbs did not bind to the Pk tag with a significantly lower binding affinity to that 
obtained for SV5-Pkl. Also shown in section 3, was that each mAb had a different 
minimal binding epitope. It was postulated, therefore, that by developing tags which 
contained a single amino acid change to the original Pk tag, the binding of the existing 
mAbs may be affected. Section 4 focuses on the determination of which amino acids within 
the Pk tag sequence were to be modified, and what effect the amino acid modifications had 
on mAb binding.
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4.1 Determination of amino acids, outside of the binding epitope, that are 
essential for antibody binding
4 .1 .1  SPO T  su b stitu tion s and in sertion s
As well as the membranes used in section 3.1. two other membranes for SPOT 
testing were synthesised (figure 41). The peptides on these membranes were also derived 
from the Pk tag sequence but instead of having amino acid deletions, there were either 
cysteine substitutions at each position (figure 41a) or the insertion of a cysteine residue 
between the amino acids at each position (figure 41b). Cysteine was chosen because these 
two SPOT membranes were originally designed for another project within the group. This 
was involved with the development of the Pk tag as a spacer arm for chemically linking 
antigens to the p subunit of the heat labile enterotoxin of E. coli (LTB) for vaccine 
purposes.
The membranes were incubated with each of the mAbs, and the results developed 
as stated in section 3.1 (figure 42). The cysteine substitutions indicated which amino acids 
could not be deleted (or substituted for another amino acid) at a specific position within the 
primary tag sequence (figure 42i). A number of conclusions could be made from the 
observations concerning the critical amino acids required for the binding of the mAbs 
within the Pk tag :
SV5-Pkl - substitutions of pro-5, asn-6, and leu-9 significantly reduce the binding of the 
mAb to the Pk tag (figure 42a). This was expected as these amino acids are all within the 
minimum binding epitope determined for SV5-Pkl in section 3.1. However, a substitution 
of leu-11 also affected the binding of the mAb to the Pk tag (figure 42a). This was 
unexpected, as from previous experiments this amino acid could be removed with no effect 
to mAb binding (see section 3.1).
SV5-Pk2 - substitutions to asn-6 and pro-7 abolish the binding of this mAb to the Pk tag 
(figure 42b). In addition to these two amino acids, the substitution of ile-4 and leu-8 
reduced the binding of the mAb to the Pk tag (figure 42b). The effects of all four amino
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b.
1 cys .lys.pro.ile.pro.asn.pro.leu.leu.gly .leu.asp.ser
2 gly,cys.pro.ile.pro,asn.pro.leu.leu.gly .leu.asp.ser
3 gly.lys.cys.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser
4 gly.lys.pro.cys.pro.asn.pro.leu.leu.gly.leu.asp.ser
5 gly .lys.pro.ile.cys .asn.pro.leu.leu.gly .leu.asp.ser
6 gly.lys.pro.ile.pro.cys.pro.ieu.leu.gly.leu.asp.ser
7 gly .lys.pro.ile.pro.asn.cys .leu.leu.gly .leu.asp.ser
8 gly .lys.pro.ile.pro.asn.pro.cys .leu.gly.leu.asp.ser
9 gly.lys.pro.ile.pro.asn.pro.leu.cys.gly.leu.asp.ser
10 gly.lys.pro.ile.pro.asn.pro.leu.leu. cys .leu.asp.ser
11 gly .lys.pro.ile.pro.asn.pro.leu.leu.gly.cys .asp.ser
12 gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.cys.ser
13 gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.cys
14 lys.pro.ile.pro.asn.pro.leu.leu.gly .leu.asp.ser .cys
1 gly .cys .lys.pro.ile.pro.asn.pro.leu.leu.gly .leu.asp.ser
2 gly .lys.cys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser
3 gly .lys.pro.cys .ile.pro.asn.pro.leu.leu.gly .leu.asp.ser
4 gly.lys.pro.ile.cys.pro.asn.pro.leu.leu.gly .leu.asp.ser
5 gly.lys.pro.ile.pro.cys .asn.pro.leu.leu.gly .leu.asp.ser
6 gly .lys.pro.ile.pro.asn.cys .pro.leu.leu.gly.leu.asp.ser
7 gly .lys.pro.ile.pro.asn.pro.cys .leu.leu.gly.leu.asp.ser
8 gly.lys.pro.ile.pro.asn.pro.leu.cys.leu.gly.leu.asp.ser
9 gly.lys.pro.ile.pro.asn.pro.leu.leu. cys.gly .leu.asp.ser
10 gly .lys.pro.ile.pro.asn.pro.leu.leu.gly. cys.leu.asp.ser
11 gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.cys .asp.ser
12 gly.ly s.pro.ile.pro.asn.pro.leu.leu.gly .leu.asp. cys .ser
13 gly.lys.pro.ile.pro.asn.pro.leu.leu.gly .leu.asp.ser. cys
F igure 41 : T he am ino acid sequences o f  the peptides on the SPO T m em branes
a. peptides containing cysteine substitutions; b. peptides containing cysteine insertions.
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i Cysteine substitutions
1 2 3 4 5 6 7 8 9 10 11 12 13 14
ii. Cysteine insertions
1 2 3 4 5 6 7 9 10 11 12 13
Figure 42 : Autorad iographs showing the results o f the SPO T tests.
The SPOT membranes were probed with each of the five anti-Pk mAb’s. Detection was by ECL. 
The numbering corresponds to that shown in figure 41.
Key : a & f - SV5-Pkl ; b & g - SV5-Pk2; c & h - SV5-Pk3; d & j - SV5-Pk4; e & k - SV5-Pk5
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acids were expected as all four are found within the minimum binding epitope determined 
in section 3.1.
SV5-Pk3 - substitution of asn-6, pro-7 and leu-8 completely abolished mAb binding 
(figure 42c). In addition, substitutions of leu-8 and leu-11 also had the effect of reducing 
mAb binding (figure 42c). All of these amino acids were found within the minimum 
binding epitope determined for the mAb (see section 3.1).
SV5-Pk4 - substitution of leu-9 abolished binding of the mAb completely (figure 42d). 
Substitutions to pro-5, asn-6. and leu-8 also acted to reduce the binding of the mAb to the 
Pk tag (figure 42d).All four amino acids were found to be within the minimum binding 
epitope determined for mAb binding (section 3.1).
SV5-Pk5 - substitutions to asn-6 and leu-11 abolish mAb binding completely (figure 42e). 
Substitutions to leu-8 and gly-10 also significantly reduce the binding of the mAb to the Pk 
tag (figure 42e). All four mAbs are found within the minimum binding epitope determined 
for mAb binding (section 3.1). However, in addition to the amino acids stated, the 
substitution of the proline at position 3 (pro-3), the serine at position 13 (ser-13), and the 
threonine at position 14 (thr-14) also affected mAh binding (figure 42e), though not as 
significantly as the other substitutions previously mentioned.
The results obtained for the cysteine substitutions have highlighted some of the 
differences observed on the amino acid requirements of mAb binding. A summary of this 
information can be seen in figure 43.
The insertion of a cysteine residue between amino acids pairs did not have the same 
noticeable effect on mAb binding that was observed for the cysteine substitutions. The 
cysteine insertions (figure 42ii) determined which part of the Pk tag amino acid sequence 
could not be altered if mAb binding was to occur. As with the cysteine substitutions, a 
number of conclusions could be drawn from this experiment.
SV5-PkI - a cysteine insertion between pro-5 & asn-6 abolishes mAb binding altogether 
(figure 42, lane f). However, cysteine insertions between leu-8 & leu-9, leu-9 & gly-10. 
and gly-10 & leu-11 also had the effect of reducing mAb binding (lane f). The effect of
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S V 5 -P k l pro.asn.pro.leu.leu.
a gly.lys.pro.ile.** . ** . * .leu.***.gly. * .asp.ser.thr
b gly.lys.pro.ile.n.d.***.***.leu.***.n.d.leu.asp
c gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser.thr
* * ** ** **
SV 5-P k2 ile.pro.asn.pro.leu
a gly.lys.pro.** . * . ****** ** . * . gly .leu.asp.ser.thr
b gly.lys.pro.***.n.d.***.***.***.leu.n.d.ieu.asp
c gly.lys.pro.ile.pro.asn.pro.leu.leu. gly.leu.asp.ser. thr
* *  *  *  *
SV 5-Pk3 pro.asn. pro.leu. leu.gly .leu
a gly.lys.pro.ile.pro.***.***.***.** . * .***. * .ser.thr
b gly.lys.pro.ile.n.d.***.***.***.leu.n.d.** .asp.
c gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser.thr
*  * *  *  *  *  *  *  *
SV 5-P k4 pro, asn. pro. leu. leu. gly.
a gly.lys.pro. * .** . ** . * . ***. ***.gly. * .asp.ser.thr
b gly.lys.pro.** .u.d.***.***.***.(**) n.d.leu.asp.
c gly.lys.pro.ile.pro. asn. pro. leu. leu. gly.leu.asp.ser.thr
* ** * * ** ** *
S V 5 -P k 5  pro.ile.pro.asn. pro. leu. leu.gly .leu
a gly.lys.pro.ile.pro.***. * . **. leu. **.***.asp.ser.thr
b gly .lys.pro.ile.n.d.***.***.***.leu.n.d.**. asp.
c gly.lys.pro.ile.pro.asn.pro. leu. leu.gly .leu. asp.ser.thr
* *H= ** ** ***
F igure 43 : A sum m ary o f  the in form ation  obtained from  the cysteine  
substitu tion s and in sertion s, and the L T B  P k  cyste in e  substitu tion s  
e x p e r im e n ts .
Key : a. - SPOT cysteine substitutions; b - LTB-Pk-cys substitutions; c - SPOT cysteine 
insertions
*** - no binding visible; ** - an effect on binding strongly visible; * - little effect to mAb 
binding; n.d. - mutant peptide not developed.
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insertions between these last amino acids on mAb binding was surprising as they are not 
within the minimum binding epitope.
SV5-Pk2 - no cysteine insertion had the effect of completely disrupting mAb binding to the 
tag (lane g). However, insertions between pro-5 & asn-6, and pro-7 & leu-8 had the effect 
of reducing mAb binding.
SV5-Pk3 - a cysteine insertion between pro-7 & leu-8 abolished mAb binding (lane h). 
Cysteine insertions between asn-6 & pro-7, leu-8 & leu-9, leu-9 & gly-10, and gly-10 & 
leu-11 significantly reduce mAb binding.
SV5-Pk4 - as with SV5-Pk2, no cysteine insertion had the effect of abolishing mAb 
binding (lane j). However, insertions between ile-4 & pro-5, and leu-8 & leu-9 reduce 
mAb binding (lane j). The isoleucine at position 4 is not found within the minimum binding 
epitope determined for the mAb, whereas the other three amino acids are.
SV5-Pk5 - an insertion between gly-10 & leu-11 abolished mAb binding completely (lane 
k). The cysteine insertions showed the greatest effect on SV5~Pk5 mAb binding. The 
binding of the mAb to the tag was affected by cysteine insertions between, gly-1 & lys-2, 
pro-3 & ile-4, asn-6 & pro-7, pro-7 & leu-8, leu-8 & leu-9, leu-9 & gly-10, and ser-13 & 
thr-14. The effect of these amino acids on mAb binding and the relatively large minimum 
binding epitope, indicated that for efficient SV5-Pk5 binding almost the whole of the Pk tag 
needed to be intact.
The cysteine insertions have shown that the position of the amino acid within the Pk 
tag sequence can have either a significant effect on mAb binding (e.g. SV5-Pk5) or have 
little effect on mAb binding (e.g. SV5-Pk2). A complete summary of this information can 
be seen in figure 43.
4.1.2 LTB-Pk-cvsteine substitutions
As stated in section 4.1.1, the substitution and insertion of a cysteine residue was 
due to the SPOT membranes having been designed for another project within our group. 
This project is concerned with the development of an immunisation system which uses the 
Pk tag as a spacer arm to form a chemical link between an adjuvant and an antigen. The
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adjuvant selected was LTB from E. coli (Tsuji et cd 1997). Within our laboratory, the 
original Pk tag, and Pk tags containing cysteine substitutions at each position, were fused 
to the C terminus of LTB (LTB-Pk-cys) and expressed in Vibrio sp. The cysteine 
substituted Pk tags were labelled A - L and the amino acid sequences for the peptide tags 
can be seen in figure 44. Once expressed the secreted soluble LTB-Pk-cys protein was 
collected.
The heat labile enterotoxin has been shown to bind to GM l. a sugar found on the 
external surfaces of most eukaryotic cells (Lindner etal 1994). ELISA plates were coated 
with GMl and used to capture the LTB-Pk-cys mutants. To ensure the LTB-Pk-cys 
mutants were captured by G M I, an anti - LTB mAb was used as a positive control (data 
not shown). The capture of the LTB-Pk-cys mutants allowed all of the anti-Pk mAbs to be 
screened for their ability to bind to the altered Pk tags, (figure 45). At the time the ELISA 
experiments were performed, the E and J cysteine substituted tags, shown in figure 44, had 
not been cloned and are not illustrated in figure 45.
" As can be seen in figure 45, the substitution in Pk tag G affected the binding of all 
five anti-Pk mAbs. This meant that for mAb binding to occur, a substitution of pro-7 was 
not tolerated. When comparing this to the results obtained for the cysteine substitutions on 
the SPOT test, there were discrepancies (see figure 42). The SPOT membranes showed 
that a substitution to pro-7 only affected the binding of SV5-Pk2 and SV5-Pk3 to the Pk 
tag.
The binding of mAb SV5-Pkl (figure 45a) was also disrupted by substitutions to 
asn-6 and leu-9. These two substitutions correlated with the SPOT test results (see figure 
42, lane a).
In addition to the disruption to mAb binding shown by the pro-7 substitution, the 
binding of SV5-Pk 2 (figure 45b) was also disrupted by the substitution of asn-6 and leu- 
8. These results confirm those obtained for SV5-Pk2 by SPOT testing (figure 42, lane b).
SV5-Pk3 binding was only affected by the substitution of pro-7, as stated earlier.
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Pk tag : leu. gly. lys. pro. lie. pro. asn. pro. leu. leu. gly. leu. asp. ser. thr.
A (1): leu. cys. lys. pro. ile, pro. asn. pro. leu. leu. gly. leu. asp. ser. thr.
B (2): leu. gly. cys. pro. ile. pro. asn. pro. leu. leu. gly. leu. asp. ser. thr.
C (3): leu. gly. lys. cys. ile. pro. asn. pro. leu. leu. gly. leu. asp. ser. thr.
D (4): leu. gly. lys. pro. cys. pro. asn. pro. leu. leu. gly. leu. asp. ser. thr.
E (5): leu. gly. lys. pro. ile. cys. asn. pro. leu. leu. gly. leu. asp. ser. thr.
F (6): leu. gly. lys. pro. ile. pro. cys. pro. leu. leu. gly. leu. asp. ser. thr.
G  (7): leu. gly. lys. pro. ile. pro. asn. cys. leu. leu. gly. leu. asp. ser. thr.
H  (8): leu. gly. lys. pro. ile. pro. asn. pro. cys. leu. gly. leu. asp. ser. thr.
I (9): leu. gly. lys. pro. ile. pro. asn. pro. leu. cys. gly. leu. asp. ser. thr.
J (10): leu. gly. lys. pro. ile. pro. asn. pro. leu. leu. cys. leu. asp. ser. thr.
K  (11): leu, gly. lys. pro. ile. pro. asn. pro. leu. leu. gly. cys. asp. ser. thr.
L (12): leu. gly. lys. pro. ile. pro. asn. pro. leu. leu. gly. leu. cys. ser. thr.
F igure 44 : the am ino acid sequences o f  the Pk peptide tags and the cysteine substituted  
Pk tags which w ere cloned onto the C term inus o f  LTB and expressed in  Vibrio spp.
The numbers in parentheses correspond to the peptides on the SPOT membranes shown in figure 41.
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Figure 45 : Bar graphs to show the effect of cysteine substitutions at each position in the Pk tag on the anti-Pk mAh binding.The binding of the five anti-Pk monoclonal antibodies to the LTB-Pk-cys mutants were tested by ELISA. LTB-Pk (LPk) was used as a positive control and the supernatant from Vibrio sp. which had not been transformed was used as a negative control (data not shown).
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and leu-8 (figure 45c). This corroborates the information obtained from the SPOT tests. 
However, the LTB-cys substitutions show no effect on mAb binding when asn-6 was 
substituted. This is a complete contradiction to the data previously obtained from the SPOT 
tests (figure 42, lane c).
For effective binding to the Pk tag, mAb SV5-Pk4 could not tolerate the 
substitution of a number of amino acids (figure 45d). In addition to pro-7, the substitution 
of lys-2, ile-4, asn-6, leu-8, and leu-9 could not be tolerated if mAb binding was to occur. 
When comparing this information to that obtained from the SPOT test, there were a number 
of differences. In the SPOT test, substitutions to lys-2 or ile-4 had not affected mAb 
binding. However, mAb binding was affected by substitutions to asn-6, leu-8 and leu-9 
(figure 42, lane d).
SV5-Pk5 (figure 45e) could not tolerate the substitution of asn-6, leu-8 and leu-11. 
This confirms the results previously obtained from the SPOT test.
A complete summary of the results obtained from the LTB-Pk-cys experiments can 
also be seen in figure 43. The discrepancies shown between the ELISA testing of the LTB- 
Pk-cys mutants and the SPOT tests have not been explained. However, it has given an 
indication of the differences in the requirements of binding exhibited by the five anti-Pk 
mAbs.
4.2 Construction and expression of pGEX-I4APk. pGEX-L8APk and 
pGEX-Ll lAPk
The main objective for altering the Pk tag was to obtain a modified tag which would 
reduce the affinity of the mAbs for the Pk tag, and allow antibody - antigen separation to be 
achieved using relatively mild elution conditions.
From the results obtained by the SPOT’s cysteine substitutions and insertions, and 
the LTB-Pk-cys substitutions, the amino acids at positions 4, 8 and 11 were chosen to be 
altered (figure 46). The amino acids to be changed were the non-polar leucine or isoleucine 
residues. The amino acids at all three positions were changed to an alanine residue, instead
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P k ta g ;
pro gly lys pro ile pro asn pro pro leu leu gly leu ser Ihr OPA
A ATT CCA GGA AAG CCG ATC CCA AAC CCT TTG CTG GGA TTG GACTCCACCTGA
GGT CCT TTC GGC TAG GOT TTG GGA AAC GAC CCT AAC CTG AGG TGG ACT TTAA
I4APk tag:
pro gly lys pro ala pro asn pro leu leu gly leu asp ser thi OPA
A ATT CCA GGA AAG CCG GCC CCA AAC CCT TTG CTG GGA TTG GAC TCC ACC TGA
GGT CCT TTC GGC CGG GGT TTG GGA AAC GAC CCT AAC CTG AGG TGG ACT TTA A
L8APk tag;
pro gly lys pro ile pro asn pro ala leu gly leu asp ser tlir OPA
A ATT CCA GGA AAG CCG ATC CCA AAC CCT GCG CTG GGA TTG GAC TCC ACC TGA
GGT CCT TTC GGC TAG GGT TTG GGA CGC GAC CCT AAC CTG AGG TGG A C G T T A  A
L llA P k  tag:
pro gly lys pro ile pro asn pro leu leu gly ala asp ser thr OPA
A ATT CCA GGA AAG CCG ATC CCA AAC CCT TTG CTG GGA GCG GAC TCC ACC TGA
GGT CCT TTC GGC TAG GGT TTG GGA AAC GAC CCT CGC CTG AGG TGG ACT TTA A
Figure 46 : The DNA linkers containing the sequences for the Pk tag and the  
m od ified Pk tags.
The positive and negative sense oligonucleotides were designed so that when annealed an EcoRl 
compatible site was created at each of the ends. The amino acid mutated in each of the Pk tags is 
shown in bold.
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of a cysteine as was performed previously. This was done to preserve the chemical 
property of the amino acid side chain, as alanine is an amino acid which also has a non­
polar side chain. This substitution would not dramatically affect the three-dimensional 
folding of the Pk tag.
Previously all antibody binding studies had been performed using recombinant His- 
Nef-Pk or the P protein of SV5. However, to test the modified tags, the model protein 
glutathione S transferase ( GST) was selected instead. This was because large amounts of 
highly purified GST can be produced using a simple protocol, in a relatively short length of 
time (see section 1.1 of the Introduction for more details). This makes GST an ideal protein 
with which to test the modified Pk tags.
The sequence for the original Pk tag had previously been cloned into the pGEX-2T 
expression vector, creating pGEXcPk (Hanke 1993). From this plasmid, a fusion protein 
in which the Pk tag was fused to the C terminus of GST was produced, known as GST- 
Pk.
“ To produce GST fusion proteins which contained the modified tags, 
oligonucleotide primers were synthesised which contained the individual 5 ’ and 3 ’ DNA 
sequences of the three modified tags. When annealed together, the DNA linkers created 
contained EcoRl compatible restriction sites at both ends. The DNA linkers were ligated 
into the EcoRi restriction site of pGEX-2T.
Positive transformants, containing the plasmids with the modified tags, were 
screened by hybridisation using the 5 ’ oligonucleotide primers as probes. As the DNA 
linkers had been ligated into a single restriction site, the orientation of the modified tags 
needed to be confirmed. This was performed by inducing the bacterial transformants at 
27°C for 2 hours with 1 mM IPTG, and analysing the TCL samples by Western blotting 
(figure 47). The nitrocellulose filters were probed with a mixture of all five anti-Pk mAbs. 
The fusion proteins produced were named: GST-Pk (from pGEXcPk), GST-I4APk, GST- 
LSAPk and GST-Ll lAPk.
To acquire sufficient protein for mAb binding studies, large scale inductions were 
performed. The resuspended cells were kept in the presence of protease inhibitors at all
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a b
GST fusion protein
Figure 47 : W estern blot analysis to determ ine the orientation o f G ST fusion proteins 
containing the m utated Pk tags.
Small scale cultures of bacteria previously transformed with pGEX-2T containing the ligated DNA 
linkers were induced with 1 mM IPTG for 2 hours. Samples were taken, the pelleted cells resuspended 
in SDS-PAGE loading buffer, and the total cell lysates were loaded onto a 10% polyacrylamide gel. 
The separated proteins were transferred to nitrocellulose filters and probed with a mixture of all five 
anti-Pk mAh’s. Detection was by ECL.
Key : a - GST-I4APk; h - GST-L8APk; c - GST-Ll lAPk
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times during cell lysis and purification, to ensure that the produced recombinant fusion 
proteins were not degraded by bacterial proteases. After ceil lysis and centrifugation, the 
soluble protein fractions containing the GST fusion proteins were immediately purified on a 
glutathione column. The proteins were eluted by the addition of an excess of glutathione to 
the wash buffer.
4.3 Binding studies for GST-I4APL GST-L8APk and GST-Ll lAPk
To determine if the mAbs recognised all 3 modified tags, ELISA plates were coated 
with the GST fusion proteins and probed with the five anti-Pk mAbs. The results showed 
that SV5-Pkl recognised all 3 modified tags. SV5~Pk2 also bound to all 3 modified tags 
but appeared to bind GST-I4APk with less affinity than GST-L8APk and GST-Ll lAPk. 
SV5-Pk3 and SV5-Pk5only recognised GST-I4APk, whereas SV5-Pk4 recognised GST- 
L8APk and GST-Ll 1 APk but not GST-I4APk (table 10).
To determine if this pattern of mAb binding was obtained when using batch affinity 
chromatography, the five anti-Pk mAbs were immobilised on PrG Sepharose beads. Each 
fusion protein was incubated with each of the mAbs bound to the PrG Sepharose beads. 
The mixture was washed with PBS and loaded onto a 10% PAG. The PAG’s were stained 
with Coomassie Brilliant Blue to visualise the proteins (figure 48).
On the stained PAG there were three bands visible (see figure 48). The very large 
and very small bands represented the heavy and light chains of the mAbs respectively. The 
heavy and light chains were visible because the mAbs had not been covalently coupled to 
the Protein G Sepharose beads, which allowed separation in the SDS-PAGE
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Figure 48 : Coom assie stained gels show ing the patterns o f bind ing o f the five anti-Pk  
m A h’s to the m od ifîed Pk tags.
Each of the anti-Pk mAh’s were immobilised on PrG-sepharose beads and incubated with each of 
the GST-Pk fusion proteins for 1 hour. The beads were washed with PBS, resuspended in SDS- 
PAGE loading buffer and loaded onto a 10% PAG. The protein bands were visualised by 
Coomassie staining.
Key : i - SV5-Pkl; ii - SV5-Pk2; iii - SV5-Pk3; iv. SV5-Pk4; v - SV5-Pk5; vi. - Protein G beads 
only (negative control)
a, e, j, n & s - GST-Pk; b, f, k, p & t - GST-I4APk; c, g, 1, q & u - GST-L8APk; d, h, m, r & v - 
GST-Ll 1 APk
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SV5-Pkl SV5-Pk2 SV5-Pk3 SV5-Pk4 SV5-Pk5
GST-Pk +++ 4-4-+ 444 444 444
GST-14APk -fH-4- 4 4—1—f- - H—1—l-
GST-L8APk ++ + _i—j—^ - 444 -
GSTLllAPk H—h + 444 - 444 -
T ab le 10 : T he b in d in g  p attern s o f  the an ti-P k  m A bs to G ST -Pk and the  
three m od ified  Pk tags.
ELISA plates were coated with each of the GST fusion proteins and probed with the anti-Pk 
mAbs. The pattern of binding was observed by a change in colour when the assay was 
developed.
Key : +++ - strong binding to the fusion protein; + - weak binding to the fusion protein; - - 
no binding to the fusion protein.
loading buffer. If a third band was present in the sample, this showed mAb binding to the 
modified tag. If only two bands were visible, then no, or reduced, binding of the fusion 
protein containing the modified tag to the anti-Pk mAb was observed. The most obvious 
example of this is shown in lanes 1 & m. This indicated that S V5-Pk3 did not bind to the 
GST-L8APk and GST-Ll lAPk altered tags.
The light chain of SV5-Pk4 separated at exactly the same size as the GST fusion 
proteins on the Coomassie stained gel (figure 48, lanes n. p, q & r). This made it 
impossible to determine which of the altered tags SV5-Pk4 recognised. To overcome this 
the samples were analysed by Western blotting and probed with an anti - GST polyclonal 
antibody. From this experiment, it became clear that SV5-Pk4 did not bind to, or showed 
reduced binding to, the GST-I4APk mutant. Binding to the GST-L8APk and GST- 
L l lAPk mutants was observed (data not shown).
In general, the results obtained from the batch affinity chromatography experiments 
confirmed the results of the previous ELISA experiment, however, there was a single 
contradiction. The ELISA experiments revealed that SV5-Pk2 showed a reduced binding to 
the GST-I4APk modified tag (see table 10), but the batch affinity chromatography 
experiments showed that SV5-Pk2 bound to GST-I4APk with equivalent strength to that of 
the other modified tags (figure 4S. lane f). The differences in the two practical techniques
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may partially explain the contradictory observations of SV5-Pk2 binding to GST-I4APk. 
However, the reduction in the binding of SV5-Pk2 to the I4APk modified tag may be a 
way of producing a protocol for the affinity purification of Pk tagged recombinant proteins.
5. THE DEVELOPMENT OF A PROTOCOL FOR THE 
AFFINITY PURIFICATION OF Pk TAGGED RECOMBINANT 
PROTEINS
Section 5 concentrates on the determination of buffers which could be used for the 
elution of purified tagged recombinant proteins from a mAb affinity column.
5.1 Determination of wash conditions for the elution of bound monoclonal 
antibodies from tagged recombinant proteins
An efficient method of testing a large number of conditions is by using ELISA. To 
test buffers which can be used for the elution of Pk tagged recombinant proteins from anti- 
Pk mAbs, or vice versa, ELISA plates were coated with the GST fusion proteins 
containing the modified tags. The plates were then probed with the five anti-Pk mAbs, 
using an anti - GST polyclonal antibody as a positive control. The anti-GST polyclonal 
antibody was used to ensure that the GST fusion proteins were binding to the ELISA 
plates, and to confirm that a reduction in the amount of mAb bound was not due to the 
fusion proteins being stripped from the plates when using harsh elution conditions. A 
number of elution buffers were tested (figure 49).
Figure 49 shows the effect that a number of elution buffers had on antibody binding 
to GST-Pk (figure 49a), GST-I4APk (figure 49b), GST-L8APk (figure 49c) and GST­
L llA Pk (figure 49d). These experiments were designed to identify any elution buffer 
which had little effect on mAb binding to the GST-Pk fusion protein, but which showed a 
drastic effect on the binding of the mAbs to a fusion protein containing a modified tag. As 
with the ELISA and batch chromatography experiments described in section 4.3, the best
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a. GST-Pk b. GST-l4APk
H  SV5-Pkl 
■  SV5-PK2 
□  SV5-Pk3 
B l SV5-Pk4 
9  SV5-Pk5
C D E F 
wash buffers
m SV5-Pkl 
■  sV5-Pk2 
□  SV5-Pk3 
0  SV5-Pk5
C D E F 
wash buffers
c. GST-L8APk d. G ST-Ll 1 APk
0SV 5-Pk1 
B  SV5-Pk2 
□  SV5-Pk4
C D E F G 
wash buffers
SV5-Pk1
B sV 5-P k2
□  sV5-Pk4
wash buffers
F igure 49 : Bar charts show ing the effect o f elution buffers on the bind ing o f the  
anti-P k  inA bs to G ST fusion  proteins contain ing  the m od ified Pk tags.Each of the mAh’s were incubated on ELISA plates with each relevant GST-Pk fusion proteins. E^ ch ELISA plate was then incubated with a number of elution buffers to determine which has the most significant effect on mAb binding.Key to elution buffers ; A - phoshate buffered saline; B - 0.2 M glycine pII2.8; C - 3.5 M Magnesium chloride; D - 3.5 M sodium thiocyanate; E - 0.1 % Sodium deoxycholate; F - 0.1 M diethyiamine; G - 20 mM hydrochloric acid
example observed was the binding of SV5-Pk2 to the GST-I4APk modified tag (compare 
figure 49a & 49b, lane e). In this example, the elution buffer 3 M magnesium chloride 
(MgCG) showed little effect on the binding of SV5-Pk2 to GST-Pk (figure 49a, lane e), yet 
appeared to completely disrupt the binding of SV5-Pk2 to the GST-14APk mutant tag 
(figure 49b, lane e).
A complete summary of all the elution buffers tested on the binding of all four 
fusion proteins to all five anti-Pk mAbs can be seen in Table 11. Table 11 also shows the 
effects that a single amino acid change to the Pk tag had on mAb binding for different 
elution buffers.
The data obtained from these ELISA experiments was used as a basis for the 
determination of buffers which could be used for the elution of tagged recombinant proteins 
from mAb coupled affinity columns.
5.2 Batch purification of Pk tagged recombinant proteins from PrG-mAb 
heads
When altering the sequence of the Pk tag to create the three new tags, it was hoped 
that for each mAb there would be a single modified tag which would change the binding of 
the mAbs and allow the elution of tagged recombinant proteins using relatively mild elution 
conditions. From the information obtained from the ELISA experiments described in 
section 5.1, it was shown that for each mAb there was a single modified tag which allowed 
protein elution under mild conditions. The modified tag selected for each mAb, and shown 
in Table 12, was to be used for further affinity chromatography studies.
The five anti-Pk mAbs were covalently coupled to Sepharose-Protein G beads 
using dimethylpimelidate (Materials and Methods). Small samples of the PrG - mAb 
coupled Sepharose beads were incubated, for 1 hour, with GST-Pk, or GST-I4APk, GST- 
LSAPk or GST-Ll lAPk, depending on the mAb. After the incubation with the GST fusion 
proteins, the beads were then incubated with a number of elution buffers. The elution
150
Table 11 : A sum m ary o f the ELISA data obtained on the effects o f  elution  
buffers on the bind ing o f the anti-Pk m A h’s to the G ST fusion proteins.
ELISA plates were coated with the four GST fusion proteins and probed with the five anti-Pk 
mAb's. Each column of wells was then washed with a different elution buffer, using PBS as 
the positive control. The effectiveness of the buffers were determined by a direct comparison 
to the PBS control.
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buffers were specifically chosen for each mAb on the basis of how well they had disrupted 
the mAb - antigen complexes in the ELISA studies described in section 5.1 (see Table 11).
Anti-Pk monoclonal antibody Fusion protein containing the modified Pk 
tag chosen for further elution analysis
SV5-Pkl GST - LSAPk
SV5-Pk2 GST-I4APk
SV5-Pk3 GST-I4APk
SV5-Pk4 GST-L8APk
SV5-Pk5 GST-I4APk
T ab le 12 : a sum m ary o f  the fu sio n  p ro te in s co n ta in in g  th e  m od ified  tags  
chosen for each  m A h for fur ther a ffin ity  chrom atography analysis.
The modified tag chosen for each mAb was based on the information obtained, by ELISA, on 
the relative effect of elution buffers on the binding of the anti-Pk mAbs to the modified tags.
After the incubation with the elution buffers, the beads were washed with PBS and 
resuspended in SDS-PAGE loading buffer. The samples were loaded onto a 10% PAG for 
electrophoresis and the protein bands visualised by Coomassie staining. To ascertain how 
effective each buffer was at eluting the GST fusion proteins containing the various Pk tags, 
from mAb affinity beads, a comparison was made of the levels of elution obtained from the 
GST-Pk and the modified GST-Pk beads (see figures 50, 52, & 53). To ensure that a 
direct comparison could be performed, each of the samples contained an equal amount of 
PrG-mAb beads.
As stated earlier, the GST-L8APk mutant tag was selected for further study with the 
anti-Pk mAbs SV5-Pkl and SV5-Pk4. PrG-mAb Sepharose beads which had been 
incubated with either GST-Pk or GST-L8APk, were then incubated with the elution buffers 
0.2 M glycine pH2.8 (glycine 2.8), 0.2 M glycine pH lL5 (glycine 11.5) and 2 M sodium 
thiocyanate (NaSCN), as well as PBS as the positive control. An efficient elution buffer is 
one which gives good protein elution when compared to the PBS control. The results can 
be seen in figure 50.
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The greatest differences observed between the binding of SV5-Pkl to the modified 
tag and to the original Pk tag, were shown for the elution buffers glycine 2.8 (compare 
lanes b & f) and NaSCN (compare lanes d & h). The presence of these two buffers, had a 
dramatic effect on the binding of SV5-Pkl to GST-LSAPk (lanes f & h), but no effect on 
mAb binding to GST-Pk (lanes b & d). It appeared that changing the leucine at position 
eight of the Pk tag, drastically affected the efficiency with which SV5-Pkl binds the Pk 
tag, allowing relatively easy separation. Glycine 11.5 showed no protein elution (lanes c & 
g) and gave protein elution equivalent to the PBS positive control (lanes a & e).
As with SV5-Pkl, glycine 2.8 (figure 50, compare lanes k & o) also showed the 
most significant effect on the binding of SV5-Pk4 to the modified tag, when compared to 
the original Pk tag. NaSCN and glycine 11.5 appeared to have no effect on the binding of 
SV5-Pk4 to GST-Pk or GST-L8APk (compare lanes m & q and 1 & p respectively), 
although there was less protein bound than that observed in the PBS positive control (lanes 
j & n).
From the ELISA data discussed in section 5.1, a number of elution buffers affected 
the binding of SV5-Pk2 to the I4APk modified tag (figure 49). As the mildest condition to 
affect SV5-Pk2 binding was 3 M MgCE, it was thought that other divalent cations may 
also effect mAb binding.To test this, the elution buffers 2 M calcium chloride (CaCG), 2 M 
manganese chloride (MnCE) and 2 M zinc chloride (ZnCl2) were examined. These elution 
buffers were originally tested by ELISA to determine which was the most effective at 
allowing protein elution (figure 51). Of the buffers tested, the most promising were found 
to be 2 M MnCL (lane D) and 2 M MgCb (lane B), with the least effective being 2 M 
ZnCl] (lane E). Due to the results obtained from this ELISA study, MnCL and MgCL, 
along with glycine 2.8, were used for the elution of the GST-Pk and GST~I4APk fusion 
proteins from SV5-Pk2 coupled Protein G - Sepharose beads. As with the previous 
experiments, PBS was used as a positive control. The results can be seen in figure 52.
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F igure 50 : Coom assie stained gels show ing the effect o f elution buffers on the bind ing  
of the anti-Pk m A h’s to GST-Pk and GST-L8APk.
The anti-Pk mAh’s SV5-Pkl (i & ii) & SV5-Pk4 (iii & iv) were covalently coupled to PrG- 
sepharose beads and incubated with the GST-Pk (i & iii) & GST-L8APk (ii & iv) fusion proteins 
for 1 hour.
Samples of each were then incubated with different elution buffers before being washed with PBS 
and loaded onto a 10% PAG. The protein bands were visualised by Coomassie blue staining.
Key to elution buffers ; a, e, j, & n - PBS; b, f, k, & o - 0.2 M glycine pH 2.8; c, g, 1 & p - 0.2 M 
glycine pH 11.5; d, h, m & q - 3.5 M sodium thiocyanate
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elution buffers
F igure 51 : bar chart show ing the effect o f e lu tion  buffers on  the b ind ing  o f  
the an ti-P k  m A h S V 5-P k 2 to the m od ified  G ST -I4A Pk tagThe data was obtained by the testing of ELISA plates coated in the GST-I4APk mutant fusion protein, and probing with SV5-Pk2. The plates were then washed with a number of elution buffers and using PBS as the positive control, assayed for their effect!vity. key : A - PBS; B- 2 M MgClz; C - 2 M CaCli: D - 2 M MnCl2; E - 2 M ZnCl2.
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An effect on mAb binding to the GST-I4APk fusion protein was seen with ail three 
buffers tested, with the largest effect elicited by glycine 2.8 (lane f). However, when 
comparing this to the protein elution obtained for GST-Pk, the differences were not so 
distinct. When a comparison was made, the largest difference between the two tags was 
seen for MgC^ (compare lanes c & g), although MnCG does not show much less of a 
difference (compare lanes d & h). Unfortunately, it was found that after elution with 
MgCb, a precipitate formed on washing the beads with PBS. To overcome this problem, 
the beads were washed with Tris buffered Saline (TBS) instead of PBS.
As the mAbs SV5-Pk3 and SV5-Pk5 only recognised the I4APk modified tag, this 
tag was compared to the original Pk tag, and used for further elution studies. Samples of 
PrG-SV5-Pk3 and PrG-SV5-Pk5 beads were incubated with either GST-Pk or GST- 
I4APk before being incubated with the elution buffers glycine 2.8, glycine 11.5 and 
NaSCN. As with the other experiments, PBS was used as a positive control (figure 53).
The differences observed for SV5-Pk3 were not as marked as those observed for 
the mAbs previously discussed. Figure 53 shows that only slightly less protein elution was 
obtained from the GST-Pk tag than the modified GST-14APk tag 1 compare figure 53 (i) & 
(ii)]. This was contradictory to the data obtained by ELISA (Table 11). Glycine 2.8 gave 
the most protein elution for both tags (lanes b & f). However, unlike the anti-Pk mAbs 
described previously, glycine 11.5 also showed a large effect on protein binding (lanes c & 
g). Of the elution buffers tested NaSCN gave the least protein elution (lanes d & h), 
although when compared to the PBS control a considerable amount of protein was still 
eluted.
When a comparison of the levels of protein eluted from S V5-Pk5 affinity beads was 
made between the original Pk tag and the modified L8APk tag, there appeared to be very 
little difference [compare figure 53, (iii) & (iv)]. For both tags, little protein elution was 
obtained when comparing each of the elution buffers to the PBS positive control (lanes j & 
n). Of the elution buffers tested, only glycine 11.5 (lanes 1 & p) gave a significant reduction 
in protein binding of the GST-L8APk fusion protein containing the modified tag. The other
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F igure 52 : Coom assie stained gels show ing the effect o f d ifferent elution buffers on the 
bind ing o f SV 5-Pk2 to GST-Pk and GST-I4APk.
The SV5-Pk2 anti-Pk mAb was covalently coupled to PrG-sepharose beads and incubated with the 
GST-Pk (i) and GST-I4APk (ii) fusion proteins for 1 hour. Samples of each were then incubated 
with different wash buffers before being washed with PBS and loaded onto a 10% PAG gel for 
Coomassie Brilliant blue staining.
Key to elution buffers : a & e - PBS; b & f - 0.2 M glycine pH 2.8; c & g - 2 M magnesium chlo­
ride; d & h - 2 M manganese chloride
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F igure 53 ; Coom assie stained gels show ing the effect o f elution buffers on the bind ing  
o f the anti-Pk m A h’s SV5-Pk3 and SV5-Pk5 to GST-Pk and GSTM APk.
The anti-Pk mAh’s SV5-Pk3 (i & ii) & SV5-Pk5 (iii & iv) were covalently coupled to PrG- 
sepharose beads and incubated with the GST-Pk (i & iii) & GST-I4APk (ii & iv) fusion proteins for 
1 hour.
Samples of each were then incubated with different elution buffers before washing with PBS and 
loading onto a 10% PAG. The proteins were visualised by staining with Coomassie Brilliant Blue. 
Key to elution buffers ; a, e, j, & n - PBS; b, f, k, & o - 0.2 M glycine pH 2.8; c, g, 1 & p - 0.2 M 
glycine pH 11.5; d, h, m & q - 2 M sodium thiocyanate
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elution buffers tested showed little observable protein elution (compare lanes k & o for 
glycine 2.8, and lanes m & q for NaSCN).
5.3 Conclusions
The data described in this section was utilised for further studies into the elution of 
tagged recombinant proteins from mAb affinity columns. The preliminary data obtained 
from these experiments showed that the conditions described for each mAb did in fact elute 
tagged proteins from PrG-mAb affinity chromatography columns, although no quantitative 
data was obtained on how much protein was eluted. This signified that although the exact 
protocol for a two - step affinity purification protocol had not been developed, the 
foundations for one had been laid.
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DISCUSSION
1. SIV GENE EXPRESSION AND RECOMBINANT PROTEIN 
PURIFICATION
In order to have a complete repertoire of cloned and purified SIVmac genes and 
proteins from the J5 molecular clone, the genes n e f  and gag were cloned into, and 
expressed from, the expression vector pQ9cPk. The conditions required to achieve optimal 
induction of nef\ and the subsequent purification of recombinant His-Nef-Pk were 
determined, and these conditions are outlined in section 1.2 of the Results. This purified 
recombinant Nef has been used for a number of purposes including, the development of 
Nef anti-sera, the isolation of anti-Nef monoclonal antibodies (mAbs), and the 
incorporation of recombinant Nef into multivalent epitope vaccines. However, a number of 
problems arose when aiming to repeat this process for gag.
Like nef, the conditions for the optimal induction of the gag gene have been 
determined, and are shown in section 1.4 of the Results. Significant problems arose, 
however, when trying to purify recombinant His-Pr558^g-Pk on a nickel affinity column. 
His-Pr55§^?-Pk was observed binding to the nickel beads, but no protein elution was seen 
when imidazole was applied to the column. In addition, no recombinant protein could be 
detected on the column by SV5-P-k once protein elution had been attempted. One 
explanation for this may be that conditions within the column environment may be 
sufficient to cause recombinant protein aggregation, and therefore, protein precipitation. 
The gag gene encodes the Pr55§®g precursor protein, which after proteolysis, produces the 
viral particle structural proteins. Within an infected cell, this precursor protein is cleaved, 
almost instantaneously after translation, by the viral protease into the constituent proteins 
(p l5 . p l7  & p24). It is possible therefore that His-Pr55?^§-Pk has an unstable 
configuration, exposing amino acid residues which allow protein aggregation. This change 
in the configuration of His-Pr55§^@-Pk may also have caused the Pk tag to be no longer
1 6 1
accessible to SV5-P-k, which would partially explain why no protein was detected within 
the column once protein elution was attempted.
To determine if the solubility of His-Pr55"‘^ ?-Pk was the problem during affinity 
purification, both the soluble protein fraction and the insoluble protein fraction, 
resuspended in 8 M urea, of the bacterial lysate were studied using identical conditions. 
The results of the soluble protein fraction gave no protein elution from a nickel affinity 
column (data not shown). The denatured insoluble protein fraction was studied under 
similar conditions due to the stable nature of the histidine tag and its ability to bind to nickel 
beads even under denaturing conditions. When eluting the denatured protein from nickel 
beads using a solution of imidazole and urea, small amounts of purified His-Pr55s^§-Pk 
protein were obtained (data not shown). The small percentage of protein eluted (approx 1% 
of the total protein detected) suggests that the recombinant protein is inherently insoluble in 
aqueous solution and that only under denaturing conditions will protein elution occur.
In a previous study by Hanke (1993), the cloning and expression of the individual 
gag gene sequences (p/5, p /7  & p24), and the subsequent purification of the gene 
products, were examined. All three genes gave high yields of recombinant protein, which 
were nickel affinity purified with little difficulty. Due to the dificulties encounted when 
trying to purify Pr55§^", it will be more efficient to express the gag genes individually and 
to purify each recombinant protein produced, instead of trying to obtain sufficient purified 
His-Pr55§^8-Pk recombinant protein.
2. THE ISO L A T IO N  OF ANTI-PRth M ONOCLONAL  
ANTIBODIES
The Pk tag, which is fused to the C terminus of recombinant proteins, was 
originally the sequence of a synthetic peptide which was used to compete with the binding 
of the mAb SV5-P-k to its antigen, the P protein of Simian Virus 5 (SV5: Southern eta l 
1991). On further analysis, SV5~P-k was shown to have an unusually high affinity for the 
Pk peptide (23.6 pmol), making it useful for the detection and analysis of tagged
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recombinant proteins, and for the incorporation of recombinant proteins into solid matrix 
antibody antigen (SMAA) complexes, but not for protein affinity purification (Hanke 1993. 
Randall a/ 1994 & 1994a).
Previously developed within the research group was an affinity purification 
protocol using the Pk tag, and another (either the hexahistidine tag or GST), to obtain full 
length recombinant proteins (Randall et al 1993). As the recombinant proteins were 
required at that time for the development of SMAA complexes, the separation of the mAb 
SV5-P-k from the tag was not necessary. However, subsequent evidence showed that 
SMAA complexes did not give protection against SIV challenge (J. Stott & R.E. Randall, 
personal communication), suggesting that this was not the way to proceed in SIV vaccine 
development. This result, however, did not invalidate the use of multiple epitope vaccines 
as a way of immunising animals to give protection against SIV challenge. This meant that 
purified full length recombinant proteins were required in which the Pk tag was not 
complexed to the mAb SV5-P-k. Initial experiments to determine conditions which could 
be used for the separation of Pk tagged recombinant proteins from SV5-P-k showed that 
only the most denaturing conditions (e.g. 8 M urea or 6 M guanidine hydrochloride) had an 
effect, but this could permanently affect the structure of the recombinant proteins to be 
purified.
In order to obtain a number of mAbs which could potentially be used for the affinity 
purification of Pk tagged recombinant proteins, a group of mice were immunised with a 
peptide containing the Pk tag known as Pk-in (figure 28). From the initial immunisation 
with this peptide, twenty four anti-Pk^ mAbs were isolated. On further analysis by 
western blotting (figure 29), ELISA (table 6) and immunofluorescence (figure 30), of these 
twenty four mAbs, only four recognised the Pk tag sequence. The other twenty recognised 
only the Pk^ H peptide.
In addition to the four anti-Pk mAbs which were tested, the binding sites of the 
twenty anti-Pk^ mAbs were also determined by SPOT testing (data not shown). All were 
found to recognise an area within the first half of the Ty cell epitope, suggesting that this 
area within the Ty cell epitope was immunodominant over the Pk tag amino acid sequence.
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The inital characterisation of the four anti-Pk mAbs indicated similarities in their 
behaviour. For example, when experiments were performed to determine conditions which 
would allow the elution of the mAbs from His-Nef-Pk coated filters (figure 40), all four 
mAbs needed strong denaturing conditions to separate the antibody-anti gen complex. When 
comparing this information to that initially obtained for SV5-P-k. it was observed that the 
four new mAbs did not allow protein elution under less restrictive conditions. The data 
obtained from these experiments was confirmed by Biosensor analysis, which asigned the 
four new anti-Pk mAbs binding affinities similar to that of SV5-P-k (table 9). All of this 
data suggests that the method used for the isolation of anti-Pk mAbs was not suitable for 
the production of low affinity mAbs, and exhibited preferential selection for high affinity 
mAbs.
In the initial immunisation protocol, the mice were injected twice before the final 
booster and removal of the spleen. The intial injection primes the immune system to a 
subsequent challenge with the immunogen. In this initial immune response, low affinity 
antibodies are generated to the immunogen, and it is only with the second challenge that 
high affinity antibodies are generated (Coding 1984, Harlow and Lane 1988, Kuby 1997). 
For the generation of mAbs to the Pk tag, it may be more advantageous to perform a fusion 
using the spleens from mice which were only challenged once with the immunogen, 
therefore selecting for low affinity mAbs. A disadvantage to this is that to develop a similar 
amount of hybridoma clones would require a lot more screening, and also that the mAbs 
produced may be of such a low affinity that they would be of no practical use.
An alternative method is phage display, which generally gives lower affinity mAbs 
than the traditional method of hybridoma technology. Phage display also allows a more 
controlled method of screening, and allows the selection of specific affinity mAbs. 
However, the disadvantage to using this method is the difficulties encountered when 
producing large amounts of antibody for further study.
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3. THE IMMUNOGENICITY OF THE Pk TAG
Using synthetic peptides which were deletions of the Pk tag to determine the 
minimum binding epitopes of the five anti-Pk mAbs. it was shown that all five needed a 
common motif to be present in order for binding to occur. This was the tetrameric amino 
acid sequence Pro (5). Asn (6). Pro (7). Leu (8). (see figure 33 of the results). The 
apparent immunodominance of these amino acids may be caused by the conformation 
induced by the spatially rigid proline residues. If the predicted conformation of the Pk 
peptide is modelled and examined (figure 54), the prolines within this tetrameric sequence 
force the peptide backbone to undergo a sharp turn to form a loop-like structure. This loop 
structure corresponds to the predictions made on the shape and properties of mAb binding 
epitopes (Kuby 1997). Generally a mAb binding epitope tends to be accessible, 
hydrophilic, have site mobility and can be continuous or non-continuous.
Accessibility and hydrophilicity ensure that the peptide can be recognised by the 
mAb. The binding epitopes of a number of large proteins, such as neuraminidases, 
influenza haemagluttinin and GST, are hydrophilic and are found as loops and turns on the 
surface. The Pk tag contains hydrophilic amino acids which ensure that it is surface 
expressed when part of a fusion protein. This hydrophilicity is also exhibited by other 
peptide affinity tags which have been specifically designed for mAb recognition e.g. 
FLAG™, Strep and c-myc.
Mobility within the binding epitope has also been shown to be important for mAb 
binding to a number of binding sites within the proteins insulin, myohemerythricin. 
cytochrome C, myoglobin and haemoglobin (Tainer etal 1984). The proposed theory for 
the importance of mobility is that site mobility maximises the complementarity of the 
antigen within the mAbs binding site. However, a mAb binding to a flexible site has a 
lower affinity than mAbs binding to a rigid region (Tainer era/ 1984, Kuby 1997). The 3- 
dimensional (3-d) structure of the Pk tag appears to contain mobile ends surrounding a 
rigid turn/loop structure. This could partially explain the high affinity that the anti-Pk mAbs 
have for the Pk tag. The mobile ends of the tag (figure 54) may allow the peptide to
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F igure 54: A representation o f the pred icted 3 d im ensional structure o f the Pk tag.
The amino acids in red represent those which form the rigid loop / turn structure (pro-3 to leu-8) 
which is required for the binding of the anti-Pk mAbs to the peptide tag. The structure was 
predicted using the RasMol programme for Macintosh.
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be sufficiently flexible to maximise the mAb binding site complementarity. However, the 
rigidity enforced on the structure by the prolines at positions 3, 5 & 7 would allow for the 
production of high affinity mAbs. This flexibility is also found within a 14 amino acid 
epitope of the myelin basic protein (Mendz etal 1995). Structural analysis revealed that this 
14 amino acid motif forms a loop between amino acids 7 and 12, which is thought to be 
targeted by mAbs. The N terminal amino acids (1 -7 )  appear flexible, whereas the loop 
itself is rigid. In the case of this tetradecapeptide, mAb binding is further enhanced by the 
twisting of the peptide backbone within the loop to expose charged amino acid side chains 
(Mendz6?ra/ 1995).
Another observation made of the five anti-Pk mAbs was the high affinity with 
which they bound to the Pk tag. All five require denaturing conditions to separate the 
antibody-anti gen complex. Antibody - antigen interactions are composed of a number of 
weak non-covalent interactions, such as hydrogen bonds, ionic bonds, hydrophobic 
interactions and van der Waals interactions. Together these weak forces combine to make 
the strong, reversible antibody-antigen interaction. These weak interactions act over short 
distances (about 10 mm), and depend upon the close fit of the epitope within the mAb 
binding site (Kuby 1997). As discussed earlier, site mobility is important in a mAb binding 
epitope. When this is combined with the natural flexibility found within a mAb binding 
site, a highly complementarity interaction is formed between the antibody and the antigen. 
The strong binding of the mAbs to the Pk tag suggest that there are a large number of these 
forces acting on the interaction and suggest that the Pk tag has adopted a conformation 
which allows the optimal number of non-covalent interactions to occur, thus greatly 
stabilising the antibody-antigen interaction (Tainer a/ 1984, Regenmortel 1989, Kuby 
1997). In order to determine how important the position of an amino acid within the Pk 
sequence is for mAb binding, cysteine residues were inserted between each amino acid in 
the tag. The results (figure 42) showed that for SV5-Pk5, the position of the amino acids 
within the tag were important for mAb binding. Even those amino acids which were found 
at the edges of the tag (figure 42, lane k). In contrast, the insertion of cysteine residues 
between amino acids had no effect on the binding of SV5-Pk2 (figure 42, lane g). This
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indicates that SV5-Pk5 utilises most of the 14 amino acids within the tag for mAh binding, 
whereas SV5-Pk2 needs only those found within the minimum binding epitope for 
successful mAb binding.
When the binding of the anti-Pk mAbs were studied by Biosensor technology, 
differences were detected between the binding of the mAbs to the Pkxn peptide and to the 
Pk tag when part of a fusion protein. When the antibodies bound to the Pk^n peptide alone, 
they showed a normal antibody-antigen interaction. However, when a similar test was 
performed on the binding of the anti-Pk mAbs to GST-Pk (data not shown), there were 
discrepancies in the results. The sensorgrams obtained showed a normal 1 : 1 antibody- 
antigen interaction for the association phase, however there appeared to be a complex 
interaction for the dissociation phase. This suggested that either the antibody or the tag was 
multivalent, that either the antibody or the tag was exhibiting cooperativity or that the mAb 
was re-associating with the immobilised Pk tag. Of the three suggestions, the third is the 
most probable explanation, although there was insufficient data to completely rule out the 
other two suggestions (Pathak & Savelkoul 1997). To date this has not been fully 
explained.
4. THE MODIFICATION OF THE Pk TAG
When the binding patterns exhibited by the five anti-Pk mAbs were studied more 
closely using synthetic peptides containing cysteine substitutions, it was observed that there 
were subtle differences. The effects of substituting amino acids at certain positions within 
the tag showed that there were more amino acids involved in the binding of the mAbs to the 
tag than just those amino acids within the minimum binding epitope. For example, SV5- 
Pk5 needs a number of amino acids, which range from the proline at position 3 to the 
threonine at position 14, for binding to occur. Although mAb binding is not abolished if 
these two amino acids are substituted, it is greatly reduced (see figure 42). In contrast. 
SV5-Pk2 and SV5-Pk4 have relatively compact binding sites, requiring only those amino 
acids which are found within the minimum binding epitopes. The other two anti-Pk mAbs.
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SV5-Pkl and SV5-Pk3. require a single amino acid (the leucine at position 11) in addition 
to those within the minimum binding epitope in order for binding to take place. In order to 
see how other amino acid substitutions would affect mAb binding, the Pk tag was modified 
by the substitution of three amino acids to an alanine residue. The positions which were 
modified were chosen on the basis of the observations made during the cysteine 
substitution experiments. The substitutions produced three "new" Pk tags; I4APk; L8APk; 
and LI lAPk.
Based on the previous substitution experiments described in section 4.1 and 4.2 of 
the Results, the effects of these modified Pk tags on anti-Pk mAb binding was as expected 
(see table 10), with a single exception. SV5-Pk4 does not bind to the I4APk modified tag. 
This was unexpected as the previous cysteine substitution experiments had shown that 
substituting ile-4 for a cysteine had no effect on the binding of SV5-Pk4. However, SV5- 
Pk4 did not recognise the modified tag when part of the GST fusion protein. An 
explanation for this could be ascribed to structural changes in the 3-d structure of the Pk 
tag, induced by the substitution of the isoleucine for an alanine.
Isoleucine is a non polar amino acid with a side chain composed of an aliphatic 
chain. Alanine is also a non polar amino acid, however its side chain consists of a single 
methyl group, making it the second smallest amino acid. From the predicted 3-d structure 
shown in figure 55a, it can be seen that the side chain of the isoleucine (highlighted) causes 
the proline at positions 3 and 7 to be pushed close together by a twisting of the peptide 
backbone. When comparing this to the predicted structure of the I4APk tag (figure 55b), 
this twisting of the peptide backbone is not as pronounced, and the two proline side chains 
are not as close together. The overall shape of the loop structure is also flattened. This 
indicates that for binding to occur, SV5-Pk4 needs the proline at position 7 to be pushed 
close to the proline at position 3, and that the sides of the loop structure need to be steep. 
The twisting of the peptide backbone can also be seen in the predicted structures of both the 
L8APk and LI lAPk modified tags (figure 55c & 55d respectively), tags to which SV5-Pk4 
readilv bind. The cause for the lack of binding of the other anti-Pk mAbs to the modified
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Pk I4A
L8A L llA
jk
F igure 55 : The pred icted 3 d im ensional structures o f the original Pk tag and the 
three m od ified Pk tags.
Those amino acids highlighted represent the three which had been modified; the isoleucine at 
position 3 (red); the leucine at position 8 (green); and the leucine at position 11 (blue). The 
amino acids highlighted in yellow represent the prolines at position 3 and 7. As can be seen the 
substitution of the isoleucine at position 4 (b) has the effect of flattening the rigid loop and 
pushing the prolines at positions 3 and 7 further apart. The other two substitutions to positions 8 
(c) and 11 (d) have no significant effect on the rigid loop but do cause the C terminus to twist.
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tags is not as apparent and appears to correspond to the data obtained from the insertion and 
substitution experiments.
The three amino acids which were substituted (ile-4, leu-8, and leu-11) were 
chosen on the basis of the data obtained from both the SPOT’s tests (cysteine insertions 
and substitutions) and the LTB-Pk-cys substitutions tested by ELISA (see section 4.1 & 
4.2 of the Reults). These amino acids were substituted on the basis that they caused an 
apparent reduction is the affinity of the mAb for the tag. These three amino acids were 
chosen as they did not completely abolish the binding of any of the anti-Pk mAbs, but did 
affect the binding of two or three. In addition to the three amino acids chosen for 
substitution, only the leucine at position 9 or the proline at position 5 were alternatives 
which were expected to have a similar effect on mAh binding. However, the proline at 
position 5 starts the loop in the peptide structure which is thought to be necessary for mAb 
binding, and was therefore discounted due to its position. The leucine at position 9 was 
also shown to be necessary for the binding of SV5-Pkl and SV5-Pk4, making it 
inappropriate for the study of these two mAbs, and for this reason was also discounted for 
substitution.
The Pk tag was modified in order to determine which of the new tags could be 
eluted from the anti-Pk mAbs using mild elution conditions. However, when testing the 
modified tags for elution capability, it was determined that only very low pH or chaotropic 
ions were effective (table 11). There was a single exception to this, the binding of SV5-Pk2 
to the I4APk modified tag. This tag could be eluted from mAb coupled beads using mild 
buffers such as 3.5 M magnesium chloride. Although the modifications to the tag were 
deemed successful for protein elution, the small non polar amino acid alanine may not have 
been the most suitable choice for a substitution which affects protein elution. Alanine forms 
a compact structure in water (Stryer 1988), and as such has no discernible properties which 
can be exploited. The decision to chose alanine was based on preserving the 3d structure of 
the peptide by not introducing a large amino acid side chain or one of a different charge. To 
allow greater control of protein elution, the substitution of isoleucine or leucine to a more 
charged amino acid may have been more appropriate. For example, histidine, glutamic acid
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or aspartic acid. All three of these amino acids are neutral or negatively charged depending 
upon the environmental conditions. Of the three, histidine would have been the most 
suitable choice for the substitution, due to its relatively neutral pK (6.5; Stryer 1988). This 
means that tagged proteins would be more probably to bind to the mAb column at a pH of 
below pH 6.5. By increasing the pH to above pH 6.5 the histidine would become 
uncharged, thus aiding in the elution of the tagged protein from the column.
As stated earlier, the Pk tag was originally derived from the P and V proteins of 
SV5, as a peptide which competed for the binding of SV5-P-k (SV5-Pkl). Simian Virus 5 
is a member of the Paramyxavirus family and is closely related to mumps virus and 
Parainfluenza virus type 2 (PIV-2; Southern etal 1991). The relevant sequence within the P 
proteins of SV5 and PIV-2 which corresponds to the Pk tag, differ in a number of amino 
acids but not in the key tetrapeptide sequence (see figure 56). Although the tetrapeptide 
motif remains intact, SV5-Pkl does not recognise and bind to the P protein of PIV-2 when 
tested by immunofluorescence assay. The reason for this is unknown as the amino acids 
whiclTare different are those which are not effected when substituted by a cysteine residue. 
One explanation may be that by the substitution of a rigid proline residue between two 
amino acids needed for mAb binding (leu-9 and leu-11) may effect mAb binding. When 
testing, by immunofluorescence, the four other anti-Pk mAbs against the P protein of PIV- 
2, some fluorescence was detected. The results are summarised in table 13. SV5-Pk2 
recognised and bound strongly to the P protein of PlV-2 in immunofluorescence assays, as 
did SV5-Pk3 and SV5-Pk4 though not as strongly. From the data obtained in the previous 
substitution experiments this was expected. The amino acids in the P protein of PlV-2 
which are different to the P protein of SV5 had no effect on the binding of these three 
mAbs when substituted. However, SV5-Pk5 did not recognise the P protein of PIV-2. 
This was also expected as this mAb requires the most amino acids for binding to occur, 
some of which are found on the periphery of the tag, where most of the differences are 
found between the two P proteins.
Simian virus 5 was originally isolated from rhesus monkey kidney cell culture but 
has also been isolated from humans and dogs. SV5-Pkl was tested previously on the P
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a. SV5W3-Pk
b. CPI-Pk
c. PIV2
gly.lys.pro.ile.pro.asn.pro.leu.leu.gly.leu.asp.ser.thr
glv.lvs.pro.ile.pro.asn.pro.pro.leu.glv.leu.asp.ser.thr
asn.thr.pro.ile.pro.asn.pro.leu.leu.pro.leu.ala.arg.pro
F igure 56 : the am ino ac id sequ en ces o f  the P k  ep itope w ith in  SV 5 (a), the  
C P I“ iso la te  (b) and P IV -2  (C ).
anti-Pk monoclonal antibody Reaction to the P protein of PIV-2
SV5-Pkl
SV5-Pk2 4—h4~
SV5-Pk3 4-4-
SV5-Pk4 4-4-
SV5-Pk5
T ab le 13 : T he resu lts ob ta in ed  for im m unoflu orescence assays on  the  
recogn ition  o f  the an ti-P k  m A h ’s for  the P protein  o f  PIV -2.
To determine if the anti-Pk mAh’s recognised the P protein of PIV-2, BALB/C cells were 
infected with PIV-2 and probed with the anti-Pk mAh’s. Any immunofluorescence produced 
was detected using a Texas Red conjugated anti- mouse Ig mAh.
Key : - no fluorescence detected; ++ - fluorescence obviously visible about background;
+++ - strong fluorescence detected.
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proteins of two canine isolates of SV5 termed CPL and CPP (Southern etal 1991). There 
are four amino acid differences between the proteins of the two isolates, one of which is 
found within the Pk motif (figure 56). This is the substitution of a leucine at position 8 for 
a proline residue. SV5-Pkl only recognised the isolate which had the original Pk sequence 
(CP1+) and not the isolate with the proline substitution (Southern etal 1991). Subsequent 
studies have shown that leu-8 is not necessary for SV5-Pkl binding to the tag, making it 
surprising that this mAb did not bind to the CPP isolate. This again suggests that it is the 
substitution for a proline which has the detrimental effect on binding and not the loss of the 
amino acid that was substituted. Although the four other anti-Pk mAbs have not been tested 
on these two isolates, it would be expected that they would not recognise the CPP isolate as 
leu-8 is required for the binding of all four mAbs to the Pk tag.
In retrospect, the methods used in this thesis may not have been the most effective 
for the production of reagents that were needed for efficient protein purification. Already 
discussed in this section are ways in which the project could have been altered. For 
example, the use of a different method for the production of the mAbs could have produced 
mAbs which would have more acceptible binding properties for protein elution. If mAbs 
with a lower affinity had been isolated, this would have removed the necessity for 
modifying the Pk tag to reduce the affinity of the mAbs. Also, instead of altering the 
method of isolating the mAbs, with the data obtained from the binding epitope studies, an 
alternative way of obtaining lower affinity mAbs would be to alter the tag with which the 
mice were immunised. By reducing the immunogenicity of the Pk tag, there would also be 
a higher probability of obtaining mAbs which would bind to different parts of the tag 
instead of the tetrameric sequence discussed in section 2 of this Discussion.
The substitution for the amino acids histidine, glutamate or aspartate when 
modifying the tag may also have been more beneficial for allowing the use of relatively 
mild conditions for protein elution. The charged nature of the amino acid side chains would 
not only alter the affinity of the mAbs for the Pk tag, but also allow pH to affect mAb 
binding to the tag, and therefore allow protein elution from a immunoaffmity column.
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